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Abstract
In the developing peripheral nervous system, neuronal survival and axonal growth 
are regulated by a variety of factors, the most extensively studied of which are secreted 
neurotrophic factors. To identify additional candidate molecules involved in regulating 
these aspects of neuronal development, I carried out a PCR screen for the expression of 
transcripts encoding receptors and selected ligands of three important superfamilies ligands 
and receptors (Wnt, TGF-P and TNF) over a broad range of developmental ages in three 
experimentally tractable populations of PNS neurons of mice (superior cervical ganglion, 
nodose ganglion and trigeminal ganglion). From these screening results I selected one 
member of the TGF-p superfamily (growth differentiation factor 5, GDF5), and one of the 
TNF receptor superfamily (B Cell Maturation Antigen, BCMA).
These studies have revealed that GDF5 is synthesized in sympathetic targets and 
promotes sympathetic axon growth and branching independently of NGF when these axons 
are ramifying in their distal targets. Mice lacking GDF5 have major deficiencies in 
sympathetic innervation without loss of neurons, indicating that target-derived GDF5 is 
essential for establishing appropriate tissue innervation during development.
Function blocking antibodies against BCMA and one of its ligands, BAFF, 
markedly impair the ability of NGF to promote the survival of cultured sympathetic 
neurons from the SCG ganglion at the postnatal age of PO.
Similarly, blocking the functions of BCMA and its other ligand, TACI, also leads to 
impaired survival, but at the earlier age of El 5. These findings reveal novel regulators of 
axonal growth and neuronal survival in developing peripheral nervous system.
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1. General introduction
1.1 A brief overview of neuronal development
1.1.1 Fertilization to Gastrulation
Embryonic development in vertebrates starts with the fertilization of the ovum,
which is then called the zygote. The zygote undergoes several divisions until it becomes a 
mass of undifferentiated cells, the morula. A fluid filled cavity develops in the dividing ball 
of cells, converting the morula into the blastocyst. This is divided into a inner cell mass and 
outer cell mass or trophoblast The inner call mass develops into the embryo, while the 
trophoblast becomes the placenta. The beginning of gastrulation in mice is evidenced by 
formation of a transient structure called primitive streak that will later form the posterior 
end of the embryo (1).
Gastrulation uses a set of morphogenetic movements coupled with cell proliferation 
to convert an embryo with two germ layers into one with three layers, namely, ectoderm, 
mesoderm and endoderm (2). These three layers will give rise to the adult body.
Once induced, endoderm forms an epithelial sheet that undergoes specification to 
distinct regions known as foregut, midgut and hindgut (3). This specification is controlled 
by factors secreted by surrounding mesoderm-derived tissues, for instance, FGF and BMP4 
together have been shown to induce hepatic fate in activin-induced endoderm (4), whereas 
retinoic acid combined with inhibition of Sonic Hedgehog (SHH) resulted in specification 
to a pancreatic fate (5).
The hematopoietic, vascular, cardiac, and skeletal muscle lineages derive from 
subpopulations of mesoderm induced in a defined temporal pattern.
Many studies have been performed to try to understand which are the mechanisms 
responsible for the induction of the hematopoietic mesoderm, concluding that a 
combination of Wnt, activin/Nodal and BMP are essential for it (6)(7). Several studies 
suggested that transient inhibition of Wnt/p-catenin signaling during mesoderm induction is 
essential for the induction of the cardiac mesoderm (8)(9).
The neural lineages of the skin are derived from ectoderm, which is induced from 
epiblast cells in the anterior region of the embryo. Inhibition of BMP, Wnt and 
activin/nodal signaling prevents neuroectodermal induction, which is consistent with
studies showing that these pathways are not active in the region of ectoderm induction in 
the early embryo (10)(11)(12).
1.1.2 Neural tube formation
Neurulation is the process of forming the neural tube, which becomes the brain and
spinal cord. The formation of the neural tube starts in early embryogenesis as the ectoderm 
thickens, and its cells increase in height, undergo pseudostratification and begin to express 
unique molecular markers (13). The neural plate induction is mediated by inhibition of 
BMPs and Wnt signaling pathways (14).
Once the neural plate is formed, it undergoes elongation by convergent extension, a 
process in which laterally placed cells move toward and are intercalated into the midline 
(15X16)(17). After the neural plate induction, its lateral borders elevate into neural folds, 
and these folds move toward the midline to fuse. After elevation has occurred, bending of 
the neural folds happens in two steps, furrowing and folding. Furrowing consists in the 
formation of median hinge (MH) and lateral hinge points (LHP). Folding occurs around 
these hinge points, with that involving the MHP resulting in elevation of the folds, and that 
around LHPs producing convergence of the folds (18)( 19).
Once the neural folds meet in the midline, they undergo fusion. Cell processes are 
extended from one to another, and cell surface coats, consisting of glycoproteins, are 
deposited at regions of fusion (20). These surface coats act as a glue to hold the folds in 
place until more permanent cell to cell contacts are established. Closure of the neural tube 
starts near the junction of the hindbrain and spinal cord, and then continues in a “zipper- 
like” fashion cranially and caudally (21). While joining, some of the cells of the neural fold 
separate laterally from the others to form the neural crest between the neural plate and the 
surface non-neuronal ectoderm (22). See figure 1 for details.
If the neural tube fails to close, it can cause several birth defects referred to as 
neural tube defects (NTDs). In humans the most common NTDs are anencephaly (a fatal 
failure of rostral neural tube to close) and myelomeningocoele (failure of the vertebral 
neural tube fusion). To date, many null mice have been generated which display NTDs, 
suggesting that there is a range of factors that can trigger NTDs (23).
3
Ectttefm
Mesoderm
fnfodenn 
Neural pale
Neural Md
Neural groove
Neural cresl
Neural tute
Figure 1: Neural tube formation. The neural tube is formed as a flat neural plate that folds toward 
the midline until it closes to form the neural tube, (www.studentconsult.com)
Regionalization o f the neural tube happens in parallel to the changes in its shape. At 
the anterior cephalic region where the brain will form, the wall of the neural tube grows, 
and undergoes a kind o f swelling, that defines the various brain compartments (Fig. 2).
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Caudally to the brain region, the development o f the spinal cord continues as a simple tube 
that elongates to caudal body axis extension.
In early development, most of the cells from the neural tube proliferate and keep 
stem-cell like properties. Classical studies using tritiated thymidine incorporation, show 
that these cells later exit the cell cycle and terminally differentiate at the periphery of the 
neural tube (24).
Telencephalon
Prosencephalon
(forebrain)
Diencephalon
Mesencephalon
(midbrain)
Metencephaion Rhombencephalon
Myelencephalon (hindbrain)
Spinal cord
Figure 2: Early embryonic CNS. Drawing showing the neural tube and vesicles. Proliferation and 
migration of progenitor cells in the walls of the neural tube will give rise to the forebrain, midbrain, 
hindbrain and spinal cord, (http://blog.vitonis.com)
As mentioned above, the proliferating cells in the neural tube will give rise to the 
CNS. In order for this event to occur, these cells require cellular and molecular events that
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control the patterning of the neural tube along its dorsal and ventral axis. The initial 
position of these cells in the neural tube defines their exposure to specific signals 
(morphogens). The best studied morphogens are the Bone Morphogenetic Proteins (BMPs), 
Fibroblast Growth Factors (FGFs), Sonic Hedgehog (SHH) and Wnt pathway (for review 
see (25)).
1.13 Neuronal migration
Cell migration is a crucial process during the development of the CNS, as both,
neuronal and non-neuronal cells are usually generated in places that differ from their final 
destination. Most neurons migrate from the place of their last division, near the ventricle, 
towards the outer surface of the CNS, where they will settle and integrate into specific brain 
circuits.
There are two types of neuronal migration during embryonic development: radial 
and tangential. Radial migration applies to neurons that migrate in a direction perpendicular 
to the surface of the brain, whereas tangential migration applies to neurons that migrate in a 
direction parallel to the brain surface (26).
Radial migration is the predominant route by which the majority (80 -  90%) of the 
precursor neurons in the mammalian cortex reach their destination (27). Apart from the 
cerebral cortex, other laminated structures like the cerebellar cortex, spinal cord, striatum 
and thalamus use either radial migration, or a mixture of both radial and tangential 
migration (28).
Tangential migratory routes have also been identified from the medial ganglionic 
eminence (MGE) to the neocortex and hippocampus, and from the lateral ganglionic 
eminence (LGE) to the olfactory bulb.
Defects in neuronal migration can lead to severe problems. Studies in null mice for 
reeler -  the gene involved in cell adhesion, show abnormal corticogenesis (Fig. 3a); 
whereas in null mice for weaver, granule cell precursors in the cerebellar cortex fail to 
migrate along glial fibers and die in ectopic positions (29). In Humans, abnormalities of 
neural migration cause a range of disorders, most notably lissencephaly, caused by the
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disruption in both radial and tangential migration and is characterized by a cortex that has 
only four layers and a brain that appears smooth with an absence of gyri and sulci (30).
a
b
Figure 3: Defects in neuronal migration, (a) Diagram shows corticogenesis in a normal and reeler 
mice. In the normal mouse, the first neurons to take their place are the subplate neurons (yellow). 
Next are the cortical plate neurons (black), which migrate past the subplate level. In the reeler 
mouse note the disorganized cellular layers, oblique angles of radial glia fibers, (b) Normal and 
Lissencephalic brain. Lessencephalic individuals have a smooth cortex lacking the characteristic 
sulci and gyri observed in the normal brain. (30)
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1.1.4 Synaptogenesis
Synaptogenesis involves the formation of a neurotransmitter release site in the
presynaptic neuron and a receptive field at its postsynaptic partners), and the precise 
alignment of pre- and postsynaptic specialization.
For a synapse to function properly four events must take place, (I) the axon of a 
developing neuron has to make contact with a postsynaptic partner; (2) a cleft between the 
synaptic partners that contains denser concentrations of material than that observed in 
normal extracellular spaces; (3) the existence of synaptic vesicles next to the presynaptic 
membranes; (4) stabilization of synaptic junctions into functional connectivity patterns 
(31 )(32). Figure 4 shows a diagram of synapse formation.
The formation of the neuromuscular junction (NMJ) is the most extensively 
characterized model of synaptogenesis. Acetylcholine (ACh) is the main neurotransmitter 
that activates the postsynaptic acetylcholine receptors (AChRs). Agrin is a neuronal factor 
that plays a key role in the accumulation of AChR at synaptic sites (33). Null mice for agrin 
die at birth because neurotransmitter function is disrupted (34). The physiological role of 
agrin appears to be to prevent the dispersion of AChR clusters on developing muscle cells 
rather than inducing initial clustered pattern (35). Receptor associated protein synapse 
(rapsyn) forms complexes with AChRs which are required for the formation of clusters 
(36).
Another postsynaptic protein, muscle specific kinase (MuSK) has also been 
implicated in receptor clustering in vivo (37). MuSK regulates synaptic formation by 
establishing the postsynaptic density (38).
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Figure 4: synaptic structure. Diagram showing a synapse between two neurons. Neurotransmitters 
contained within synaptic vesicles are released from the presynaptic cell, traverse the synaptic cleft 
and bind to receptors on the postsynaptic membrane. (http://universe-review.ca/R10-16-ANS.htm)
1.2 O rganization and  development of the peripheral nervous system
1.2.1 Introduction
The CNS which develops from the neural tube (as described above), includes the 
brain and spinal cord. The peripheral nervous system (PNS) consists o f nerves and ganglia 
that provide communication between the CNS and the periphery. The PNS is subdivided
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into an afferent and efferent components. PNS afferents (also named sensory), convey 
impulses from the periphery to the CNS, whereas PNS efferents (autonomic and somatic 
motor) transmit impulses from the CNS to the peripheral organs. The work described in this 
thesis is centered on the roles of the growth differentiation factor 5 (GDF5) and B cell 
maturation antigen (BCMA), in regulating the survival of discrete populations of sensory 
and autonomic neurons and establishing sensory and autonomic innervation during 
development. In this section I will therefore describe the organization of the PNS and 
provide a brief overview of the embryonic development of the PNS.
1.2.2 Organization of the somatic PNS
The somatic nervous system consists of nerves that innervate the skin and muscles,
and is involved in conscious activities. The somatic PNS signals through twelve pairs of 
cranial nerves (Fig. 5), and thirty one pairs of spinal nerves (Fig. 6). There are seven pairs 
of cranial sensory ganglia whose axons form part of five of the twelve cranial nerves. The 
trigeminal ganglion is located on the cranial nerve V, and its neurons innervate 
mechanoreceptors, thermoreceptors and nociceptors in the face, nasal and oral cavities. The 
geniculate ganglion is located on cranial nerve VII and innervates taste buds on the anterior 
two thirds of the tongue. The vestibular and spiral ganglia of cranial nerve VIII innervate 
hair cells in the inner ear. The petrosal ganglion is located on cranial nerve IX and 
innervates taste buds on the posterior one third of the tongue and sensory receptors in the 
carotid body. The superior glossopharyngeal ganglion of cranial nerve IX innervates part of 
the skin of the pinna and tympanic membrane. The jugular and nodose ganglia of cranial 
nerve X innervate various sensory targets in the pharynx, thorax and abdomen.
Each spinal nerve is connected to the spinal cord by a dorsal root consisting of 
sensory fibers and a ventral root of motor fibers. The cell bodies of the sensory neurons of 
spinal nerves are located in the dorsal root ganglia (DRG), and the motor-neuron cell 
bodies are located in the ventral grey matter. The two roots join to form the spinal nerve 
just before the nerve leaves the vertebral column via an intervertebral foramen. Each spinal 
nerve subsequently divides in dorsal and ventral rami, consisting of mixed sensory and 
motor fibers. See Figure 6 for details.
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Figure 5: Cranial nerves. Illustration showing the roots of the twelve cranial nerves and the main 
tissues they innervate, (www.web-books.com)
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Figure 6: Dorsal root ganglion. Illustration showing the dorsal root ganglia organization. 
(www.acceleratedcure.org/msresources/neuroanatomy/)
1.2.3 Organization of the autonomic PNS
The autonomic nervous system consists o f nerves that connect the CNS to the
viscera, various glands, blood vessels and the arrector pilorum muscles of hair follicles. It 
mediates unconscious activities. The autonomic nervous system can be subdivided into 
three divisions: the sympathetic nervous system, parasympathetic nervous system and the 
enteric nervous system.
The sympathetic nervous system prepares the organism for “fight or flight”, 
whereas the parasympathetic system is responsible for “rest and digest”. In order to respond 
to emergency situations, the hypothalamus activates the sympathetic nervous system, 
resulting in an increase o f the sympathetic outflow to the heart and other viscera, peripheral 
vasculature, sweat glands, and arrector pilorum muscles. In contrast, the parasympathetic 
system maintains basal heart rate, respiration, and metabolism under normal conditions.
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The cell bodies of the preganglionic sympathetic neurons are located in the lateral 
grey column of the spinal cord segments T1 and L2 (39). The preganglionic fibers travel a 
short distance in the mixed spinal nerve and then branch off as white rami (myelinated) to 
enter the paravertebral sympathetic chain. The short preganglionic fibers enter the chain 
and a synapse with postsynaptic neurons in ganglia either higher, lower or the same level, 
in the chain and then the longer postganglionic fibers usually return to the adjacent spinal 
nerve via grey rami (unmyelinated) and are conveyed to the effector organs. Some 
preganglionic fibers pass through the sympathetic chain and travel in the splanchnic nerves 
to terminate on postganglionic neurons located in prevertebral sympathetic ganglia located 
close to the viscera. At the preganglionic synapse the neurotransmitter released is ACh, 
whereas at the postganglionic ending the chemical transmitter in the majority of cases is 
noradrenaline. Sympathetic stimulation results in pupillary dilatation, increased heart rate 
and contractility, bronchodilation, contraction of the arrector pillorum muscles, 
vasoconstriction of the mesenteric circulation and vasodilatation of the skeletal muscles 
arterioles.
Preganglionic outflow of the parasympathetic nervous system arises from cell 
bodies of preganglionic parasympathetic nuclei related to the cranial nerves III, VII, IX and 
X and in the lateral grey column of sacral spinal segments (S2, S3 and S4). This is referred 
to as the cranio-sacral outflow. Preganglionic fibers synapse in ganglia close to or within 
the organ they innervate, giving rise to relatively short postganglionic fibers. Cranial 
postganglionic parasympathetic ganglia related to the cranial nerves III, VII and IX 
promote pupillary constriction, visual accommodation and salivary gland secretion, 
whereas the terminal ganglia of cranial nerve X innervates the heart, lungs, stomach, upper 
intestine and ureter. The sacral parasympathetic outflow innervates the distal colon, rectum, 
bladder and sexual organs.
Physiologically, the parasympathetic system reduces heart rate and blood pressure, 
and facilitates digestion and consequently nutrient absorption. The neurotransmitter at both 
pre and postganglionic synapses in the parasympathetic system is ACh.
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The enteric nervous system controls the coordinated muscular contractions and 
secretion o f glands along the gastrointestinal tract. The neurons and their processes are 
located predominantly in two plexuses: the submucosal plexus innervates the mucosa and 
regulates secretion; and the myenteric plexus innervates the circular and longitudinal 
smooth muscle layers and regulates motility.
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1.2.4 Development of the peripheral nervous system
With exception of certain cranial sensory neurons, all neurons and glial cells of the
peripheral nervous system are derived from the neural crest.
The neural crest originates from the neural folds after interactions between the 
neural plate and the presumptive epidermis (40X41). Migration and differentiation of neural 
crest cells from the dorsal neural tube give rise to a wide variety of cell types including 
peripheral nervous system neurons, Schwann cells, satellite cells, melanocytes, facial 
cartilage, bone and connective tissue (42). The fate of neural crest cells is largely dependent 
on the migratory route taken and the final position of cells.
The trunk neural crest is a transitory structure whose cells begin to migrate as the 
neural tube closes. The neural crest cells emerge from the dorsal region of the neural tube 
and rapidly disperse along different pathways. There are two major migration routes, the 
dorsolateral pathway and the ventral pathway. Cells that migrate through the dorsolateral 
pathway become melanocytes, whereas cells that migrate through the ventral pathway give 
rise to the DRG, sympathetic ganglia and cells of the adrenal medulla. Neurons of the 
parasympathetic nervous system derive from the mesencephalic neural crest and the enteric 
nervous system derives from the vagal and lumbosacral neural crest (43). All Schwann and 
satellite cells in the sensory and autonomic ganglia have been shown to be neural crest 
derived (44). Both BMP and FGF signaling have been implicated in neural crest induction 
(40)(45). Mouse embryos in which p-catenin has been inactivated have malformed neural 
crest derivatives, including the DRG and various craniofacial regions, implicating Wnt 
signaling in neural crest formation and differentiation (46).
Neurogenic placodes are focal thickenings of embryonic cranial ectoderm that are 
induced by signals from the surrounding cranial tissue. These placodes can be further 
divided in dorsolateral and epibranchial, based in their position in the developing head. The 
dorsolateral placodes give rise to the neurons of the vestibular ganglia and ventrolateral part 
of the trigeminal ganglia, whereas the epibranchial placodes give rise to the neurons of the 
nodose, petrosal and geniculate ganglia.
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13 Regulation of neuronal survival in the PNS
13.1 Introduction
Apoptosis or programmed cell death (PCD) has long been shown to be crucial for 
the correct development of the nervous system. During development between 20 and 80% 
of neurons generated in various populations undergo PCD.
The occurrence of PCD in the early development of the nervous system has been 
reported in a large spectrum of organisms, from C. elegans to mouse. A common feature 
between species is that it happens within proliferative or newly post-mitotic cells, and it is 
usually among the earliest cell deaths during development.
All pathways to apoptosis converge on the activation of caspases (which are 
proteases that coordinate the efficient dismantling of doomed cells). These pathways are 
governed mainly (though not exclusively) by the Bcl-2 family of proteins (47). For details 
see figure 8. Two distinct pathways, both resulting in caspase activation, can be 
distinguished depending on whether or not the Bcl-2 family of proteins is involved and by 
which caspases are decisive for cell death. They are (1) the intrinsic pathway -  activated by 
developmental cues or cytotoxic insults, such as growth factor deprivation, viruses, or 
stress, and is strictly controlled by Bcl-2 family of proteins; (2) the extrinsic pathway -  
triggered by ligation to death receptors where two distinct intracellular pathways can be 
engaged. “Type I cells” pathway is activated if there are sufficient levels of caspase 8, or 
“type II cells” pathway when a low level of caspase 8, without any involvement of the Bcl- 
2 family (48).
The Bcl-2 family is usually grouped into three classes of proteins depending on 
their action: (1) those that inhibit apoptosis (Bcl-2, Bcl-XL, Bcl-W, Bcl-B and Al); (2) 
those that promote apoptosis (BAX, BAK and BOK); (3) Bcl-2 homology domain (BH-3)- 
only proteins (BAD, BIK, BID, HRK, BIM, NOXA and PUMA) (49).
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Figure 8: The molecular basis of apoptosis. Diagram showing the intracellular machinery 
that regulates and executes apoptosis. (48)
Neuronal apoptosis is regulated by a tightly controlled balance of surviving- 
promoting neurotrophic factors and cell death promoting signals. As an example, nerve 
growth factor (NGF) binding to TrKA activates pro-survival pathways such as PI-3 kinase, 
Akt and MEK/MAPK. This will be further explored in a later section o f the introduction.
1.3.2 Neurotrophic theory
During the normal development of the nervous system, neurons are generated in
excess. A proportion undergo a phase of cell death shortly after axons reach their targets, 
eliminating unnecessary neurons and neurons with inappropriate synaptic connections,
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leaving the appropriate number of neurons relative to the target field (50)(51). According to 
the neurotrophic theory, neurons that fail to acquire neurotrophic support die of apoptosis, 
and the others survive. The neurotrophic theory was substantiated by classical experiments 
carried out by Levi-Montalcini Cohen and Hamburger, leading on from the discovery of the 
first neurotrophin, nerve growth factor (NGF). Their experiments showed that populations 
of developing neurons whose survival depends on NGF in vitro, also depend of NGF in 
vivo (52X53).
Whereas populations of sensory and sympathetic neurons that are dependent on 
NGF in vitro are eliminated by administration of anti-NGF antibodies in vivo during the 
period of target innervation, administration of NGF during this period prevents naturally 
occurring death in these populations (54X52)(55X56X57). Genetic deletion of genes 
encoding NGF and its receptor tyrosine kinase (TrkA) also results in decreased numbers of 
peripheral sensory and sympathetic neurons (58X59X60). The production of NGF begins in 
target tissues with the arrival of the earliest axons (61), and the removal of the target tissue 
increases programmed cell death in the relevant peripheral ganglia (62). The neurotrophic 
theory, as described above, is an over-simplification because neurons require trophic 
support before and after synaptogenesis from sources other than the target field (51). 
Furthermore, many populations of neurons switch their dependence from one neurotrophic 
factor to another at certain stages of development (63X64). In vitro studies have shown that 
populations of PNS neurons survive independently of the neurotrophic factors at the stage 
when axons begin to sprout For several populations of neurons, the duration of the 
neurotrophic factor independence is proportional to the distance and time needed for axons 
to grow toward and reach their targets (65)(66).
Since the discovery of NGF, much research has been done attempting to identify 
additional neurotrophic factors. Brain-derived neurotrophic factor (BDNF) was the second 
neurotrophic factor to be purified (67). Since then, several other neurotrophic factors have 
been identified. The neurotrophin family of proteins includes nerve growth factor (NGF), 
brain-derived growth factor (BDNF) neurotrophin-3 (NT-3), neurotrophin-4/5 (NT-4/5), 
neurotrophin-6 (NT-6) and neurotrophin-7 (NT-7) (among the vertebrates, the latter two
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neurotrophins are only found in fish). The neurotrophins are structurally and functionally 
related and signal through two classes of receptors: the high-affinity tyrosine kinase 
receptors of the Trk family (TrkA, TrkB and TrkC) and a common low-affinity receptor, 
p75. Several other families of neurotrophic factors have been identified to promote survival 
of various neuronal populations at various stages of development. These include the glial 
cell-derived neurotrophic factor (GDNF) family (GDNF, neurturin, artemin and persephin), 
the neurotrophic cytokines [ciliary neurotrophic factor (CNTF), leukaemia inhibitory factor 
(LIF), oncostatin-M (OSM), cardiotrophin-1 (CT-1) and interleukin-6 (IL-6)] and the 
related cytokines hepatocyte growth factor (HGF) and macrophage-stimulating protein 
(MSP) (63)(68) (69)(70).
In addition to regulating neuronal survival during development, neurotrophins have 
a role in diverse processes from cellular proliferation, differentiation and process outgrowth 
to synaptic plasticity (71)(72)(73)(74X75). The original research described in this thesis has 
a bearing on the role of neurotrophins in the regulation of neuronal survival and process 
outgrowth during the development of specific populations of the peripheral sensory and 
sympathetic neurons. Although the individual neurotrophic requirements of PNS neurons 
during development have been described, the downstream signaling events mediating 
neuronal survival and neurite outgrowth are only beginning to be elucidated. I will 
therefore briefly describe the neurotrophic requirements of the relevant peripheral ganglia, 
followed by an introduction to the biology of the neurotrophic factors and their receptors.
1 3 3  Neurotrophic requirements of selected peripheral ganglia
The studies described in this thesis were performed on sensory neurons of the
mouse nodose ganglion and trigeminal ganglion, and on the sympathetic neurons of the 
superior cervical ganglion (SCG).
In vitro survival of nodose neurons has been shown to depend mainly on BDNF 
support and to a lesser extent NT-3 and NT-4 (66)(76)(77). Null mice for BDNF, NT-3 and 
NT-4 show increased cell death in the nodose ganglion (78)(79)(80)(81). Early in 
development, the survival of a small subpopulation of nodose neurons is supported by NGF
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in vitro. This observation was further supported by the slight decrease in the number of 
neurons in the nodose ganglion in NGF 7' mice (82). Subpopulations of the nodose neurons 
respond to a variety of other neurotrophic factors, notably neurotrophic cytokines CNTF, 
LIF OSM and CT-1 (83). The in vitro survival of neonatal nodose neurons is equally well 
supported by both BDNF and these neurotrophic cytokines.
Trigeminal neurons have been shown to switch their dependence between 
neurotrophins at different stages of development. Early trigeminal neurons are dependent 
on both NT-3 and BDNF for survival but by embryonic day 12 (E12) most neurons become 
NGF-dependent (84). The switch in neurotrophin response is correlated with a change in 
the appropriate Trk receptor expression and a switch of neurotrophin from BDNF to NGF 
in the target tissue (64X84X85X86).
The sympathetic neurons of the SCG originate from precursor cells in the neural 
crest. During their development, SCG neurons respond to a variety of neurotrophic factors, 
and the in vitro survival of SCG neurons can be supported by a wide range of neurotrophic 
factors between early embryonic and early adult life. Artemin promotes sympathetic 
neuroblast proliferation and hepatocyte growth factor (HGF) promotes differentiation of 
sympathetic neuroblasts into postmitotic sympathetic neurons (73)(87)(88). SCG neurons 
respond to NGF at E14 and remain dependent on NGF for survival throughout the rest of 
their embryonic life (89). By birth and into early adulthood the survival of SCG neurons in 
vitro can be supported by both NGF and NT-3. The dependence of SCG neurons on NGF 
and/or NT-3 correlates with expression of TrkA and not TrkC during and after the period of 
naturally occurring death (90). Late postnatal SCG neurons also respond to CNTF, LIF and 
HGF in vitro (91)(92).
Cell culture systems, described herein, were used to analyze neuronal survival 
and/or process outgrowth in embryonic or postnatal neurons from the trigeminal (supported 
by NGF), nodose (supported by BDNF) and SCG (supported by NGF) ganglia. The biology 
of these neurotrophic factors and their associated receptor systems is introduced in the 
upcoming sections.
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13.4 NGF
NGF, the founder member of the neurotrophic family, was first described the 
1950’s, after its isolation from mouse salivary glands (93)(94). In the subsequent years 
researchers identified the amino acid sequence of NGF (95) and its 3D structure (96). All 
NGF is synthesized in its precursor form, i.e, pro-NGF. It is then enzymatically cleaved, to 
give rise to mature NGF. Mature NGF is a homodimer consisting of two 118 amino acid 
subunits, each containing a cysteine rich motif and two anti-parallel p strands (95X96)(97).
NGF has been shown to be expressed in many regions of the CNS, such as 
neocortex, basal forebrain and hippocampus (98). The targets of NGF-dependent neurons 
also secrete NGF, including the heart, submandibular gland and whisker pads (61)(99). 
Several non-neuronal cells also express NGF, namely cells from the immune, reproductive, 
endocrine and cardio-vascular system, although the function of NGF in these tissues is 
poorly understood (100). NGF7' mice lose substantial numbers of sensory and sympathetic 
neurons, during development, demonstrating the crucial role of NGF signaling during 
development (58). More than regulating neuronal survival, NGF is required for terminal 
innervation of target tissues. The excessive death of sensory neurons in NGFA mice can be 
prevented in NGF'VBAX7' mice (101). These double knockout mice have reduced 
peripheral innervation, suggesting that NGF signaling regulates the extent of terminal 
branching in target tissues (101). In this way, NGF has been shown to play a crucial role in 
establishing the innervation of distal sympathetic targets (102).
13.5 BDNF
BDNF was identified in 1982, becoming the second member of the neurotrophin 
family. Just like NGF, BDNF was reported to be a target-derived factor and to promote 
neuronal survival and neurite outgrowth during development (67). BDNF is synthesized as 
a precursor and then cleaved to form mature, biologically active BDNF (103). BDNF 
shares approximately 50% of its sequence with NGF (67)
BDNF expression is widespread in the CNS including cerebral cortex, 
hippocampus, cerebellum, basal forebrain, striatum, hypothalamus and brain stem (104).
21
BDNF has been implicated in several aspects of development including cell proliferation, 
learning and memory (105). BDNF has been shown to play an important role in long term 
potentiation (LTP) (106)(107)(108). BDNF has emerged as a major regulator of synaptic 
plasticity and key target in neurological diseases (109).
BDNF is also expressed in certain populations of peripheral sensory ganglia and in 
target tissues of BDNF-dependent neurons, including the heart, skin, muscle and lung 
(84X110)(111). BDNF promotes survival of placode derived trigeminal, nodose, petrosal, 
geniculate and vestibular neurons during development (112)(113X114)(115). BDNF'7' mice 
die perinatally and display severe defects in the populations of sensory neurons that depend 
on BDNF for survival (116X117). BDNF has been implicated in neurite outgrowth in 
vestibular, DRG, sympathetic and nodose neurons (118)(119)(120X121)(122) 
(123X124X125) of the PNS and in neurite outgrowth and maintenance of cortical and 
hippocampal processes (126X127X128)(129X130X131X132)(133).
13.6 Trk receptors
The Trk receptors are receptors tyrosine kinases that primarily regulate growth, 
differentiation and programmed cell death of neurons in both the peripheral and central 
nervous systems. These receptors were first described in 1986 as the product of the trk 
oncogene, rather than for their trophic actions on neuronal cells (134)(135). Only a few 
years later, researchers gathered enough evidence to show that the biological role of the Trk 
tyrosine protein kinase was to serve as signaling receptor for NGF (136)( 137)(138)( 139). 
Subsequent studies showed Trk tyrosine kinase was a member of a small family of 
receptors that included TrkB (140X141)(142), and TrkC (143). TrkB mediates the 
biological activity of both BDNF (141)(144X145) and NT-4 (146)(147)(148), and TrkC is 
the primary receptor for NT-3 (149). There is also some physiologically relevant, lower 
affinity binding between NT-3 and TrkA and TrkB and between NT-4/5 and TrkA 
(147)(144)(145)(146).
All peripheral neurons express Trk receptors, with the exception of parasympathetic 
ciliary neurons (86)(150)(140)(151)(152X143).
In general, the populations of neurons that are lost in Trk 7' mice overlap with those 
lost in the knockout mice of the primary neurotrophin ligand. TrkA"7' mice have decreased
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neuronal number in trigeminal and sympathetic ganglia (59). TrkB7' mice loose a 
substantial proportion of trigeminal and nodose neurons (153), while TrkC'7* mice have 
decreased numbers of myelinated axons in the dorsal roots accompanied by the loss of a 
subpopulation of DRG neurons (154).
13.7 p75
p75 was discovered and identified as an NGF receptor in 1986 (155), and was 
subsequently shown to be able to bind all neurotrophins (156). p75 is expressed both in the 
CNS and PNS as well as non-neuronal cells and its expression increases after trauma (157). 
p75 has been shown to modify the function of Trk receptors (157), to bind to pro- 
neurotrophins in a complex with a co-receptor called sortilin to elicit apoptosis 
(158)(159)(160), and can therefore either promote (161)(162)(163) or inhibit (164) cell 
death.
1.4 Regulation of neurite outgrowth
1.4.1 Axon extension and guidance
Neuronal connections form during embryonic development when each individual
differentiating neuron sends out an axon, tipped at its leading edge by the growth cone, 
which migrates through the embryonic environment to its synaptic targets. Observations of 
developing axonal projections in vivo have revealed that the great majority of axons extend 
to the vicinity of their appropriate target regions in a highly stereotyped and directed 
manner, making very few mistakes (165).
The first axons that develop navigate through an axon-free environment when the 
embryo is still relatively small, but most axons face an expanding environment crisscrossed 
by a scaffold of earlier projecting axons (166) Axons respond to coordinate actions of four 
types of guidance cues: attractive and repulsive, which can be either short or long-range
(167). Many of these attractive and/or repulsive cues have been identified and include 
semaphorins, netrins, slits, epherins, morphogens and associated receptor systems
(168)(169).
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1.4.2 The role of neurotrophic factors in regulating neurite growth from PNS neurons
The role of neurotrophic factors in regulation of neurite outgrowth in vitro has been 
well established over many years (102)(170)(120)(171)(172)(173)(174). The role of 
neurotrophic factors in neurite outgrowth in vivo has been much more difficult to ascertain, 
however, because the effects of neurotrophic factors on neuronal survival have impeded 
efforts to investigate the requirement of neurotrophic factors for axon extension and 
peripheral target innervation. The separation of survival effects from effects on neurite 
outgrowth was achieved by studying NGF/7TrkA /' double knockout (101). BAX deletion 
prevents programmed cell death in developing peripheral neurons (175), so crossing these 
double knockout mice provided an ideal framework for analyzing the growth-promoting 
effects of NGF/TrkA signaling in vitro and in vivo (101). Further work has shown that 
peripheral axons can be induced to grow towards ectopic sources of neurotrophic factors, a 
process that can be reversed by application of function-blocking antibodies to NGF, BDNF 
or NT-3 (119). Furthermore, in vivo analysis of the neurotrophin-overexpressing mice has 
revealed that increased levels of NGF or NT-3 in the brain, pancreas, heart or skin leads to 
increased axonal growth in sensory and sympathetic neurons in these tissues 
(81)(176)(177)(178).
More recently, Kuruvilla et al, have reported that NGF and NT-3 control sympathetic 
development through differential control of TrkA internalization and retrograde signaling. 
NT-3 signals via TrkA to promote outgrowth but not survival, whereas NGF controls both 
survival and outgrowth (170).
1.43 Intracellular signaling pathways downstream of neurotrophic factors regulating 
neuronal survival and neurite outgrowth
Trk receptors are activated through ligand-mediated dimerisation followed by
phosphorylation of several conserved cytoplasmic tyrosine residues, providing docking 
sites for adaptor molecules and enzymes mediating intracellular signaling pathways 
(74X153)(154X155). Neurotrophin signaling through Trk receptors leads to the activation 
of many intracellular signaling molecules such as Ras, PI3-K and PLCy (156). 
Neurotrophin signaling in the cell soma and nucleus is crucial for neuronal survival 
(52)(157). However, especially in the PNS, the source of neurotrophic factor may be at
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quite a distance from the soma. These observations prompted investigations into the 
mechanisms of retrograde signal transduction after ligand engagement. Ligand engagement 
stimulates internalization of Trk receptors through clatherin-coated pits and by 
macropinocytosis in cell surface ruffles (158)(159). After internalization, neurotrophins are 
localized with the Trk receptors in endosomes that also possess activated signaling 
intermediates, such as She and PLCyl (160). NGF-TrkA internalization and retrograde 
transport to the soma is required for transmission of the neurotrophin survival signal 
(161)(162). Recent data describing NGF-promoted neuronal survival without NGF 
internalization (163) and the lack of retrograde signaling of NT-3/TrkA in sympathetic 
neurons have added layers of complexity to neurotrophin signaling cascades.
Once neurotrophins bind to their respective Trk receptors, they are known to 
activate protein kinase A (PKA), Ras/phosphotidyl inositol 3’-phosphate-kinase (PI3- 
K)/Akt, (hereafter referred as PI3-K/Akt) and Ras/Raf/mitogen-activated protein kinase 
(MAPK) and MAPK/extracellular signal-regulated kinase (ERK) (hereafter referred as 
MAPK/ERK) signaling pathways (179)(180)(181)(182)(183)(184)(185)(186).
Activation of PI3-K/Akt or MAPK/ERK signaling pathways in the absence of 
neurotrophins has been show to be enough to both sustain the survival of 
(187)( 188)( 189)( 190) and enhance neurite growth fromsome neuronal populations (191).
Many studies have shown the link between PI3K/Akt pathway and cell survival 
downstream of growth factors, oncogenes and cell stress. Akt promotes cell survival when 
it blocks the function of pro-apoptotic proteins, like the Bcl-2 homology domain 3 (BH3)- 
only proteins, preventing them from binding to and subsequently activating pro-survival 
Bcl-2 protein members. Akt can also inhibit the expression of BH3-only proteins by 
blocking transcription factors like FOXO and p53, or even by blocking MDM2, an E3 
uniquitin ligase that triggers p53 degradation. Akt activation by any of die previous routes 
prevents the processing of pro-caspase9, preventing apoptosis (192).
The role of the MAPK cascade in neurite outgrowth has been extensively studied in 
the PC 12 neuronal cell line, and to a lesser extent in primary neurons.
Following differentiation of naive PC 12 cells to a sympathetic neuron like cell, 
neurite outgrowth stimulated by NGF is not dependent on the MAPK cascade (Sano and
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Kitaj ima, 1998). Thus, activation of the MAPK cascade appears to be a permissive signal 
involved in making naive PC 12 cells competent to extend neurites in response to a growth 
factor stimulus.
Binding of NGF to TrkA results in phosphorylation of cytoplasmic tyrosine residues 
on the cytoplasmic domains of these receptors, and phosphorylation of these residues 
further activates the receptor. Therefore, MAPK/ERK, PI3-K/Akt and phospholipase C 
(PLC) yl are activated (193X194X195X196).
BDNF and NT4/5 have also been shown to activate PI3-K and MAPK pathways to 
promote neuronal survival (184X197)(198X199).
1.5 Wnt Signaling
1.5.1 Introduction
In 1982, Nusse and Varmus reported the identification of a proto-oncogene Wntl 
(originally called Int-1), as a signaling molecule involved in the development of mammary 
tumors (200). Several years later, Wntl and Wingless (WG), its Drosophila melanogaster 
orthologue, emerged as key morphogens that regulate the embryonic body plan (201)(202). 
It is now well established that Wnt proteins are important mediators of intracellular 
communication, and that signaling by members of the Wnt family of molecules is crucial 
for normal embryonic development in various systems including the nervous system.
Wnts have been shown to regulate diverse cellular processes, including cell 
proliferation and fate, cell polarity and movement, and programmed cell death (203). They 
can influence tissue organization and growth by functioning locally, in an autocrine 
manner, and can also act at a distance, by generating a gradient across a tissue. Studies in 
various developmental systems have contributed to our extensive understanding of Wnt 
signaling, and have shed new light on the mechanisms through which cells interpret their 
environment.
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1.5.2 Wnt signaling pathways
Wnts are secreted glycoproteins with an unusual post-translational modification, a 
palmitoylation (covalent attachment of fatty acids that enhances the hydrophobicity of 
proteins and contributes to their membrane association.) at a conserved cysteine residue 
that is essential for their function. The current model proposes that Wnts signal through 
their Frizzled receptors (FZD), which consist of seven-pass transmembrane proteins (204). 
The Wnt-FZD receptor complex activates Dishevelled (DVL), a cytoplasmic scaffold 
protein that brings together components of the pathway for efficient transduction (205). 
There are many Wnts and FZD receptors in the genome of a number of species, for 
example, 19 wnt and 9 fed  genes have been identified in the mouse genome. Recent studies 
show that Wnts can also signal through the tyrosine kinase related receptor RYK (206), 
which interacts with FZD and DVL (207)(208). Downstream of DVL, the Wnt pathway 
diverges into at least three branches: the canonical or Wnt/p-catenin pathway, the planar 
cell polarity (PCP) pathway and the Wnt/Calcium pathway. Evidence is emerging that these 
main pathways also bifurcate leading to a daunting array of signaling branches in response 
to Wnt ligands (209)(210).
In the canonical pathway (see fig 8a), Wnts control early cell fate decisions through 
the regulation of gene expression by inducing p-catenin-mediated transcriptional activation. 
Activated DVL induces the disassembly of a complex consisting of Axin, adenomatosis 
polysis coli (APC), glycogen synthase kinase 3p (GSK3p) and p-catenin. In the absence of 
Wnts, GSK3p phosphorylates P-catenin, which targets it for degradation via the 
proteosome. Wnt binding to FZD receptors results in GSK3p inhibition, which leads to an 
increase in the levels of p-catenin in the cytoplasm. P-catenin then translocates to the 
nucleus and forms a complex with the T-cell specific transcription factor (TCF). This p- 
catenin/TCF complex than activates the transcription of target genes (211).
The interaction of the FZD proteins with their co-receptors, low-density lipoprotein 
receptor-related protein 5 (LRP5) and LRP6, which are proteins containing a single 
transmembrane domain, is specifically required for signaling through the canonical 
pathway (212).
Complex regulation of LRP5 and LRP6 occurs at the cell surface that can modulate 
Wnt signaling through the canonical pathway. For example, LRP5/6 can interact with
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Dickkopf 1 (DKK1), a secreted Wnt antagonist (213X214) which prevents the formation of 
the ternary complex between Wnt, FZD and LRP, and consequently, activation of the 
canonical pathway (215)(216)(217). Another level of control is achieved through the 
interaction of DKK1 with the kringle-containing transmembrane protein 1 (kremenl) and 
kremen2 (218). Binding of DKK1 to kremenl or kremen2 results in the removal of the 
DKK-LRP complex from the membrane and inhibition of the canonical pathway (218). 
LRP5/6 can also activate the canonical pathway by binding to the intracellular axis 
inhibitor Axin, and inducing its degradation (213X219).
The second branch of the Wnt pathway is known as PCP pathway (see fig 8b) 
(220). This pathway controls the orthogonal polarity of cells within an epithelium (221), the 
convergent extension movements during gastrulation (222) and the orientation of cochlear 
cells in the inner ear (223).
In Drosophila melanogaster, activated FZD signals to DVL, which, in turn, 
activates the small GTPase RhoA and c-Jun amino (N)-terminal kinase (JNK) (221).
In vertebrates, DVL can signal through both Rho and Racl (another small GTPase) 
to regulate convergent extension movements during gastrulation (224). This role for the 
Rho GTPases and JNK pathways indicates that both the actin cytoskeleton and 
microtubules are likely to be affected by activation of the PCP pathway. However, it should 
be noted that despite its name, in some cases the PCP pathway may affect cell behavior 
without changing cell polarity (203).
The third branch of the Wnt pathway is the Wnt/Calcium pathway (see fig 8c). The 
Wnt/Calcium pathway induces a ventral fate while it antagonizes a dorsal fate in early 
Xenopus laevis embryos (225). This pathway also regulates cell movement during 
gastrulation and heart development (226X227). Binding of specific Wnts to FZD receptors 
leads to DVL activation which induces calcium influx, activation of protein kinase C (PKC) 
and calcium/calmodulin dependent protein kinase II (CaMKII) (226)(227)(228). The role of 
this pathway in other developmental systems is yet to be established.
More recently, novel components of the Wnt pathway have been described. Seven- 
pass transmembrane receptors usually signal through trimeric G proteins (a family of 
proteins involved in second messenger cascades). They are so-called because of their 
signaling mechanism which uses the exchange of guanosine diphosphate (GDP) for
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guanosine triphosphate (GTP) as a general molecular “switch” function to regulate cell 
processes) (229)(230). Pharmacological and overexpression studies have indicated that G 
proteins are involved in Wnt signaling (231)(229). Recent loss-of-function studies also 
showed a clear role for G proteins in Wnt signaling. Furthermore, studies in Drosophila 
melanogaster have shown that G proteins are required for the canonical and PCP pathways 
(230). These new findings indicate that G proteins are likely to have a crucial role in Wnt- 
FZD signaling in vertebrates (for detailed reviews on Wnt signaling see (232)(233)(234).
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Figure 9: The three main branches of the Wnt signaling pathway. (235)
1.5.3 Wnt signaling in neuronal development
In recent years it has emerged that Wnt proteins are key regulators in
embryogenesis and, in particular, during CNS development.
In mammals, the role of canonical Wnt signaling in developmental processes has 
been investigated principally by knocking down individual Wnt genes, FZD receptors or 
LRP co-receptors. Results from these studies have shown that Wnt signaling plays an 
important role during nervous system development. W ntl^' mice have a significant loss of 
neurons in the cerebellum and midbrain (235). Furthermore, in support o f these findings, 
Wnts have been shown to be crucial for the development o f midbrain dopaminergic
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neurons (236). Further studies have supported these initial findings as Wnt3a'A mice display 
significant reductions in neural crest derivatives and a loss of hippocampal neurons 
(237)(238). Hall and colleagues (2000) showed that Wnt7a"/_ have a delayed maturation of 
synapses in the cerebellum (239). This conclusion was supported by a subsequent study by 
Hirabayashi and colleagues (2004) suggesting that Wnt7a may promote neural 
differentiation (240).
Mice lacking various FZD genes also show selective defects in CNS development. 
Mice lacking FZD3 showed defects in fibre tracts in the rostral CNS (241). Furthermore, a 
role for FZD3 in the anterior posterior guidance of commissural axons has been shown 
(242). Mice lacking FZD4 display cerebellar defects (243).
Amongst the downstream Wnt signaling components whose function has been 
addressed in vivo, is the T cell factor/lymphocyte enhancer factor 1 (TCF-LEF1) complex. 
LEF1 is expressed in the developing hippocampus, and LEF1"A embryos lack dentate gyrus 
granule cells but do contain glial cells and intemeurons of the dentate gyrus (244).
Aside from a role in CNS formation and patterning, important roles for canonical 
Wnt signaling have been described at a cellular level. These include control of neural 
precursor cell proliferation and differentiation in the cortex and midbrain 
(245)(246)(236X240) axonal/synaptic maturation in the cerebellum (247)(239)(248) and 
synaptic function/plasticity in hippocampal neurons (249).
Constitutively active Wnt signaling can be mimicked by overexpressing a stabilized 
form of p-catenin, that cannot be degraded. Using this approach, the effects of constitutive 
Wnt signaling in neuronal precursors and in differentiated, mature neurons could be 
addressed. Overexpression of a stabilized form of P-catenin from the nestin promoter (a 
neuronal stem-cell specific promoter) demonstrated a role for canonical Wnt signaling in 
the proliferation of the cortical NPC pool (245). Conversely, stimulation of canonical Wnt 
signaling by overexpressing either a stabilized for of p-catenin or Wnt7a in maturing NPCs 
promotes the differentiation process (246)(240).
These data indicate that Wnt signaling can promote NPC self-renewal or NPC 
differentiation depending on the stage of maturation of neuronal precursors. In fully 
differentiated, mature neurons constitutively active Wnt signaling does not result in 
detectable abnormalities (250). In the cerebellum, Wnt signaling can promote axonal
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remodeling and synaptic differentiation (247X251)(239), with Wnt7a being proposed as a 
synaptogenic factor (251). The recently acknowledged importance of p-catenin as a 
modulator of synaptic strength in response to depolarization (249) has paved the way for an 
understanding of the role of Wnt signaling in neuronal plasticity, which is thought to be 
instrumental in higher brain functions such as memory and cognition. Thought this role of 
p-catenin in neuronal plasticity is closely associated with its role in cell to cell adhesion, 
there is evidence that the pool of P-catenin involved in neuronal plasticity is also controlled 
by Wnt signaling (252X249X253). Indeed, it has been shown that activation of the 
canonical Wnt signaling pathway causes membrane depolarization in neurons (249) 
suggesting that Wnts play a role in the function and plasticity of mature, differentiated 
neurons. Additionally, evidence exists that one outcome of canonical Wnt signaling is the 
stabilization of axonal microtubules (254), an event which would be consistent with the role 
of Wnts in the modulation of neuronal plasticity. Accumulating evidence therefore points to 
canonical Wnt signaling as a key player in the development and patterning of the CNS and 
in NPCs proliferation, in their differentiation and in the maturation, homeostasis and 
function in mature neurons.
Although it is clear that Wnt signaling plays as important role during the normal 
development of the nervous system, it has also been shown that deregulation of Wnt 
signaling can be associated with pathological brain conditions, such as Alzheimer’s disease.
The processing of the amyloid precursor protein (APP), the precursor of the 
amyloid p (AP) peptide involved in Alzheimer’s disease, can be modulated by Wnt 
signaling (255). Evidence also exists that implicates deregulation of canonical Wnt 
signaling in the ontogeny of many CNS tumors and of neurodegenerative diseases. LiCl has 
been well characterized as an agent capable of mimicking Wnt activity (256)(257). In fact 
one of the earliest, albeit indirect, pieces of evidence implicating Wnt signaling in neuronal 
degeneration comes from the neuroprotective activity of LiCl in virtually all models of 
neurodegeneration in vitro and in vivo (258). Although the effects of LiCl are complex and 
are not limited to inhibition of GSK3P activity (258), recent evidence indicates that at least 
a component of LiCl’s neuroprotective effects is mediated through inhibition of GSK3p 
and consequent activation of the canonical Wnt pathway by p-catenin stabilization 
(259)(260). One proposed theory is that neurodegeneration is associated with decreased
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Wnt signaling (261)(262). Support for this theory came when it was shown that 
overexpression of GSK3p caused neurodegeneration and neuronal death, both in vivo and 
in vitro (263)(264)(261). Furthermore, the neuroprotective effects of LiCl could be 
reproduced by addition of Wnt to the culture medium. For example Wnts protect against 
Ap-mediated neurotoxicity, which is used as a model of neurodegenerative events 
occurring in AD (265X266)(267).
The observation that constitutive activation of Wnt signaling in NPCs or in mature 
neurons is not per se sufficient to result in tumor formation, supports the notion that 
multiple mutagenic events are required to induce oncogenic transformation of CNS cells. 
The Wnt family members can be subdivided into three distinct groups based on their 
“transforming ability”: the high transforming, the intermediately transforming and those 
that fail to induce transformation (268X269). The initial theory that Wnts were only 
tumorigenic is no longer true as it has been reported that some Wnts are able to act as 
tumors suppressors or affect the signaling of others, dependent on the cell type. Liang 
(2003) showed that Wnt5a acts as a tumor suppressor, as Wnt5a*A mice develop lymphoid 
malignancies (270). However data exist which contradict this claims, Weeraratna (2002) 
showed that increased Wnt5a expression increased the motility and invasion of melanoma 
cells and was correlated to higher grade tumors (271).
Howng and colleagues (2002) analyzed the expression of a panel of four Wnt genes 
{wntl, wnt5a, wnt 10 and wntl3) in a subset of brain tumor samples (from astrocytic tumors, 
meningiomata and adenomata). Wntl was described as a highly transforming member. 
Wnt5a was associated with different processes: proliferation of breast tumor cells, motility 
and invasion of melanoma cells, a negative regulator of Wntl or as a tumor suppressor. 
Wnt 10b and Wnt 13 (or Wnt2b) were suggested to direct cell-growth regulation during 
development. The outcome of the study showed that Wnt5a, Wnt 10b and Wnt 13 were 
found in most brain tumors and Wntl was shown only in few (4/45). Wnt expression 
pattern analysis of some brain tumor cell lines showed increased Wnt 14 (or Wnt9a) and 
Wnt 10a mRNA levels (272X273). Wnt8a and Wnt8b mRNAs were undetectable in brain 
tumor cell lines, but present in NT2 cells of cells were not differentiated into neuronal cells, 
suggesting that Wnt8a and Wnt8b might play key roles in embryonic tumor development 
(274).
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1.5.4 Conclusions
Although much is known regarding function of Wnts and Wnt signaling during the 
development of the CNS, we know very little about their roles during the development of 
the PNS. The roles of Wnt signaling in neuronal survival and neurite growth in the CNS 
suggests that Wnt might possibly play roles in the development of the PNS. However, in 
order to identify which Wnts and cognate receptors that are relevant, I carried out screens to 
identify components of the Wnt family that are expressed in developing sensory and 
sympathetic ganglia of the PNS, in order to begin understanding these signaling pathways 
during PNS development.
1.6 Transforming growth factor p (TGFP) superfamily
The transforming growth factor p (TGFp) family of cell signaling active
polypeptides have attracted much attention because their ability to control cellular functions 
that regulate embryo development and tissues homeostasis from nematodes to mammals 
(for reviews see, (275X276). For example, in the same healing wound TGFp may stimulate 
or inhibit cell proliferation depending on whether the target is a fibroblast or a keratinocyte 
(277). In mammary epithelial cells TGFp will cause arrest or metastatic behavior depending 
on the level of oncogenic Ras activity present in the cell (278).
As a founder member of the TGFp superfamily, TGFp was initially discovered in 
the medium of transformed mouse fibroblasts (279)(280), where it inhibits tumor 
formation. Subsequent studies have shown that TGFp is a tumor suppressor and a potent 
inhibitor of cell proliferation (for review see (281). These studies have shown that TGFp 
may have potential as a therapeutic agent for cancer therapy (for reviews see 
(281)(282)(283).
1.6.1 Prototype of the TGFp precursor
The TGFp superfamily is divided into subfamilies based on sequence similarities.
These subfamilies include the TGFps (type 1-3), the bone morphogenetic proteins (BMPs), 
the growth differentiation factors (GDFs), the Nodals, the Activins, the Anti-Mullerian
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hormone, and may other structurally related factors in vertebrates, insects and nematodes 
(276).
Despite the diversity of TGFp members in the animal kingdom all members if the 
TGFp superfamily are structurally related. TGFp family members signal by binding to two 
types of serine-threonine kinase receptors, type I and type II receptors (284)(285). Upon 
ligand binding, a tetrameric complex is formed, consisting of two type I and two type II 
receptors: this induces phosphorylation of the cytoplasmic domain of the type I receptor by 
the type II receptor. This activates an intracellular signaling cascade which culminates in 
the activation of Smad proteins, causing them to translocate into the nucleus and affect 
transcription (286). BMPs can signal through any of several type II receptors and either of 
two type I receptors, BMPR-Ia or BMPR-Ib (287)(288).
1.6.2 Diversity of ligands
The TGFp superfamily includes a large variety of multifunctional locally acting
polypeptides. Until 2004, no less than 45 members have been identified in humans and 
most of them appear to have orthologous representatives in the vertebrate lineage. The 
initial discovery that the decapentaplegic (Dpp) locus in Drosophila melanogaster harbors 
a gene encoding a protein exhibiting significant sequence homology with vertebrate TGFP 
members indicates of an early origin of this superfamily within the animal kingdom 
(289)(290).
The genes that encode the BMPs and the Vg-related proteins are mammalian 
members of a group of TGFp-related genes, designated the DVR family, that includes the 
Dpp gene of D. melanogaster and Vgl gene of X  .laevis. Members of the DVR 
(decapentaplegic-Vg-related) family have been implicated in diverse processes during 
development, particularly in epithelial-mesenchymal interactions (291)
1.63 The DVR subfamily
The largest subfamily of the TGFp superfamily is the DVR subfamily of related
proteins. The DVR subfamily is made up of BMPs and growth differentiation factors 
(GDFs). These proteins play a crucial role during developmental organogenesis in
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delivering positional information in both vertebrates and invertebrates. They are also 
involved in the development of hard as well as soft tissue (290).
1.6.3.1 Bone morphogenetic proteins
The BMP ligands are subdivided into groups, based on their structural homologies.
Thus, BMP2 and BMP4 belong to the Dpp subgroup; BMP5, BMP6 and BMP7 belong to 
the 60A subgroup.
Although initially discovered for their ability to induce bone formation, BMPs have 
been found to play diverse roles in the development of many tissues, including the nervous 
system (292X293), heart (294X295), gut (296)(297) and kidney (298)(299). They are 
members of the TGFp superfamily except for BMP1, which does not have the C terminal 
sequence of the TGFp superfamily (276)
In the nervous system, BMPs act at different stages of neural development and in 
different regions of the CNS to regulate cell fate, proliferation and differentiation (287). 
The first involvement of BMPs in the development of the CNS is in mediating an early 
embryonic cell fate decision that determines whether cells will form neural or non-neural 
ectoderm. The CNS initially develops from the dorsomedial region of the embryonic 
ectoderm, a process that requires the active expression of BMP signals. Experiments in frog 
embryos provided the first clues to the role of BMPs in this fate decision. The dorsal side of 
the frog embryo normally becomes neural tissue, whereas the ventral side forms ventral 
tissues, such as the body wall and blood. Classic experiments by Spemann and Mangold 
showed that transplantation of tissue from the dorsal side of the early embryo to the ventral 
side caused the formation of neural tissue and suppression of non-neural fates (300)(301). 
Genetic studies in zebrafish and mice also highlight the importance of BMP signaling in 
ventral tissue formation (blood and central body wall/gut) and the suppression of BMP 
signaling by endogenous antagonists in the formation of neural tissue. Although the single 
knockouts of noggin and chordin do not produce a phenotype that is revealing in terms of 
the neural/ectodermal fate decision, mutations in both genes lead to the loss of anterior 
head structures (302). It is speculated that the loss of head structures is due to the loss of 
this early inductive event. Molecular embryology and genetic experiments therefore
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provide convincing evidence for a contest between BMP and their antagonists in the 
induction of neural versus ectodermal fate (301).
Once neural induction has been completed, BMPs can influence cell fate decisions 
within the CNS. It has been shown that BMPs cause apoptosis in early CNS precursor cells 
(303), neural differentiation in midgestation CNS precursors (304)(305), and glial 
differentiation in late embryonic or adult CNS precursors (306).
TGFp and BMP signaling has been implicated in retinal neurogenesis, RGC 
differentiation, and axonal pathfinding. The BMP receptor BMPR-Ib/Alk6 is preferentially 
expressed in ventral retina during embryonic development and is required for normal axon 
pathfinding of ventral RGCs at the optic nerve head (307). Lonn and colleagues (2005) has 
shown that stimulating PC 12 cells with NGF plus BMP4 substantially increases neurite 
outgrowth compared to NGF alone (308).
Previous studies have shown that BMPs do not affect the sustained NGF-induced 
phosphorylation of ERK1/2 (309), considered to be a prerequisite for neural differentiation 
(194). A remaining question is where the NGF and BMP activated pathways converge to 
enhance neuronal differentiation and neurite outgrowth. An obvious possibility is that these 
parallel pathways cooperate to regulate transcription of effector genes participating in the 
differentiation process (308).
1.6.3.2 The growth differentiation factors
The growth differentiation factors (GDFs) are a subfamily of the highly conserved
class of BMP molecules known to play a variety of roles in the musculoskeletal system. As 
discussed by Storm (2004), molecules in any given BMP subfamily share 74-92% of their 
mature C-terminal signaling region amino acid sequence, whereas members of different 
subfamilies share only 40-60%. On the basis of their high degree of homology in the 
signaling domains of GDF5, 6 and 7 (80-86% identity with the exception of the glycine- 
rich sequence of 26 amino acids in GDF7), these three molecules have been grouped 
together in their own subclass within BMP family (310).
Members of the BMP and GDF subfamilies play critical roles in skeletal 
development (311). GDF5 (also known as cartilage-derived morphogenetic protein 1 or
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BMP 14) is one of these molecules that has received particular interest, because naturally 
occurring mutations in the mouse and humans gdfi gene results in defects in the 
appendicular skeleton. Heterozygous mutations in the gdfi gene cause brachydactyly type 
C (312), characterized by underdevelopment or absence of the phalanges and metacarpals. 
Homozygous mutations in gdfi result in more severe conditions known as brachypodism in 
mice (310) and the chondrodysplasias Grebe type I (CGT) and Hunter-Thompson type 
(CHTT) in Humans (313)(314). These conditions are characterized by pronounced 
shortening of the skeletal elements, with more severe effects distally and the loss of one or 
more joints. Interestingly, although no functional GDF5 protein is made in CGT and CHTT 
patients, no neurological impairments have yet been reported in these patients.
In the developing chick limb, GDF5 is expressed in the condensing mesenchyme of 
cartilage elements prior to joint formation and within the developing joint capsule at a later 
stage (310)(315). GDF5 has been found to be involved in the development of skeletal 
elements, in part by accelerating the initial steps of chondrogenesis by increasing cell 
adhesion, and later in control of chondrocyte proliferation and differentiation 
(316)(317)(318X319). GDF5 signals through the BMPR-Ib receptor to induce 
mesenchymal condensation, but other receptors are necessary for its role in differentiation 
and proliferation of chondrocytes. It has recently been reported that GDF5-induced 
chondrogenesis depends on the receptor Ror2, a tyrosine kinase receptor (320).
GDF5 has also been shown to play roles in tendon and ligament formation (321) 
(322), tooth formation (323), morphogenesis of joints (324) and angiogenesis (325). One 
potential clinical application of GDF5 may be to improve the healing of articular cartilage, 
which heals poorly following damage caused by, for example, arthritis (326).
1.6.4 TGFp superfamily receptors
The TGFp superfamily of ligands binds to and initiate signal transduction through a
family of transmembrane serine/threonine kinases -  the TGFp receptor superfamily (327). 
Based on their structural and functional properties, the TGFp receptor family is divided into 
two subfamilies consisting of type I and type II receptors. These receptors cluster separately 
in two distinct polyphyletic groups. Type I receptors form a group that is related to, but 
excludes type II, and vice-versa. Within each sub-group, receptors are clustered according
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to the type of ligand they bind to. Thus, by implication, type I and type II receptors are 
divided in three categories: binding Activins, BMP and TGFp (290).
1.6.4.1 Type I receptors
Type I receptors are not crucial in determining pathway-specificity in regard to
ligands. Their affinity for ligand is usually relatively weak and lacks specificity. While type 
I receptors specifically bind ligand bound type II they also easily form 
heterotetracomplexes in which different subtype I receptors can aggregate together 
(328)(329)(330).
There are seven type I receptors designated as activin receptor-like kinases (Aiks) 
(331). They include the type I receptors to TGFp (Alk5 and Alkl), Activins (Alk4), several 
BMPs/GDFs (Alk3, Alk6 and Alk2) and Nodal (Alk7) (332)(333)(334).
1.6.4.2 Ligand specific type II receptors
The specificity of the response by TGFp superfamily of ligands is determined by
their specific binding to type II receptors. In mammals five type II receptors have been 
identified(286), including activin type II and type IIB (ActR2 and ActR2b, respectively) 
receptors, BMP type II receptor and AMH type II receptor (290).
The serine/threonine kinase domains of type II receptors is constitutively active and 
phosphorylate Gly-Ser (GS) domains in the type I receptors upon ligand binding leading to 
the activation of the type I receptor kinases (335).
During BMP signaling, ligand binding results in a hetero-multimer formation 
between type I and type II BMP receptors (336). Within the hetero-multimer, type II 
receptors then phosphorylate type I in a Gly/Ser rich domain located immediately upstream 
of the kinase domain. This phosphorylation leads to activation of the kinase activity of type 
I receptors and allows them to phosphorylate downstream targets such as Smads 
(336)(337).
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1.6.5 The Smads
The activated type I receptor signals to a subset of intracellular protein mediators: 
the Smad family. Smad family members were originally identified through genetic screen 
on flies (mad drosophila mutants) and worms (sma caenorhabditis mutants). Subsequently, 
the family quickly increased to include eight mammalian orthologous counterparts, now 
known as the Smads (290).
After ligands and receptors, the central importance o f these major components of 
the TGFp superfamily signaling pathway is to convert and integrate the type I receptor 
phosphorylation state into gene expression and regulation (290).
O f the eight Smad proteins identified in mammals, Smadl, Smad5 and Smad8 are 
receptor-regulated Smads (R-Smads) activated by BMP type I receptors (BR-Smads) 
whereas Smad2 and Smad3 are activated by activin and TGFp type I receptors (AR- 
Smads). Smad4 is the only common-partner Smad (co-Smad) in mammals that is shared by 
both BMP and TGFp activin signaling pathways. Smad6 and Smad7 function as inhibitory 
Smads (I-Smads) (335).
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Figure 10: BMP signaling through Smad proteins. (335)
39
1.7 The tumor necrosis factor (TNF) superfamily
The term “tumor necrosis factor” was coined when it was shown that tumor masses
which became contaminated by bacterial infection would, on occasion regress and 
disappear. It was thought that the bacteria were releasing a factor which made the tumor 
cells undergo necrosis and die. This factor was termed “tumor necrosis factor” or TNF 
(338). It was not until more recent advances in immunology that it became clear that 
antigens from the bacterial invader caused the release of the patient’s own TNF, which then 
caused tumor regression. The hunt was on to isolate and purify this TNF, in the hope that it 
could be used as a “magic therapy” to control cancer growth and persistence. Furthermore, 
the isolation of this TNF would also provide insight into understanding the ways a cell dies. 
The first TNFs to be identified were TNF-a and lymphotoxin (LT). It was discovered that 
TNF and LT were secreted from macrophages and lymphocytes and were capable of lysing 
many cell types, including some tumor cells (339)(340).
Today, the TNF superfamily is a large family of related ligands which activate 
signaling pathways important to cell survival, death and differentiation. They orchestrate 
the development, organization and homeostasis of lymphoid, mammary, neuronal and 
ectodermal tissues.
Members of the TNF family are either membrane-bound or secreted from the cells 
in which they are produced. These ligands bind to specific cell surface receptors known as 
tumor necrosis factor superfamily receptors (TNFRs). Over 40 distinct ligand-receptor 
systems have been identified. Indeed the size of the family has grown to such an extent that 
a portrait of the family must be presented as a composite (see below). The active 
investigation of these cytokines and their discovery by different groups has created a 
nomenclature nightmare, although the introduction of a numeric system to help standardize 
gene names has helped, especially in tracking TNF genes in the genome. Nonetheless, the 
use of more common acronyms continues (341).
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Figure 11: The TNF superfamily. (341)
1.7.1 TNF ligands
Biochemically isolated in 1984, TNF has since been found to be a pleiotropic 
cytokine produced mostly by activated macrophages and monocytes, but also by many
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other cell types including B lymphocytes, T lymphocytes and fibroblasts (342). TNF has 
also been referred to as TNF-a, cachectin or differentiation inducing factor (DIF) (343). It 
is the founder member if a superfamily of nearly 20 different homologues including TNF- 
p/lymphotoxin-a, lymphotoxin-p and other more specific ligands (such as RANKL and 
TRAIL which are involved more particularly in bone tissue and lymphocyte processes) 
(344). Almost all of the TNF ligands are expressed by cells of the immune system, 
including B cells, T cells, NK cells, monocytes and dendritic cells. The only exception is 
VEGI, which is expressed in other kinds of tissue, like cardiac and hepatic tissue.
All members of the TNF superfamily are type I transmembrane bound proteins 
(343). However, they are also form non-covalently-bound homo-trimers which are capable 
of becoming a secreted form. As such, cell-cell contact allows the transfer of signaling 
information between neighboring cells in a local area, but cleavage of TNF ligands into 
their soluble forms may allow more dispersed cytokine effects. As well as causing necrotic 
cell death, TNF-a also causes apoptotic cell death, cellular proliferation, differentiation, 
inflammation, tumourigenesis, and viral replication. The primary physiological TNF role is 
in the regulation of immune cells, but it is known to be heavily involved in pathological 
conditions such as rheumatoid arthritis, asthma, septic shock, irritable bowel disorder, 
hemorrhagic fever and cachexia (345).
Up until 2003, 19 ligands were identified as belonging to the TNF superfamily. 
Unlike TNF-a and Lymphotoxin, the ligands for Fas (CD95), CD27, CD30, CD40, 4-IBB, 
0X40 and herpes virus entry mediator (HVEM) were identified and cloned not by protein 
sequence, but by direct expression-cloning strategies (346X347). The description of the 
amino acid sequences of several ligands and receptors of the superfamily led to the 
identification of certain regions of homology conserved between members. Instead of an 
expression-cloning strategy, the availability of Human genome sequences permited 
homology searches using conserved regions to identify several additional members of the 
TNF superfamily. TNF-related apoptosis-inducing ligand (TRAIL) also known as AP02L, 
was identified independently by two different groups, followed by the identification of 
receptor activator of nuclear factor-kB (NF-kB) ligand (RANKL), also known as TRANCE 
(TNF-related activation-induced cytokine) pr osteoprotegerin ligand (OPGL) (348)(349), 
vascular endothelial cell-growth inhibitor (VEGI) also known as TLIA (350)(351), and B-
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cell-activator factor (BAFF) (347X352) also known as p-lymphocyte stimulator (BLYS), 
all by similar approaches. In many cases, because numerous groups discovered the same 
cytokine independently and simultaneously, numerous names exist for each TNF family 
member.
An intriguing feature of TNF superfamily ligands is that when certain ligands are 
secreted, they inhibit the function of the ligand-receptor complex. For example, whereas the 
membrane-bound CD95 ligand (CD95L) kills Human peripheral-blood T cells, soluble 
CD95L inhibits this killing effect (353). The fact that some soluble ligands act as agonists 
whereas others act as antagonists is intriguing. Furthermore, the transmembrane expression 
of most of the TNF superfamily members indicated that they are meant to act locally. Only 
under non-physiological conditions, when these ligands are released, do they prove 
harmful. Perhaps the best example is TNF-a, which when released binds to various cell 
types to mediate various diseases, such as brain ischemia (354), and steatohepatitis (a type 
of liver disease) (355).
1.7.2 TNF receptors
The TNFRs are an ever increasingly superfamily of proteins that consist of at least
41 members characterized by their extracellular sequence homology. The TNFRs are 
expressed by a wide variety of cells. For example, no cell type in the body as yet been 
found that does no express TNFR1 (also known as p55TNFR, p60, CD120a, TNFRSFla), 
whereas TNFR2 (also known as p75TNFR, p80, CD 120b, TNFRSFlb) is mainly expressed 
in endothelial cells and cells of the immune system (356)(357).
The more well known members of the TNFR family include the TNF receptors 
(TNFR1 and TNFR2), Fas, CD40, the low-affinity nerve growth factor receptor p75, 
TRAIL receptors, RANK and death decoy receptors (344)(358). Many of these receptors 
are known by multiple names and are activated by specific ligands. TNF-a only binds two 
of these receptors, TNFR1 and TNFR2. TNF-a achieves all its different physiological and 
pathological effects by its binding to TNFR1 and TNFR2 (359). Both, TNFR1 and TNFR2 
contain an extracellular pre-ligand-binding assembly domain (PLAD) that pre-complexes 
receptors and encourages them to trimerize particularly upon activation by TNF ligand 
(360). The PLAD region is required for the assembly of TNFR complexes that bind TNF
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and mediate signaling. Other members of the TNFR superfamily, including TRAIL 
receptor 1 (TRAILR1) and CD40, show similar homotypic associations. TNFRs and related 
receptors seem to function as preformed complexes rather than as individual receptor 
subunits that oligomerize after ligand binding (361).
In general, TNFR superfamily members are characterized by the presence of a 
cysteine-rich domain (CRD) in the extracellular portion. These include four decoy receptors 
known as DcRl, DcR2, DcR3 and OPG, which reduce the ligand signaling. The TNFR 
superfamily members are broadly classified in two groups: those containing a “death 
domain” in their C-terminus and those that do not The death domain is a region of 
approximately 80 amino acids residues first identified independently by two different 
groups in the cytoplasmic domain of CD95 and the TNFRs; their deletion abolishes ligand- 
induced apoptosis (361).
A number of conditions have been identified which shed light on the physiological 
role of some of these receptors. For example, mutations in the extracellular domain of 
TNFR1 have been shown to suppress the secretion of the receptor leading to a family of 
dominantly inherited autoinflammatory syndromes (359).
1.73 TNF and TNFR interactions and cell signaling
As the most extensively studied member of TNF superfamily, numerous
physiological roles have been assigned to TNF-a, perhaps because its receptors are 
expressed by all cell types. This fact might also account for the non-specific toxicity of 
TNF-a. Whereas most TNF superfamily ligands bind to a single receptor, others bind to 
more than one. For example, TRAIL binds to as many as five receptors (DR4, DR5, DcRl, 
DcR2 and OPG), whereas BAFF binds to three receptors: transmembrane activator and 
cyclophilin ligand interactor (TACI), B-cell maturation antigen (BCMA) and BAFFR. Why 
there are several receptors for the same ligand is unclear. Both homomeric and heteromeric 
complexes of DR4 and DR5 have been described leading to the recruitment of downstream 
cell signaling intermediates (356X357). In the case of TRAIL, although DR4 and DR5 
transduce most signals, DcR2 transduces partial signals only (362). Through sequestration 
of the ligand DcRl, DcR2, DcR3 and OPG have been shown to inhibit cell signaling. An
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OPG variant that has two death domains, but lacks a transmembrane domain, however, has 
also been shown to function as a ligand through as unknown receptor (363).
After binding to the receptor, members of the TNF superfamily mediate a variety of 
cellular responses including apoptosis (such as TNF, LT, CD95L, TRAIL, VEGI, TWEAK 
and LIGHT), survival (such as RANKL and BAFF), differentiation (such as TNF, RANKL 
and DR6) or proliferation (such as TNF, CD27L, CD30L, CD40L, OX40L, 4-1BBL, 
APRIL and BAFF) through the activation o f several signaling pathways involving NF-kB, 
JNK, p42/p44 MAPK and p38 MAPK. Signaling through TNF and CD95 has been a 
paradigm for most other members of the TNF superfamily. None o f the receptors of the 
mammalian TNF superfamily has any enzymatic activity. By using the yeast two-hybrid 
system for protein-protein interaction, co-precipitation and dominant negative approaches, 
several proteins that mediate TNF signaling have been identified (fig 11) (361).
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1.7.5 Structural and functional footprints of the TNF/TNFR superfamily
Recently, there has been great interest in understanding another aspect of TNFR1
signaling cross-talk, namely the relation between the activation of NF-kB and JNK 
pathways (364). For example, it has been documented for many years that inactivation of 
JNK in response to inflammatory stimuli, including IL-1, TNF and toll receptor ligands is 
transient. Until recently the mechanisms and functional significance of this were poorly 
understood. Nevertheless, previous studies of TNFR signals in RelA or IKKp deficient 
embryonic fibroblasts (MEFs) demonstrated prolonged activation of JNK when compared 
to that observed in wild type MEFs (365X366).
Several explanations were proposed, including the induction by NF-kB of XIAP 
and GADD45b which in turn negatively regulated kinase pathways upstream of JNK; 
according to this model, expression of these negative regulators would be absent in RelA or 
IKKp deficient cells. However, further analysis of cells deficient in XIAP and GADD45b 
failed to demonstrate anomalies of JNK activation (367)(368), and so alternative 
mechanisms were sought. Attempts to establish a relation between NF-kB activation and
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the activity of specific phosphatases which regulate MAPK activation, including JNK, 
proved to be more fruitful. Recent published data have demonstrated unambiguously that 
the missing link is the induction by TNF of reactive oxygen species (ROS) (369). In NF-kB 
deficient cells there is a massive accumulation of hydrogen peroxide, increased oxidative 
stress, and inactivation of phosphatases through oxidation of a critical cysteine residue in 
their catalytic domain. When taken in conjunction with the interactions between NF-kB and 
the caspase pathway, we can now begin to think of acute and chronic TNF responses as 
being rather distinct at biochemical level (370).
1.7.6 Conclusions
A bewildering array of proteins interact with TNF receptors. Whether this is the tip 
of the iceberg is unknown, but advances in molecular biology have driven our 
understanding of TNF accessible signaling pathways. There is no doubt much is still to be 
learnt about the molecular mechanisms of TNFR1 and TNFR2, with many advances 
coming from studies on related receptors and ligands. The signaling processes are vastly 
more complicated than was first imagined. Clearly, much has been learned about TNF 
receptors and their signal transduction patterns since the first published reviews just over a 
decade ago. This is due in part to technological improvements in research, but it has also 
been driven by the quest to understand how TNF and its related cytokines can signal for 
such a range of assorted cellular actions. It is intriguing how one ligand acting at two 
receptors can generate such a variety of cellular responses. It is probable that the TNF 
receptors to not always act in exactly the same way each time they are activated. The subtle 
differences in expression patterns of associated machinery and the modulation of the 
proteins it interacts with in its immediate environment, will account for much of the 
observed signaling diversity in different cell types and tissues.
1.8. NF-kB signaling
NF-kB was first described as a nuclear factor that, when activated by bacterial
lipopolysaccharides binds to the enhancer region of the gene encoding the k light chain of 
antibodies in B cells (371). Five NF-kB family members have been cloned and 
characterized, c-Rel, NFkBl (p50/pl05), NFkB2 (p52/pl00), RelA (p65) and RelB. All 
members of the NF-kB family contain a characteristic Rel homology domain (RHD)
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involved in DNA binding, dimerization and interaction with inhibitory proteins called IkB 
(372). All NF-kB proteins form either homo or hereodimers, NF-kB being the original 
name for the p50-p65 heterodimer, which is the most abundant form in the nervous system. 
NF-kB is widely expressed throughout the nervous system (373)(374)(375)(376)(377)(378) 
and has been implicated in plasticity, learning and memory, development and 
neurodegenerative disease. p65 is located distally in dendrites and basal synaptic input has 
been shown to stimulate retrograde transport of p65, in association with dynein/dynactin to 
the nucleus (379X380X381). The relationship between synaptic activity and nuclear 
translocation of p65 implies that NF-kB may be involved in synaptic plasticity. NF-kB 
signaling is also regulated during development and plays a role in proliferation and 
migration of early neurons (377X382)(383). NF-kB promotes the survival of cortical 
neurons, cerebellar granule cells and sympathetic and sensory neurons (164)(377)(384) 
(385)(386)(387). Inhibiting NF-kB decreased neurite growth and arborization in the 
neonatal somatosensory cortex and nodose ganglion (388). Increased NF-kB activity has 
been demonstrated in brain tissue from Alzheimer’s disease patients (389)(390)(391).
Recently, NF-kB signaling has been show to inhibit as well as promote neurite 
growth, depending on the phosphorylation status of the p65 subunit. Phosphorylation at 
serine 536 confers a profound neurite growth-inhibitory effect on activated NF-kB 
(Gutierrez et al., 2008).
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2. Material and methods
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2.1 Introduction
The research described in this thesis uses a variety of in vitro and in vivo protocols 
to analyze neuronal survival and axonal growth in wild-type and various transgenic 
animals. The in vitro protocols developed in this lab are well established, widely used and 
serve as a powerful tool to investigate the mechanisms of neuronal survival and neurite 
outgrowth. In certain cases, in vitro observations were substantiated by using in vivo 
quantification of neuronal number and target field innervation density.
2.2 Mouse maintenance
Animal rights were respected according to the regulations of the Home Office
Animals (Scientific Procedures) Act, ASPA, 1986.
Embryonic and postnatal wild-type mice were obtained from timed matings of CD1 mice. 
Adult CD1 mice were fed with rodent global diet pellets (Harlan) and given water ad 
libidum.
GDF57 mice were obtained from overnight matings of GDF5+/* mice (resulting 
from a mating between GDF5'7" and CD1). Breeding was confirmed by the presence of a 
vaginal plug and the period of gestation was considered to be embryonic day (E) 1. 
Animals were fed with rodent global diet pellets (Harlan) and given water ad libitum.
2.3 Preparation of dissection and culture media
2J.1 Dissection media (L-15)
In an autoclaved conical flask 1L of distilled water was added to 13.90g of L-15
powder (Gibco). The flask was placed on a magnetic stirrer to dissolve all the powder, and 
supplemented with penicillin (60mg/L) and streptomycin (lOOmg/mL). pH was adjusted to
7.2 -  7.4. The supplemented L-15 medium was then filter sterilized using a 0.2pm bottle 
top filter (Nalgene) and stored at 4°C.
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23.2 Washing media (F-12)
In an autoclaved conical flask 1L of distilled water was added to 10.63g of F-12
powder (Gibco). The flask was placed on a magnetic stirrer to dissolve all the powder, and
filter sterilized using a 0.2pm bottle top filter (Nalgene). 225ml of filtered media was
mixed with 25ml horse serum (Gibco) and supplemented with Penicillin (60mg/L) and
streptomycin (lOOmg/L). The media was re-filtered and stored at 4°C.
2 3 3  Culture media (F-14)
In an autoclaved bottle, 500mg of Sodium Hydrogen Carbonate was added to 250ml
of distilled water. The bottle was placed on a magnetic stirrer to dissolve all the powder, 
and 25ml were discarded and replaced with 10X stock F-14 (JRH Biosciences) solution 
previously supplemented with penicillin (60mg/l) and streptomycin (lOOmg/ml). To 
complete the media, 2.5ml of a 200mM glutamine (Gibco, Invitrogen) (2mM final) solution 
and 5.5ml of an Albumax I solution containing Albumax I (Gibco, Invitrogen), 
progesterone (60pg/ml), putrescine (16pg/ml), L-thyroxine (400ng/ml), sodium selenite 
(38ng/ml) and tri-iodothyronine (340ng/ml) (all Sigma) were added. Media was finally 
filter sterilized using a 0.2pm bottle top filter (Nalgene) and stored at 4°C.
2.4 Preparation of Tungsten needles
Two pieces of 0.5mm tungsten wire were placed in a needle holder (interfocus). The
top 3cm of the wire were bent to a 90° angle and electrolytically sharpened in 1M KOH 
with a 3-12 V AC current passed through the solution until de desired shape was obtained. 
Tungsten needles were sterilized using ethanol and a Bunsen burner flame before and after 
each use.
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2.5 Dissections
All instruments used for dissection were washed before use and flamed in 70% 
ethanol previous to use.
All dissections were carried out in a sterile environment inside a laminar flow unit which 
was previously wiped with 70% ethanol in order to prevent contamination.
2.5.1 Embryonic ages
Pregnant females were killed by carbon dioxide asphyxiation followed by cervical
dislocation at 13, 15, and 18 days of gestation. The female abdomen was swabbed with 
70% alcohol and then embryos were isolated by laparotomy and placed in a Petri dish 
(Greiner) containing L-15.
Embryos were carefully removed from the embryonic sac and placed in a new Petri dish 
(Greiner) containing fresh L-15 medium. The precise stage of development was determined 
by the criteria of Theiler (http://genex.hgu.mrc.ac.uk/Databases/Anatomy).
Dissection of the nodose, SCG and trigeminal ganglia was carried out using forceps and 
scissors (El5 and E l8) followed by tungsten needles to remove adherent connective tissue; 
or for younger ages (El3) tungsten needles were used for the whole dissection.
2.5.2 Post-natal mice
When post-natal mice pups were required, mice were sacrificed by CO2
asphyxiation followed by decapitation with a pair of sharp scissors.
Dissection of the peripheral ganglia was carried out using forceps and scissors followed by 
tungsten needles to remove adherent connective tissue.
2.6 RNA extraction
2.6.1 Background
Obtaining high quality, intact RNA is the first and often the most critical step in 
performing many fundamental molecular biology experiments, including, RT-PCR, in vitro 
translation and cDNA library construction. To be successful, however, the RNA isolation
52
procedure should include some important steps both before and after the actual RNA 
purification.
This technology combines the selective binding properties of a silica-based 
membrane with the speed of microspin technology. A specialized high-salt buffer system 
allows up to lOOpg of RNA longer than 200 bases to bind to the kit silica membrane. 
Samples are the first lysed and homogenized in the presence of a highly denaturating 
guanidine-thiocynate-containing buffer, which immediately inactivates RNases to ensure 
purification of intact RNA.
RNA stabilization is an absolute prerequisite for reliable gene expression analysis. 
Immediate stabilization of RNA in biological samples is necessary because, directly after 
harvesting the samples, changes in the gene expression pattern occur due to specific and 
nonspecific RNA degradation as well as to transcriptional induction. Such changes need to 
be avoided for all reliable quantitative gene expression analysis such as quantitative RT- 
PCR, such as TaqMan®, and other nucleic acid-based technologies.
2.6.2 Method
Total RNA from the unprocessed ganglia was extracted using RNeasy ® Kit 
(Qiagen) according to the manufacturer’s protocol. RNA concentration was measured 
spectrophotometrically. Briefly, Qiagen protocol involved dissociation of the ganglia in 
RLT buffer (provided in the kit) with 1% (3-mercaptoethanol through a 26gauge needle, 
washes in RW1 and RPE buffer (provided in the kit), DNase 1 incubation (Qiagen, UK) and 
elution in RNase-free water (provided in the kit).
2.7 Reverse Transcriptase
2.7.1 Background
The reverse transcriptase-polymerase chain reaction (RT-PCR) technique is a highly 
sensitive method for detecting and characterizing RNA molecules in small samples of cells 
or body fluids. It employs reverse transcription of the target RNA followed by PCR 
amplification of its cDNA. Widely used primers for cDNA synthesis are oligo (dT), 
random hexanucleotides or a sequence-specific antisense oligonucleotide primer.
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2.7.2 Method
The RNA was reverse transcribed for 1 hr at 37°C with StrataScript reverse 
transcriptase (Stratagene) in a 40 pi reaction containing the manufacturer’s buffer 
supplemented with 5mM dNTPs (Stratagene) and 10 pM random hexamers (Amersham).). 
cDNA was synthesized from 3pL of total RNA extracted from the peripheral ganglia at 
different stages, 4pL of Stratascript lOx buffer (Stratagene), 2pL of lOOmM dNTPs 
(Stratagene), 2pL of random hexamers (Amersham Biosciences), 28.6pL of distilled water 
and 0.38pL of RT enzyme (Stratagene), and kept at 37°C for 90minutes. After this 
incubation period, samples were stored at -20°C until required. Together with the reverse 
transcription reaction of the samples, a negative control was created. This negative control 
contained 4pl of distilled instead of RNA, and undergone the same conditions as the 
samples. This negative control is also used to create the standard curve for the real time 
PCR.
2.8 Real time PCR:
2.8.1 Background
PCR is a method that allows logarithmic amplification of short DNA sequences 
(usually 100 to 600 bases) within a longer double stranded DNA molecule. PCR entails the 
use of a pair of primers, each about 20 nucleotides in length that are complementary to a 
defined sequence on each of the two strands of the DNA. These primers are extended by a 
DNA polymerase so that a copy is made of the designated sequence. After making this 
copy, the same primers can be used again, not only to make another copy of the input DNA 
strand but also of the short copy made in the first round of synthesis. This leads to 
logarithmic amplification.
PCR is the most sensitive method and can discriminate closely related mRNAs. It is 
technically simple but, it is difficult to get truly quantitative results using conventional 
PCR. In contrast to regular reverse transcriptase-PCR and analysis by agarose gels, real­
time PCR gives quantitative results. An additional advantage of real-time PCR is the 
relative ease and convenience of use compared to some older methods.
The most accurate quantitative result from real time PCR is to compare the experimental 
sample with the reference gene. The reference gene is to be used as a loading control (or
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internal standard) and should have various features, such as: having the same copy number 
in all cells; be expressed in all cells, and have a medium copy number, to permit more 
accurate comparison. The reference gene used in this study was glyceraldehyde-3- 
phosphate dehydrogenase (GAPDH).
GAPDH is an enzyme that catalyzes the sixth step of glycolisis and thus serves to break 
down glucose for energy and carbon molecules.
The amount of DNA theoretically doubles with every cycle of PCR. After each 
cycle, the amount of DNA is twice what it was before, so after two cycles there is 2 X 2 
times as much, after 3 cycles - 2 X 2 X 2 times as much or 8 (23) times as much, after 4 
cycles 2 X 2 X 2 X 2 times as much or 16 times (24) as much. Thus, after N cycles we shall 
have 2n times the amount of starting template. As the reaction cannot go on forever, and it 
eventually tails off and reaches a plateau phase.
In most reactions the amplification in the earlier parts of the PCR cycles cannot be detected 
because the changes are too small. Eventually, in the last few cycles the experimental 
sample rises above the baseline being exponentially amplified until it reaches the plateu 
phase, when there is nothing left to be amplified.
In real-time PCR using SYBR green binding to amplified cDNA, we are simply 
measuring the fluorescence increase as the dye binds to the increasing amount of DNA in 
the reaction tube. We hope that this increase in fluorescence is coming from the DNA that 
we wish to measure but some of the signal could come from DNA other than that which we 
are trying to amplify. The way to make sure that the correct fragments were amplified is 
checking the products’ melting curve.
TaqMan real-time PCR is one of the two types of quantitative PCR methods. Unlike 
the SYBR Green method, TaqMan uses a fluorogenic probe which is a single stranded 
oligonucleotide of 20-26 nucleotides and is designed to bind only the DNA sequence 
between the two PCR primers. Therefore only specific PCR product can generate 
fluorescent signal in TaqMan PCR. To do TaqMan PCR, besides reagents required for 
regular PCR, additional things required are two PCR primers with a preferred product size 
of 50-150 bp, a probe with a fluorescent reporter or fluorophore such as 6- 
carboxyfluorescein (FAM) and tetrachlorofluorescin (TET) and quencher such as 
tetramethylrhodamine (TAMRA) covalently attached to its 5' and 3* ends, respectively.
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The standard curve for the real time PCR was prepared with E l5 limb cDNA which was 
synthesized using the same method for the samples as described on section 2.7. This 
standard curve consisted on consecutive dilutions from 1 to 1/64 which were diluted in a 
“blank” RT reaction mixture (see section 2.7 for details)
Each real-time PCR reaction was prepared using 2.5pL of cDNA, 2.5pL of Brilliant 
QPCR core buffer (Stratagene), 1.5pL of 3mM MgCb (Stratagene), 0.5pL of primers, 
0.4pL of (1/500) reference dye (Stratagene), 0.25 pL (1/1000) Sybr Green® (Invitrogen), 
lpL of 20mM dNTPs (Stratagene), 15.8pL of distilled water and 0.33 pL of Hot Taq® 
enzyme (Stratagene).
The following table shows the primer set for each gene and the respective annealing 
and melting temperatures.
Gene
FZD1
FZD2
FZD3
FZD4
FZD5
FZD6
FZD7
FZD9
LRP5
Primer
F
R
F
R
F
R
F
R
F
R
F
R
F
R
F
R
F
R
Locus
NM 021457
NM 020510
NM 021458
NM 008055
NM 022721
NM 008056
NM 008057
XM 284144
NM 008513
Sequence (5’ to 3 ’)
GCT GTC CCT GTG GCT TCC 
CGC TAT CGG TCG GTT ACT G 
TCA GAG GAC GGT TAT CGC 
CCA GGT GAG GGA CAG AAT C 
TTC TGA ACC ATT ATG ACC AAC 
ACG GGA CAC CAA ACA TCT C 
ATG TTA TCG GAG TTT GGT CTA 
GCA TTC TGG AGG TTC ATT AGG 
CAC ACC CAC TCT ACA ACA AG 
GGA GAT GAA GCA CAG CAC A 
GCT ACT TTG CGA CTG TGA TAG 
AAC CTA CCA TCT TAC CTG CTG 
TCG CTT CTA CCA CAG ACT CAG 
ACC TCC AAA TAA CTT CTC ACT 
TCC
GCT CTC TTC CAT ATC CGC AAA 
ATC
AGC AGA CAA TGA CGC AGG TG 
AGT TCT CAG CCC ATC CTT G 
CAC TCT GGT CAG CAC ACT C
Annealing Melting 
temperature temperature
54.8°C
52.2°C
52.6°C
50.4°C
56.3°C
52.1°C
55.9°C
53.5°C
57.2°C
90.6°C
87.8°C
89.0°C
84.9°C
93.5°C
87.0°C
91.5°C
87.4°C
94.5°C
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LRP6
Ryk
Kremenl
Kremen2
Dkk
Gene 
Aik 3 
Aik 6 
BMP II
GDF 5
Aik 7 
Aik 5
Aik 4
Aik 2 
Aik 1
F
R
F
R
F
R
F
R
F
R
NM 008514
NM 013649
NM 0323%
NM 028416
NM 010051
CTA CTC CCT GAA TGC TGA CAA C 
GCT GTG GAT AGG AAG GAT GAT G 
AAGTCC AAGGTT GAA TAT AAG C 
GAC CCG AAA CAC TGA TAA AG 
CAC ATA CAG ATC GGT TTC C 
GAT GAC ACA TGG TAG TTG G 
GCA TCT ATG AAG TGT CTG TGG 
GAA GGC ACG GAG TAG GTT G 
GGT GTG CTA CAT TGC CTT G 
CCG ACT ATT CCA TTT CTC CTT AC
53.5°C
50.3°C
52.5°C
56.2°C
48.3°C
88.3°C
85.7°C
89.4°C
93.0°C
81.7°C
Primer Locus Sequence (5* to 3*)
Annealing Melting 
temperature temperature
F
R
F
R
F
R
R
R
R
F
R
F
R
TGC TGT CAT CAT CTG TTG TC 
GGA AAT CTG CCC TGG AAT AG 
GCA TTA AAC ACC AGC AAA GC 
GCA CAT AGA AGG AAC AAG CC 
CGC TTG GAC TCA TCT ACT G 
TCT GCT TCT CTC TGG ACA C 
GAC ACT CAG ACT GAG GAG AAA  
GC
TCA ATG ACA CCA CAG AGA AAG 
GC
AAG AAG AAC CGT GCG AAG G 
AGT GGT GAA TGG AAC AGG ATA G 
GCA TCT GTC TAA GTG GAA ACG 
AAC
TTC AAG CAC ATC TGG GTA GGA G 
CCT GGC TGT GGG TGG TGA TTT G 
NM 007395 ACT GAA CTA TGT GCG TTT GAG
TCT GG
ACT GTT CAC ACC ACA AAG AC 
CGA AAG ATA CGC AGA GAG C 
GGT AGA GTG TGT GGG AAA GG 
CAG GAC TGC TCA TCT CGT G
NM 009758
NM 007560
NM 007561
NM 008109
XM 194020
NM 009370
NM 007394
NM 009612
49.0°C
51.4°C
50.7°C
57.8°C
48.7°C
50.1°C
51.1°C
53.3°C
53.4°C
81.8°C
86.2°C
86.0°C
92.8°C
81.8°C
82.8°C
82.4°C
89.2°C
88.7°C
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ActR2b
ActR2a
TGFpRII
Noggin
Gene
DR6
LTp-R
Light
TL1A
April
Tweak
LTp
BAFF
CD30
DR5
Fas
CD27
F TGA ACG ACT TTG TGG CTG TG
NM 007397 55.3°C
R “  CCC TTG AGG TAA TCC GTG AG
F TTG AGT CAC TTT AAC ATC CAT AC
NM 0073% 48.7°C
R ~ ACA GAG ACA ACG CAC AGT
F CGC CAA CAA CAT CAA CCA CAA C
AF4066755 56.5°C
R CCA CGG TCT CAA ACT GCT CTG
F CGA GAT CAA AGG GCT GGA G
NM 008711 57 .1°C
R “  AGA CTT GGA TGG CTT ACA CAC
Annealing
Primer Locus Sequence (5* to 3 ’)
temperature
F GAT TCC AAC TCT ACT GCC TGT G
AKO 43 823 51.2°C
R GGT CCT ATT AGT GCC TTC CTT C '
F CTG TCG CTG GTC CTC TTT CTG
U29173 56.9°C
R AAA TGT GGG TCG GCT CTT GG
F CCT TCA GTG TTT GTG GTG GAT GG
NM 019418 58.5°C
R “  GCG TTG GCT CCT GTA AGA TGT G
F CAA AGT GTC AGT CAT CAA ATC C
NM 177371 47.9°C
R -  ACT CCT TGT GGC ATC TAC C
F GGT GGT ATC TCG GGA AGG
NM 023517 51.1°C
R “  GCG GAG AAA GGC TAA GTT T
F CGC TAC GAC CGC CAG ATT G
NM 011614 51.8°C
R ~ GGT AGA CAG CCT TTC CCT CAT’
F CTA CAG GAG AGG GAA GAC C
NM 008518 51.9°C
R “  CGG ACA TCA CGA TTC ACA C
F GGG AAA GCC GTC AGC GAA AG
NM 033622 55.3°C
R “ AAG GTT GCG GTG CGT GTT G
F GAA GAA TAT GAC CTT GGA GC
NM 009401 53.7°C
R CCC GTG GAC AAT GGA GAG
F AGT AGT GCT GCT GAT TGG AG
BC065141 52.9°C
R TGT TGT GGT TAG AGT CAT TTG TC
F GAC TTC TAC TGC GAT TCT C
NM 007987 51.3°C
R ~ GCG ATT TCT GGG ACT TTG
F ATA GCC AGC GGT CAT CCC ATA G
XM 284241 53.5°C
R ~ GCA CCC AGG ACG AAG ATA AGA
91.4°C
83.0°C
91.4°C
94.0°C
Melting
temperature
85.1°C
92.4°C
93.8°C
81.4°C
86.4°C
85.6°C
87.5°C
89.5°C
90.7°C
88.1°C
87.7°C
86.8°C
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AAC
F TCT TCA TTA CTC TCC TGT TCT CTG
4-1BB NM 011612 51.8°C 86.3°C
R “  CTC ATA GCC TCC TCC TCC TC
F GCT TGG CGT TGA CTG TGT TC
0x40  X85214 55.1°C 89.9°C
R GGT GGC GGG TCT GCT TTC
F CCC TTG CCC TGA CCA CTC
OPG AF053713 55.3°C 90.7°C
R TAA CGC CCT TCC TCA CAC TC
F GTG ACA GAG GCT TGC GAC
TACI AF257673 56.2°C 92.6°C
R CGT GTA TCC CGA GCG AAC
F ATT GCC ATC GTT CCT GTC
RELT AK088621 54.8°C 92°C
R GCA TTC TCT TTC TTC TCT GTC
F GCA CCG CAG AAT CAG ACA C
CD40 M83312 53.7°C 88.4°C
R GCC ATC TCC ATA ACT CCA AAG C
CTG GAG AAG ATG CCG CCG
F
F nl4 AF156164 AGA ATG AAT GAA TGG ACG ACG 55.6°C 90.9°C
R
AG
F AGT TCC TTG TGG GAG ACG AG
HVEM AY264405 56.3°C 56.3°C
R CCG CAG GGC AGA CAC TTG
F TGA CCA GTT CAG TGA AAG G
BCMA NM 011608 51.6°C 87.1°C
R GGG TTC ATC TTC CTC AGC
F GAC AGC AAC ACC CAC AAA G
EDAR AF160502 54.2°C 90.1°C
R AGC GAC AGC AGA CAT AGC
F AAG ACA GTG GAG GAG GAT TC
XEDAR AK034909 50.8°C 85.7°C
R AGG ATG GAG TTA AGT GGT TTG
F TGT GTG CCC TGC GGA GAC
TROY AK083283 54°C 87.5°C
R GCT GGA GAC GGT GGA GGA G
F AAT CAT ACT CCT TCA ACT GTC
mSOB AY165625 50.7°C 86.7°C
R GCC ATT ATC TTT CCC TGT G
F CCT CCG CTC AAA GAA GAT G
BAFF-R Ak008142 56.1°C 86.8°C
R CCT CCA CTG CTG CTA TTG
F CCA GGT GCT TCT AGG AGT CG'
DR3 AF329969 55.5°C 90.8°C
R GCC AGT CTG TGG TGA GGC
F CCA GTC TGT GTC CTT CTA AC
TNF-a NM 013693 50°C 89.1°C
R CCT GAC CAC TCT CCC TTT G
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2.9 Cell culture
All in vitro work was carried out in a sterile laminar flow cabinet using strictly 
aseptic techniques. Every experiment was repeated at least 3 times with at least three 
separate dishes per experiment.
2.9.1 Preparation of dishes
Neurons were cultured on a laminin/poly-omithine substratum. Dishes were
prepared by adding 2ml of 500mg/L poly-DL-omithine (Sigma) / borate solution to 35mm 
tissue culture dishes (Greiner) and left overnight at room temperature. The poly-omithine 
solution was aspirated after 24 hours and the dishes were washed three times with sterile 
distilled water before being allowed to air dry in a laminar flow hood for 2 hours. 50 -  
150|il of a 20mg/ml solution of laminin (Sigma) in Hank’s Balance Salt Solution (HBSS) 
(Gibco, Invitrogen) was added to the centre of each dish. The dishes with laminin solution 
were then placed in an incubator at 37°C for 2 hours. After dissection and dissociation, 
neurons were plated onto the prepared dishes once the excess laminin had been removed by 
aspiration.
2.9.2 Dissection of the trigeminal, nodose and superior cervical ganglia
The trigeminal, nodose and superior cervical ganglia were removed from embryonic
or postnatal pups as follows, using standard sterile technique, in a laminar flow hood.
The top of the skull and underlying forebrain was removed and the head was cut in half 
along the sagittal plane. The jugular foramen was opened up by deflection of the occipital 
bone using watchmaker’s forceps, revealing the nodose and superior cervical ganglia at the 
mouth of the foramen. The nodose ganglion was identifiable due to its spherical appearance 
and prominent vagus nerve attached to its distal aspect (Davies book chapter). The SCG is a 
more elongated structure lying above the carotid artery, attached caudally to the 
sympathetic chain (Davies book chapter). The trigeminal ganglion was dissected from 
neonatal mice by removing the top of the skull and forebrain in a plane above the eyes and
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whisker pads. Trigeminal ganglia were found bilaterally on the base of the skull and 
identified by their elongated appearance.
2.93 Dissociation of the ganglia
After dissection, ganglia were added to 950pl HBSS (Gibco, Invitrogen) containing
50pl of 0.05% trypsin (Worthington). The trypsin-HBSS mixture was then incubated at 
37°C for a period of time suitable for that developmental stage as it follows:
Developmental age Time in 0.05% trypsin (min)
E13 5
E15 10
E18 20
P0 25
P5 30
The trypsin-HBSS mixture was then aspirated and the ganglia were washed twice 
with 10ml of F-12 (Gibco, Invitrogen) (see appendix A) to inactivate any residual trypsin. 
Ganglia were then gently triturated using a fire-polished siliconized glass pipette to provide 
a dissociated cell suspension.
After dissociation, a sample of lOpl was analyzed under the microscope in order to 
estimate the required numbers of neurons that would be plated. For low density cultures, an 
average of 100 to 300 cells was plated per 35mm dish. Neurons were grown in defined F- 
14 serum-free medium (see appendix A) in 35mm tissue culture dishes in the presence of 
either NGF (for SCG and trigeminal neurons) or BDNF (for nodose neurons) at 
concentrations ranging from O.Olng/ml to 1 OOng/ml where indicated. All exogenous factors 
were added at the time of plating.
2.9.4 Quantification of neuronal survival
To quantify the percentage neuronal survival under different experimental
conditions, a standard graticule for examining each culture dish was constructed from the
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base of a 900mm plastic Petri dish, where a scalpel blade was used to inscribe a 12 x 
12mm2 grid consisting of 36 squares each of 2mm2. The numbers of cells attached to the 
bottom of the culture dish were counted_2 hours after plating. The number of neurons 
surviving in this grid was counted again 24h (and in some cases 48h) later. The number of 
surviving neurons in the grid at these time points was expressed as a percentage of the 
initial count.
2.9.5 Quantification of neurite outgrowth
Twenty four hours after plating, 3pl of the vital dye Calcein AM (Invitrogen) were
added to each dish and incubated for 15min. This dye is up-taken by healthy cells and 
metabolised to a fluorescent dye, allowing visualisation of the cell soma and associated 
axonal architecture. Following this 15min incubation, the media containing calcein was 
removed and replaced with fresh F-14 medium. Greater than 40 images of individual 
neurons were taken using and inverted fluorescence microscope (Zeiss). For this, 
concentric digitally generated rings, 30 pm apart were centered on the cell soma, and the 
number of neurites intersecting each ring was counted (392)
2.10 Transfections
2.10.1 Plasmid preparation
Competent E. coli HI07 (Promega) cells was transferred from -80°C and thawed on
ice. To 100pi of these bacteria, 5 to 20ng of plasmid DNA was added in a volume of 1 to 
5pi and incubated on ice for 30min. Competent E. coli were heat shocked at 42°C for 30sec 
and returned to ice for 2min before adding 800pl LB broth (see appendix A). The bacteria 
were set shaking at 37°C at 200rpm for 45min. lOOpl of transformation reaction was 
subsequently spread onto selective LB/agar plates and incubated overnight at 42°C. The 
following day, a single colony was selected and added to 100ml LB media in a sterile bottle 
and incubated shaking overnight at 37°C at 200rpm in a shaking incubator. The following
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day, LB containing the bacteria was then centrifuged for lOmin at 6000rpm. Plasmid DNA 
was isolated from the resulting bacterial pellet using a plasmid midi kit (Qiagen) according 
to the manufacturer’s protocol. The concentration of plasmid DNA was then measured 
spectrophotometrically.
2.10.2 Preparation of the gold microcarriers for transfection
Ballistic transfection was carried out by shooting gold microcarriers coated with
plasmid DNA and YFP into dissociated neurons. Gold particle cartridges were prepared 
using the manufacturer’s protocol (Bio-rad). Briefly, 20mg of 1.6pm gold particles were 
suspended in lOOpl of 50mmol/l spermidine and 2pg of pYFP together with the lOpg of 
target plasmid or lOpg of an empty plasmid (pcDNA3.1). The gold particles were 
precipitated with lOOpl of 2M CaCL, washed three times with 100% ethanol, ressuspended 
in 1.2ml of 100% ethanol, ressuspended in 1.2ml of 100% ethanol plus 0.01 mg/ml 
polyvinylpirrolidone and loaded into Teflon tubing. The gold particles were then 
thoroughly dried and stored at 4°C for up to 30 days.
2.103 Ballistic transfection
Gold microcarriers coated with the relevant plasmid DNA and YFP were shot into
dissociated neurons using a hand-held gene gun (Helios Gene-gun, BioRad Hercules, CA 
USA). Approximately 1000 to 3000 neurons were plated in a 50pl droplet of defined F-14 
medium in the centre of a 35 mm diameter tissue culture dish that had been pre-coated with 
poly-omithine (Sigma) and laminin (Sigma). Neurons were incubated at 37°C in a
humidified 5% CO incubator for 2 hours to allow the cells to attach. The medium was
2
removed from the dish just prior to transfection. The coated gold particles were shot into 
the cultured neurons with the gun pressurized at 200psi. A 70pm nylon mesh screen was 
placed between the gun and the culture to protect the cells from the shock wave. After 
transfection, 2ml of F-14 containing the appropriate neurotrophic factor were added and 
cells returned to the incubator at 37°C overnight.
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2.10.4 Electroporation
Plasmids for BCMA were electroporated into dissociated neurons using a Digital Bio® 
microporator. Approximately 300 to 500 neurons were dissociated in 12 pi of electrolytic 
buffer. To the dissociated neurons lpg of YFP and lpg of plasmid were added, and 
electroporated three times at 1500volts with a 10ms width. Neurons were than plated in a 
50pl droplet of defined F-14 medium in the centre of a 35 mm diameter tissue culture dish 
that had been pre-coated with poly-omithine (Sigma) and laminin (Sigma). Neurons were 
incubated at 37°C in a humidified 5% C02 incubator overnight.
2.11 Immunocytochemistry
To visualize protein expression in dissociated neurons, after 24 hours in culture,
neurons were fixed with ice-cold methanol for 10m in at room temperature. After washing 
with phosphate-buffered saline (PBS), cells were incubated in a PBS-based blocking buffer 
containing 0.1% Triton X and 5% of albumin bovine serum albumin (BSA) for lhour at 
room temperature. The cells were incubated with primary antibodies diluted in the 
respective blocking buffer overnight at 4°C (for dilutions of antibodies see below). Cells 
were incubated with the appropriate secondary antibodies (anti-mouse, anti-rabbit, anti-goat 
and/or anti-rat conjugated to either FITC, TRITC or Cy5; Alexa Fluor 1:500) for 1 hour at 
room temperature, and then washed three times with PBS. To visualise all cells present in 
the cultures, nuclei were stained using DAPI (Invitrogen; 50ng/ml).
The following primary antibodies and dilutions were used:
Antibody name Antibody type Company Dilution
BCMA Mouse monoclonal R&D systems 1:200
ActivinRIB Mouse monoclonal R&D systems 1:1000
P-III Tubulin Mouse monoclonal R&D systems 1:1000
Alkl Mouse polyclonal R&D systems 1:500
Alpha Tubulin Rat monoclonal Serotec 1:200
MAP2a Mouse monoclonal Sigma-Aldrich 1:100
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Tyrosine hydroxylase (TH) Rabbit polyclonal Chemicon 1:250
GDF5 Mouse monoclonal R&D systems 1:250
BMPR-IB Mouse monoclonal R&D systems 1:250
TACI Mouse polyclonal R&D systems 1:200
BAFF Mouse polyclonal R&D systems 1:200
April Rabbit polyclonal R&D systems 1:200
2.12 Histology
Histology is the study of tissue. To examine the tissue components, it is necessary 
to process the tissue. The steps of processing involve fixation, sectioning, and visualization.
Fixation involves processing the tissue to prevent its decomposition; cell 
metabolism is stopped. It is usually, done before sectioning. The most common fixative is 
Formalin, a 37% aqueous solution of formaldehyde, which is either used on its own or in 
combination with other chemicals. Formaldehyde reacts with the amino groups of proteins, 
and thus preserves the general structure of the cell and extracellular components.
To allow a specimen to be examined, it must be thinly sliced. Tissue can be frozen 
and sectioned at a low temperature, using a cryostat with a razor blade knife. The fresh or 
fixed tissue is frozen to a "chuck" which is placed in a holder in a refrigerated chamber (- 
20°C). When a wheel is turned, the holder advances towards the blade by the required 
width of the tissue; if 7 um thick sections are wanted, the holder moves 7 um. During this 
process, the holder also moves up and down, which brings the edge of the tissue down on 
the top of the blade.
Another way of sectioning requires a microtome. A microtome works similarly to a 
cryostat but does not require cold. Instead, the tissue is fixed, dehydrated and completely 
permeated with paraffin. It is then embedded in a paraffin block. This block is stuck to a 
chuck, and then placed in a holder, which is progressed by a rotating wheel.
When observing a freshly fixed section of tissue through a microscope, very little contrast 
is observed between adjacent regions of tissue which may have vastly different composition 
and function. As a result, individual cells or parts of cells are difficult or impossible to
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visualize. To solve this problem, staining and imaging techniques allow different cell types, 
or structural or molecular components, to be preferentially visualized. Stains can also be 
used in combination on a single tissue sample. When a stain is dissolved in ethanol, all of 
the water in the tissue must be replaced by ethanol before the staining can take place.
2.12.1 Frozen sections
After dissection, the tissues were fixed for 48h in formalin at 4°C and then
transferred to a 20% sucrose solution in order to cryo-protect them. Tissues were stored in 
sucrose at 4°C. Prior to the sectioning, tissues were embedded in OCT and let to freeze 
inside the cryostat (Leica). 20pm sections were cut and placed directly onto to Superfrost- 
plus slides, and let to dry overnight
2.12.2 Wax sections
After dissection, the tissues were fixed for up to 1 week in formalin at 4°C, and then
transferred to a 10% EDTA solution for 1 week to decalcify the tissue. The 10% EDTA 
was changed every 3 days. To begin the embedding process, tissues were then washed 
twice in dP^O for 30min then dehydrated in 75% ethanol overnight. Tissues were 
transferred to two 96% ethanol solutions during 15min , followed by two 100% ethanol 
solutions and (1/1) ethanol/chloroform solution each for 15min before being incubated in 
100% chloroform overnight Tissues were then incubated in liquid wax twice for 1 hour 
and new wax overnight at 58°C. Tissues were finally embedded in wax before sectioning. 
Each third section of 5 pm was attached to slides and incubated in a 65°C oven overnight.
For cresyl fast violet (CFV) staining, slides were washed in 100% Xylene solution 
for 5min each, 100% ethanol for 5min, 96% ethanol for 5min, 74% ethanol for 5min, PfeO 
for 5min, crystal fast violet for 5min, PfeO for 5min, 74% ethanol for 5min, 2 solutions of 
96% ethanol for 5min each, 2 solutions of 100% ethanol for 5min each, 2 solutions of 
100% Xylene for 5min each and let to dry. The slides were mounted and coverslipped using 
the permanent mount DPX.
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2.123 SCG total counts
Pieces of tissue containing the SCG from PO and P5 GDF5 7 and GDF5+/' mice were
treated according to the description on section 2.12.2. The slides were then placed under the 
microscope and images acquired. Images were then analyzed using a Matlab® application 
to predict the total number of neurons present in the SCG ganglion.
2.13 Measurement of sympathetic innervation in target tissues
SMG and Nasal mucosa from PO and P5 GDF5 7' and GDF5+/' mice were treated
according to the description on section 2.12.1. Next day the sections were blocked by 
incubation in PBS containing 5% horse serum (Gibco, Invitrogen) and 0.1% Triton X for 
lhour at room temperature. Sections were the incubated with rabbit anti-TH polyclonal 
antibody (Chemicon) diluted in the blocking buffer overnight at 4°C. Following the 
sections were washed thoroughly in PBS to remove unbound primary antibody. Sections 
were then incubated in the appropriate secondary antibody for lh at room temperature, and 
then washed three times with PBS. Slides were mounted in a 50% glycerol solution in PBS 
before being coverslipped.
Images were acquired in a confocal microscope (Zeiss), and further analyzed using Adobe 
Photoshop® software.
2.14 Western Blotting
2.14.1 Preparation of culture extracts
E15 Nodose ganglia were dissected and dissociated according to previous sections
(2.5.1 and 2.9.2, respectively). Neurons were plated in a high density culture in a 96 well 
plate (Greiner) previously treated with laminin/poly-omithine solution (section 2.9.1) and 
incubated overnight in the presence of Caspase Inhibitors. The following day BDNF was 
added to the wells for the indicated times. Culture medium was removed, 50pl of RIP A 
buffer (50mM Tris pH7.4, 150mM NaCl, 10% Glycerol, 1% Triton X-100, ImM EDTA
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and lOOpg/ml PMSF) were added and the cell extract was kept in ice for lhour. Insoluble 
debris was removed by centrifugation t lOOOOrpm for lOmin, and the supernatant stored in 
an eppendorf tube at -80°C.
2.14.2 Western Blotting
Protein extracts were analysed by sodium dodecyl sulfate (SDS) polyacrylamide
gels, following the protocol of Laemmli (1970) with modifications.
A 10% or 12% SDS-polyacrylamide separating minigel with a 5% stacking gel was used 
(Bio-Rad, Mini-PROTEAN® 3 Cell). Equal amounts of protein extract and sample buffer 
were added in an eppendorf tube and boiled for 5min before being loaded in the gel. 
Biotinylated molecular weight markers (Amersham), diluted 1:10 according to the 
manufacturer’s instructions were loaded onto the gels to confirm molecular weights. The 
gel was assembled and run for 20min at 80V followed by 45min at 140V.
Proteins were blotted to polyvinyl-idene difluoride (PVDF) membrane (Amersham). 
Electrophoretic transfer was carried out at a constant current of 100V for lhour in transfer 
buffer according to the manufacturer’s instructions.
After transfection, the membrane was blocked for lhour in 5% w/v milk in lOmM 
phosphate buffered saline (PBS) with 1% tween-20 (PBS-T) at room temperature with 
gentle agitation on an orbital shaker.
The blocking solution was removed and the membrane rinsed twice in PBS-T 
before being incubated at 4°C overnight with the primary antibody (in 1% BSA in PBS-T) 
The membranes were then washed (5 x 10 min) in PBS-T and incubated at room 
temperature in the adequate secondary antibody in 1% BSA in PBS-T for lhour at room 
temperature with gentle agitation on an orbital shaker.
Following washing as above, visualization of the antibody complexes was carried 
out using ECL-Plus (Amersham) according to the manufacturer’s instructions. ECL-plus 
reagent was applied to the blot for lmin, and then drained from the membrane. The 
membrane was sandwiched between two sheets of acetate and was placed in an 
autoradiography cassette and exposed to Hyperfilm™ (Amersham). The film was 
developed and fixed manually (Kodak GBX developing and fixing solution, Sigma). After
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visualization of the antibody complexes had been completed, the blot was stripped of all 
primary antibodies and incubated in mouse anti-p-tubulin (1:10,000, Chemicon) in 1% 
BSA in PBS-T for lhour at room temperature. The blot was then washed as described 
above and incubated in anti-mouse secondary antibody in 1% BSA in PBS-T for lhour at 
room temperature. After washing as described above, visualization of the antibody 
complexes was carried out as above.
2.15 siRNA
2.15.1 Background
Small interfering RNA (siRNA) is also known as short interfering or silencing 
RNA. siRNA constitutes a new level of gene regulation in eukaryotic cells. It is based on 
the observation that the presence of double stranded RNA in a cell eliminates the 
expression of a gene having the same sequence, whereas expression of other unrelated 
genes are left undisturbed. siRNA usually consists of a 21 nucleotide long double-stranded 
RNA molecule. Recently, many constructs have been engineered for in vivo expression of 
siRNA upon transient or stable transfer into mammalian cells. In order to obtain the best 
possible siRNA, some the following characteristics should be considered (1) the double 
stranded nature of siRNA makes it relatively resistant to ribonucleases, even when based on 
natural nucleotide chemistry; (2) siRNAs are not immunogenic and do not trigger an 
immune response; (3) siRNA is at least 100 times more potent than conventional antisense- 
based drugs; (4) siRNA has an unprecedented high specificity for the gene that has a 
perfect match to the siRNA sequence.
2.15.2 Method
siRNA against BCMA was designed using ambion’s online siRNA designer tool. 
The mRNA sequence of the gene of interest obtained from PubMed was used as key to
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obtain the possible target sequences. The following sequences were chosen as the siRNA 
targets:
B C M A l: AACTGCTTTGCAAAGTGTCAT; 
BCMA_2:AAGCCAACTCACACTAGATAA;
BCM A 3: AACTCACACTAGATAATGAGC;
The siRNAs were than blasted in order to determine whether they shared any significance 
with other genes. The targets with lower known homology were used to design the 
respective 21 nucleotide sequence. The two single stranded sequences where then annealed 
to form a double-strand siRNA according to manufacturer’s guidelines.
Bacteria were transformed as described in section 2.10. Next day five individual colonies 
where selected and the bacteria grown for 2hours in LB media. The DNA was extracted 
using mini-prep® Qiagen kit, and sent to be sequenced. The DNA sequenced was than 
analyzed using Bioedit program to assure the presence of the insert. The plasmid DNA 
from the selected colonies was used to transform new bacteria as described in section 2.10 
and once purified, the plasmids were electroporated into neurons using procedure described 
in section 2.10.4
2.16 Statistical analysis
Data are presented as means ± SEM, and statistical significance was determined by
student’s T-test or, if there were more than two sets of data to compare, the one-way 
analysis of variance (ANOVA) with Fisher’s post hoc test was used. The level of 
significance accepted was P<0.05. For neurite growth analysis, between 40 and 70 neurons 
were sampled per condition and each experiment was repeated at least three times. All 
other studies presented were performed on litter mate-controls and were repeated using at 
least three separate litters and the error calculated using the average values obtained from 
each repeat.
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3. RT-QPCR based screening for the expression of 
Wnt, TGF p and TNF superfamily mRNAs in the
developing PNS
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Real Time Polymerase Chain Reaction (PCR) amplification of reverse transcribed 
mRNA (RT-PCR) has proved to be a very useful method for quantifying developmental 
changes in mRNA expression. Making use of this method, I screened for the expression of 
transcripts encoding several receptors and ligands of the Wnt, TGF-p and TNF 
superfamilies in developing mouse nodose and trigeminal sensory neurons and sympathetic 
neurons of the SCG. The aim of the work described in this chapter was to characterize the 
developmental expression patterns of receptors and ligands in these experimentally 
tractable populations of neurons in order to identify potential ligands of the Wnt, TGF-p 
and TNF superfamilies that may play an important role in promoting the survival of and/or 
target field innervation by developing neurons.
3.1 Polymerase Chain Reaction
PCR was first described in 1987 (392). In the PCR procedure, trace amounts of 
DNA can be quickly and repeatedly copied to produce a quantity sufficient to investigate 
using conventional molecular biological methods.
The basic principle of PCR is very simple. As the name implies, it is a chain 
reaction. One molecule of DNA originates two copies, then four, then eight and so forth. 
PCR can increase the copy number of specific nucleic acid sequences of 100 to 2000 base 
pairs in length by 106 fold in an in vitro reaction of only a few hours in duration (393).
PCR consists of repeated cycles, each of which consists of three steps: (1) the 
reaction mix, that contains the DNA template to be amplified as well as oligonucleotide 
primers, nucleotides and thermostable DNA polymerase, is heated to 95°C, leading to 
separation of the strands of DNA. This process is known as denaturation; (2) Lowering the 
temperature of the reaction mix allows the primers to bind to the DNA template re-forming 
a short region of double stranded DNA. The polymerase then slowly begins to attach 
additional nucleotides to the 3* end of the primer that are complimentary in sequence to the 
DNA template, thereby increasing the length of double stranded DNA and thus 
strengthening the bond between primers and the DNA template. This process is called 
annealings (3) The temperature of the reaction mix increases to 72°C, the ideal temperature 
for DNA polymerases derived from thermophylic bacteria, and this rapidly adds further 
nucleotides that are complimentary in sequence to the original template DNA to the
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developing DNA strand. At the same time, any loose bonds that have formed between the 
primers and DNA segments that are not fully complementary will be broken. This process 
is known as extension.
Each o f these three steps is repeated on average between 20 to 40 times per reaction. 
Whilst this is the basic method for a PCR reaction, each reaction is individual and may 
require optimization of several parameters.
(A)
P fv w i— — w-w w v I »__ *_____ f «
t n r t r r r i T f i  m r r w  n ; u y
denaturing
in i Jnr'yifimtrniuiniinr 
hybridisation
yrr^TTrmr^ii! t s i jir trrrm rrn n T riT  >-
V, " N - ^ U U ! J i u v
% 11 Z 1 polymerase JT
rZHjtSUi 1 *  jMi ~ '** * '  N
extension
(B)
I I f  I h 
1 1 1 1 1 1 1 1 “
I I I I I I I I I I I I I I I I* 
llllllll llllllllllllllll lllllllh
Figure 14: The PCR principle. (A) Steps required for amplification of a DNA sequence by PCR. A 
cycle of PCR consists of denaturation, annealing or hybridization and extension. (B) Schematic 
representation of the method, from one molecule of DNA template to hundreds
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When the PCR method was first invented DNA polymerase had to be added freshly 
during the annealing step of each cycle (because the high temperature reached during 
extension and denaturation destroyed it), causing the reaction to be very time-consuming. 
In modem PCR procedures, however, thermostable DNA polymerases are used The first 
thermostable DNA polymerases were isolated from Thermits aquaticus, a thermophylic 
bacterium found in the hot springs of Yellowstone National Park in the USA, and called 
Taq polymerases. Because Taq is not destroyed by the high temperature of PCR, it is only 
necessary to add it once, at the beginning of the reaction (394).
Another crucial component of a PCR reaction is the design of the two 
oligonucleotide primers that are complementary to target sequences several hundred base 
pairs apart from each other (393). Good primer design is essential to the success of any 
PCR reaction (see below).
3.2 Primer design
In order to obtain the best set of primers, i.e., those primers that anneal to and
specifically amplify only a specific target sequence, there are a number of crucial details 
that should be considered. These are: (1) primer length -  it’s generally accepted the 
optimal length of a primer to be 18 -  22bp. This is long enough to ensure high specificity, 
and short enough to allow easy binding of the primer to the template; (2) melting 
temperature (Tm) -  primers with Tm between 52-58°C usually produce the best results. 
Primers with a high Tm tend to have secondary annealing, leading to non-specific products 
in the PCR reaction; (3) annealing temperature (Ta) -  primers that require a high Ta 
usually lead to insufficient primer-template hybridization resulting in low PCR product 
yield; primers requiring a low Ta may also amplify non-specific products due to 
mismatches; (4) GC content -  GC content should be between 40-60%; if the GC content is
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too high, requires a high Ta, if the GC content is too low it leads to a low Tm; (5) GC clamp 
-  where possible primers should be designed to include G or C bases in the last five bases 
from the 3’end of the primer helps to promote specific binding due to the strength of the 
GC bond; (6) secondary structures -  secondary structures like hairpins, self dimers and 
cross dimers, should be avoided because they lead to poor product yield; (7) repeals -  a 
repeat is a di-nucleotide occurring consecutive times like ATATATAT, di-nucleotides 
repeats should not be greater than four, (8) runs -  long runs of a single base should be kept 
in numbers below five, as they lead to mismatches.(395)(396)(397)(398)
33  Real-time PCR
As previously mentioned, PCR can be used to amplify a specific DNA segment for
subsequent purification and manipulation, a process known as qualitative PCR. PCR can 
also be used to quantify the levels of a specific template or “target” DNA/cDNA that was 
present in a mixed DNA/cDNA sample prior to PCR amplification, a technique known as 
quantitative PCR. Many protocols have been developed over the years for quantitative 
PCR, but presently the most flexible approach is known as real-time PCR or QPCR.
QPCR monitors the fluorescence emitted by accumulating PCR products at a set 
point in each PCR cycle. The intensity of fluoresence in each sample is proportional to the 
concentration of amplified “target” DNA present, which in turn is proportional to the pre- 
amplification concentration of the specific “target” DNA. In its simplest form, QPCR 
measures the fluorescence produced by the incorporation of intercalating fluorescent dyes 
into amplified double-stranded DNA. Such dyes only fluoresce strongly in the presence of 
an appropriate excitatory light source when they incorporate themselves into double­
stranded DNA. The most commonly used intercalating dye for QPCR is SYBR Green. In 
some cases, to ensure higher specificity of amplification, fluorescence is produced in 
response to accumulating “target” DNA by incorporating dual-labeled hybridization probes 
or dual-labeled Molecular Beacon probes into the PCR reaction mix,. The data presented in 
this chapter was mostly obtained using RT-QPCR with SYBR green incorporation. One
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advantage of using SYBR Green is that it is exquisitively sensitive and can detect 
extremely low copy number DNAs and cDNAs. Another advantage of using this dye is that 
only unmodified oligonucleotide primers are required for PCR amplification, which 
facilitates primer design and reduces cost. However, SYBR Green does not discriminate 
between the amplification products of the correct “target” DNA and the non-specific 
amplification of related sequences and/or primer artifacts. Whilst the amplification of the 
correct product can be verified retrospectively following the PCR reaction by melting curve 
analysis of PCR products, PCR reactions can require extensive optimization of several 
parameters, like primer concentration, annealing temperature and MgCfe concentration, in 
order to produce melting curves with a single sharp peak of the correct melting 
temperature. For some “target” DNA templates, the reliable production of such a melting 
curve peak proves to be impossible even after trying several primer sets. In these rare cases, 
I used Molecular Beacon probes to confirm the amplification of specific target DNAs 
during QPCR reactions.
Molecular beacons are single-stranded oligonucleotide hybridization probes (essentially 
they are modified primers) that form a stem-and-loop structure. The loop contains a probe 
sequence that is complementary to a sequence in the “target” DNA that is being amplified, 
and the stem is formed by the annealing of complementary arm sequences that are located 
on either side of the probe sequence. A fluorophore is covalently linked to the end of one 
arm and a quencher molecule is covalently linked to the end of the other arm. Molecular 
beacons do not fluoresce when they are free in solution and the stem loop structure is intact. 
However, when they hybridize to a nucleic acid strand containing a sequence 
complementary to the probe sequence they undergo a conformational change that separates 
the fluorophore from the quencher molecule enabling them to fluoresce brightly. Like 
SYBR Green, the amount of fluorescence is directly proportional to the amount of PCR 
product being formed. Whilst Molecular Beacon probes are highly specific and guarantee 
that the correct “target” DNA sequence is being amplified and quantified, they are less 
sensitive than SYBR green, difficult to design and expensive.
Whichever method is used (SYBR Green or molecular beacons), QPCR remains a 
quantitative method for measuring the levels of cDNAs that have been reverse transcribed 
from mRNA. The fluorescence produced in each reaction is constantly monitored, and data
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stored in a computer attached to the thermocycler. The principal behind the quantification 
lies in the inverse correlation between cycle number and product concentration. As a rule, 
the lower the cycle number required for the sample to pass threshold, the higher the initial 
concentration of the relevant cDNA in the sample, and vice-versa. In order to directly 
compare the levels of a specific reverse transcribed cDNA, I generated a dilution series or 
standard curve of cDNA that had been reverse transcribed from a tissue known to express 
high levels of the mRNA under investigation. In this way it was possible to directly 
compare cDNA levels between unknown samples, by comparing them to the standard 
curve.
Each set of QPCR reactions were set up with unknown samples and several 
consecutive dilutions of the standard curve cDNA (1/1, 1/4, 1/16, 1/64). For accuracy, the 
1/1 standard cDNA was serially diluted using a blank solution which consisted of the same 
reagents as the RT reaction but with water added instead of RNA (for details see Section 
2.7.2). If the standards were diluted in water, a linear regression would not be obtained, the 
reason being that reagents in the RT mastermix (most notably the RT enzyme and Random 
Hexamers) are known to inhibit the real time PCR reaction. Therefore, if the standards were 
diluted in water the efficiency of the reaction would increase slightly with every dilution.
As mentioned above, all data from each real-time reaction was stored in a computer 
attached to the thermocycler. I used the MX3000P® thermocycler and software 
(Stratagene). At the end of the reaction, the MX3000P® allows the user to view several 
parameters of the reaction in a graphical format. These parameters include the following, 
(a) Amplification plots showing the fluorescence versus cycle number for each sample 
well. They resemble a sigmoidal curve that is easily recognized if samples have been 
amplified, (b) A melting curve showing the rate of change of fluorescence versus 
temperature, where all samples should show a sharp peak for the calculated Tm. This graph 
is particularly important as it allows the user to know if the amplified product is the desired 
one or not. Each set of primers generates a specific product with a particular Tm, so this 
graph should one have one sharp peak at the right temperature, (c) A standard curve
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showing Ct (threshold line, above which the program starts to quantify the DNA) versus 
cycle number. The linear regression of the standard curve should have an RSq (R ) value as 
close to 1 as possible. The coefficient of determination B2 is the proportion of variability in 
a data set, in the case of linear regression, Z?2 is simply the square of a correlation 
coefficient which indicates the strength and direction of a linear relationship between 
random variables. The correlation is 1 in the case of an increasing linear relationship, -1 in 
the case of a decreasing linear relationship, and some value in between in all other cases, 
indicating the degree of linear dependence between the variables. Rsq values <0.95 were 
deemed unsatisfactory and results were not calculated from these data sets). The efficiency 
of the reaction was calculated from the slope of the standard curve by the software. 100% 
efficiency corresponds to a doubling of the product in the end of each cycle. For most 
reactions efficiencies of 80-100% were obtained after optimization. In cases where 
reactions generated false products or primer artifacts, as determined by the melting curve, 
the efficiency of the reaction was often seen to be over 100%. In these cases data was 
rejected
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Figure 15: Real-time PCR Program graphs. (A) Amplification plots, (B) melting curve, (C) Standard curve
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Normalizing to a reference gene is a popular and simple method to internally 
control for variation in the efficiency of reverse transcription and pipetting errors in RT- 
QPCR. This method uses RNAs encoded by genes that have been collectively called 
“housekeeping genes”. The most commonly used reference genes include p-actin, 
glyceraldehydes-3-phosphate dehydrogenase (GAPDH), hypoxanthine-guanine 
phosphoribosyl transferase 1 (HPRT1) and 18S ribosomal RNA (399). These housekeeping 
genes act has endogenous controls that allow for the correction of experimental variations 
caused by pipetting errors, inhibitory compounds, RT efficiency or quality of starting 
material (400). Due to their key roles in metabolism (GAPDH and HPRT 1), cytoskeleton 
(p-actin) and ribosome structure (18S ribosomal RNA) it is generally assumed that they are 
expressed at a constant level in different tissues, cells or experimental treatments
In all the RT-QPCR screening data presented in this chapter, I used GAPDH as a 
“housekeeping gene”.
3.4 Experimental design
The Wnt, TGF-P and TNF superfamilies are large groups of related proteins
encoding both ligands and receptors that play diverse roles in many different tissues. Some 
members of these superfamilies have been shown to play important roles within the 
nervous system. For example, the Wnt receptor, FZD5 has been implicated in promoting 
survival, but not axonal growth of parafascicular neurons of the thalamus (401), whilst 
FZD3 has been shown to control neural tube closure and axonal growth and guidance in 
the spinal cord and forebrain (402X403). ). Wnt7b and disheveled activate signaling 
pathways to promote dendritic branching in hippocampal neurons (404). Alterations in 
Wntl signaling leads to functional cognitive impairment (405) and retinal degradation 
(406), and mutations in Wntl lead to failure of the midbrain development and partial or 
complete failure of the cerebellar development (407X408). Mutations in Wnt3a (409) or 
Lefl (410), a downstream effector of Wnt signaling block the normal expansion of 
hippocampal precursors. Moreover, the phenotype of Wntl/Wnt3a double knock-out mice 
shows that these two Wnts act redundantly to expand the number of dorsal neural crest 
precursors along the length of the spinal cord (411). Consistent with these loss-of-function
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phenotypes, ectopic expression of Wntl in the developing spinal cord causes a local 
increase in cell proliferation (412).
In the TGF-P superfamily studies have shown that BMPR-Ib is an important 
mediator of glial differentiation and cell survival in hippocampal progenitor cells (413). 
Overexpression of constitutively active Alkl induces NF-kB activation and subsequent 
enhanced neuroprotection in rat hippocampal neurons (414); whilst Alk5 has been reported 
to play an essential role in the survival of post migratory cardiac neural crest cells (415). 
BMP2 has been show to induce neurogenesis in neural crest stem cells (416). Although 
BMP4 has been shown to have no effect on promoting/reducing survival in neurons 
cultured from spiral ganglion, but it decreases the neurite length in the same cultures (417). 
BMP7 has been shown to promote dendritic growth in sympathetic neurons (418), and 
hippocampal neurons (419). The BMP antagonist, noggin has been shown to be able to 
inhibit BMP signaling and promote neuronal differentiation of subventricular zone neurons 
(420);
There is less known about the functions of various TNF superfamily members in the 
nervous system compared to Wnts and TGF-ps. TNF-a, has been the most extensively 
studied and has been shown to be expressed in many types of cells including glial cells and 
neurons. TNF-a regulates responses to NGF, promoting neural cell survival in 
neuroblastoma cells (421). TNF-a pre-treatment provides tolerance to ischemia (422). 
TNF-a increases cellular proliferation in the adult cortex (423). In contrast, a pro-death 
effect of TNF-a has been demonstrated in cultures embryonic sympathetic and trigeminal 
sensory neurons (424)
Recently GITR and its ligand GITRL have been shown to promote neurite growth 
from sympathetic neurons (425) and TRAIL has been shown to be expressed in 
macrophages and induced in neurons by p-amyloid peptide (426). Induced TRAIL may 
cause apoptosis of brain cells as well as virally infected cells (427). It has also been 
suggested that aberrant expression of CD40 and its ligand CD 154 has been linked to 
neurodegenerative diseases such as multiple sclerosis or Alzheimer’s (428).
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As can be seen from above, members of Wnt, TGF-p and TNF superfamilies play 
multifunctional roles during nervous system development. However, the “transcriptome”, 
for ligands and receptors of these families within the developing peripheral nervous system, 
i.e., those genes that are transcribed in the developing peripheral nervous system, is largely 
unknown. Here I have used a RT-QPCR based screening approach to document which 
mRNAs are expressed in the SCG, trigeminal and nodose ganglia at a number of embryonic 
(E l3, E l5, E l8) and post-natal (PO, P5) ages. These studies have revealed complex patterns 
of gene expression for each superfamily that show ganglion-specific and age-specific 
differences. The developmental mRNA expression patterns that have emerged for receptors 
and ligands within each ganglion suggests that some members of the Wnt, TGF-p and TNF 
superfamilies may play important roles in regulating the development of certain neuronal 
populations. From this information, one member of the TNF superfamily and one member 
of the TGF-p superfamily were chosen, based on their expression patterns, for further 
functional analysis. The results of this functional analysis are reported in Chapters 4 and 5.
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3.5 Results/ Discussion
In this chapter I describe a RT-QPCR based screen to determine the developmental 
expression patterns of the ligands and receptors that comprise the Wnt TGF-P and TNF 
superfamilies in the developing SCG and nodose and trigeminal sensory ganglia. This was 
carried out in order to identify new candidate signalling molecules involved in regulating 
either neuronal survival and/or the growth of neuronal processes in the developing PNS. 
What is clear from this screen is that the mRNA expression patterns of members of the 
Wnt, TNF and TGFp superfamilies in developing ganglia of the PNS are very diverse and 
show distinct temporal changes in expression levels. An exhaustive discussion of the 
biological function of each of these receptors and ligands is beyond the scope of this thesis. 
Instead, I will discuss the relevance of my findings in relation to what is already known 
about the functions of these molecules in the nervous system. One important caveat about 
my data that must be bom in mind when interpreting the physiological relevance of the 
mRNA expression patterns that I describe is that RT-QPCR cannot give information as to 
the site of expression of mRNAs within developing sensory and sympathetic ganglia. Wnt 
TGF-P and TNF superfamily mRNAs, and subsequently proteins, may be expressed in 
neurons, non-neuronal cells or both and the exact site of expression will dictate the 
biological functions of these ligands and receptors within the developing PNS.
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3.5.1 Wnt superfamily
The Wnt signalling pathway plays a crucial role in cell fate determination, survival, 
proliferation and movement in variety of tissues. Abnormalities in the WNT signalling 
pathway have been implicated in a number of diseases, most notably cancer (429).
Frizzleds (FZD) are cell surface receptors for Wnt proteins that belong to a class of 
seven-pass transmembrane receptors (204). There are ten known members of the FZD gene 
family in humans and nine in mice. Little is known about the specificity or affinity of FZDs 
for individual WNTs but there is likely to be some redundancy because there as twice as 
many WNTs as FZDs (430).
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Figure 16: Expression profiles for FZD1 and FZD2. The data show the relative expression of (A) FZD1 and 
(B) FZD2 mRNA relative to GAPDH (in arbitrary units) at a number of different stages of development 
between E l3 and P5 in the SCG (blue lines), nodose (pink lines) and trigeminal ganglia (green lines). Means 
and standard errors of data from three separate sets of ganglia at each stage are shown
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Figure 17: Expression profiles for FZD3 and FZD4. The data show the relative expression of (A) FZD3 and 
(B) FZD4 mRNA relative to GAPDH (in arbitrary units) at a number of different stages of development 
between E l3 and P5 in the SCG (blue lines), nodose (pink lines) and trigeminal ganglia (green lines). Means 
and standard errors of data from three separate sets of ganglia at each stage are shown
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FZD1
The mRNA levels of FZD1 (fig. 16A) steadily increased in the trigeminal ganglion 
from E13 up to E18 and then decreased back to E13 levels by P5. The levels of FZD1 
mRNA relative to GAPDH in the nodose ganglion and the SCG were considerably lower 
than those in the trigeminal ganglion. There are no published studies on the roles of FZD1 
in the PNS, although it has been shown that FZD1 mediates chemoresistence in 
neuroblastoma cells through activation of the Wnt/p-catenin canonical pathway (431).
FZD2
The levels of FZD2 mRNA expressed in E l3 nodose ganglia was approximately 
three- and ten-fold higher than that expressed by E l3 trigeminal ganglia and SCG, 
respectively (fig. 16B). The developmental expression pattern of FZD2 mRNA was similar 
in both nodose and trigeminal ganglia, with mRNA levels being highest at E13 and E15 
and dropping thereafter to much lower levels by P5. Interestingly, the developmental 
expression pattern of FZD2 mRNA in the SCG was exactly the opposite to that in the two 
sensory ganglia, with FZD2 mRNA levels being low at E13 and E15 before increasing 
some five-fold between E l5 and P5. The expression levels of FZD2 mRNA in the SCG at 
P5 are in fact greater than those in nodose or trigeminal ganglia at this age. Although, to 
date, there are no published studies documenting a role for FZD2 in the PNS, the 
expression data I have produced raises the possibility that Wnt/FZD2 signalling may play a 
role in the differentiation and survival of early sensory neurons and/or in the establishment 
of peripheral innervation by SCG neurons and subsequent terminal arborization. (432).
FZD3
FZD3 mRNA levels decreased six-fold between E13 and P5 in the developing 
nodose ganglion (fig.l7A). The expression of FZD3 mRNA showed a similar pattern in the 
developing trigeminal ganglion, although the developmental decrease was only four-fold 
and was not entirely linear. In contrast, the expression of FZD3 mRNA was maintained at 
almost constant, relatively low levels, between E l3 and P5 in the developing SCG.
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Lyuksyutova and colleagues (2003) suggested that an interaction between Wnt4 and FZD3 
contributes to the caudal-rostral projection of commissural axons in the ascending somato­
sensory pathway (403). FZD3 is also implicated in the formation of several major axon 
tracts within the forebrain (402). Deardorff and Wang, (2001; 2002) have shown that FZD3 
mediates Wnt signalling in the formation of the neural crest in the developing Xenopus 
embryo, as well as in the development of major fibre tracts in the rostral CNS (433)(402). 
suggesting that disruption of frizzled 3 may result in neurodevelopmental abnormalities 
(434). As in the case of FZD2, my data would seem to suggest that Wnt/FZD3 signalling 
could play a role in regulating some aspects of early sensory neuron development.
FZD4
As in the case of FZD2 mRNA, FZD4 mRNA is expressed at the highest levels in 
sensory ganglia during the embryonic period and its expression decreases markedly by P5 
(fig. 17B). Whilst the developmental decrease in FZD4 mRNA expression is only 
approximately 2-fold in the trigeminal ganglion, it is more than 5-fold in the nodose 
ganglion. The expression pattern of FZD4 mRNA also bears a resemblance to that of FZD2 
mRNA in the developing SCG, with the lowest levels being present at E l3 and expression 
increasing thereafter. However, whereas FZD2 mRNA expression peaked at P5 in SCG, 
FZD4 mRNA expression peaked at P0 and fell 30% from P0 and P5.
Loss of function studies have shown that FZD4 plays a crucial role during 
development. FZD4 7 animals present three distinct defects: (1) progressive cerebellar 
degeneration associated with severe ataxia, (2) absence of a skeletal muscle sheath around 
the lower esophagus associated with progressive esophageal distension and dysfunction, 
and (3) progressive deafness caused by a defect in the peripheral auditory system that is not 
associated with a loss of either hair cells or other auditory neurons (435). Once again, as in 
the case of FZD2 and FZD3, my data would seem to suggest that Wnt/FZD4 signalling 
could play a role in regulating some aspects of early sensory neuron development. My data 
also raises the possibility that Wnt/FZD4 signalling modulates target field innervation by 
developing late embryonic and neonatal SCG neurons.
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Figure 18: Expression profiles for FZD5 and FZD6.. The data show the relative expression of (A) FZD5 and 
(B) FZD6 mRNA relative to GAPDH (in arbitrary units) at a number of different stages of development 
between E13 and P5 in the SCG (blue lines), nodose (pink lines) and trigeminal ganglia (green lines). Means 
and standard errors of data from three separate sets of ganglia at each stage are shown
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Figure 19: Expression profiles for FZD7 and FZD9. The data show the relative expression of (A) FZD7 and 
(B) FZD9 mRNA relative to GAPDH (in arbitrary units) at a number of different stages of development 
between E13 and P5 in the SCG (blue lines), nodose (pink lines) and trigeminal ganglia (green lines). Means 
and standard errors of data from three separate sets of ganglia at each stage are shown
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FZD5
The developmental expression profile of FZD5 mRNA is in marked contrast to 
those of FZD2, FZD3 and FZD4 mRNAs. Whilst the former mRNAs are expressed at 
maximal levels in embryonic sensory ganglia and decrease as development proceeds, FZD5 
mRNA is expressed at its lowest level in E13 nodose ganglia, increases 3-fold to peak at 
PO and then falls 2-fold to reach lower levels by P5 (fig 18A). FZD5 mRNA is barely 
expressed in developing trigeminal ganglia. In contrast to FZD1, FZD2, and FZD4 
mRNAs, FZD5 mRNA expression in the developing SCG is highest at E l3 and gradually 
decreases by 50% between E13 and P5. The levels of FZD5 mRNA expressed in the SCG 
are of the same order of magnitude as those expressed in nodose ganglia and are 
significantly higher than FZD5 mRNA expression levels in developing trigeminal ganglia. 
Liu and colleagues (2008) have shown that FZD5 is required continuously and in a cell 
autonomous manner for the survival of adult parafascicular nucleus neurons of the thalamus 
(436). My data is the first indication that Wnt/FZD5 signalling may mediate some aspects 
of the development of nodose sensory neurons and SCG sympathetic neurons.
FZD6
The expression pattern of FZD6 mRNA in developing nodose ganglia and SCG 
bears some resemblance to the expression patterns of FZD2 and FZD4 mRNAs in these 
ganglia, with an initial high expression of FZD6 mRNA in nodose ganglia that declined 3- 
fold to reach a minimum at P5 and low level expression of FZD6 mRNA at E13 in the SCG 
that increased to postnatal ages (fig. 18B). Although FZD6 mRNA was expressed at 
relatively high levels within the trigeminal ganglion throughout the period studied, there 
was no clear developmental pattern of expression. Previous studies have shown that FZD6 
controls the hair patterning of the skin (437), and together with FZD3, controls neural tube 
closure and the planar orientation of hair bundles on a subset of auditory and vestibular 
sensory cells (438)
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FZD7
The developmental screening results for FZD7 mRNA (fig. 19A) showed that the 
expression levels of this mRNA were very low in E13 SCG, but thereafter gradually 
increased with age to be some 3-fold higher by P5. Early embryonic trigeminal ganglia 
expressed significantly more FZD7 mRNA than SCG neurons of any age. After peaking at 
E l5, the magnitude of FZD7 mRNA expression fell by 80% to P0 within this ganglia and 
expression was maintained at these lower levels at P5. Although the pattern of FZD7 
mRNA expression was similar in nodose neurons compared to trigeminal neurons between 
E13 and P0, with peak levels of expression at early ages falling to much lower levels by P0, 
there was a dramatic 6-fold increase in the levels of FZD7 mRNA expressed within nodose 
ganglia between P0 and P5. Little is known about the functions of FZD7 in either the CNS 
or PNS. (439). However, the striking expression patterns of FZD7 mRNA expression 
within immature sensory neurons may indicate that Wnt/FZD7 signalling has a role to play 
in sensoiy neuron development.
FZD9
The developmental expression pattern of FZD9 mRNA within nodose ganglia is 
similar to that of FZD7 mRNA (fig. 19B). FZD9 mRNA levels were highest at E13 and 
E l5, dropped between E l5 and P0 and then increased greatly between P0 and P5. In 
trigeminal ganglia, FZD9 mRNA was also expressed at maximal levels at E l3. FZD9 
mRNA levels within developing trigeminal ganglia decreased approximately 3-fold 
between E l3 and E l8 and remained relatively stable thereafter. Developing SCG expressed 
relatively low, stable levels of FZD9 mRNA throughout the period studied. The only 
published literature linking FZD9 to the nervous system is a study showing its expression 
in hippocampus, astrocytes and dentate gyrus of adult mice (440).
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Figure 20: Expression profiles for LRP5 and LRP6. The data show the relative expression of (A) LRP5 and 
(B) LRP6 mRNA relative to GAPDH (in arbitrary units) at a number of different stages of development 
between E l3 and P5 in the SCG (blue lines), nodose (pink lines) and trigeminal ganglia (green lines). Means 
and standard errors of data from three separate sets of ganglia at each stage are shown.
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Figure 21: Expression profiles for DKK and Ryk. The data show the relative expression of (A) DKK and (B) 
Ryk mRNA relative to GAPDH (in arbitrary units) at a number of different stages of development between 
E l3 and P5 in the SCG (blue lines), nodose (pink lines) and trigeminal ganglia (green lines). Means and 
standard errors of data from three separate sets of ganglia at each stage are shown
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Figure 22: Expression profile of Kxemenl. The data show the relative expression of Kremen 1 mRNA relative 
to GAPDH (in arbitrary units) at a number of different stages of development between El 3 and P5 in the SCG 
(blue lines), nodose (pink lines) and trigeminal ganglia (green lines). Means and standard errors of data from 
three separate sets of ganglia at each stage are shown.
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LRPs
LRP5 and LRP6 are FZD co-receptors that are necessary for activation of the 
canonical Wnt signalling pathway (212). The developmental mRNA expression screen for 
LRP5 (fig 20A) revealed that trigeminal ganglia expressed barely detectable levels of this 
mRNA at any of the time points examined. In contrast, LRP6 mRNA was expressed at high 
levels in E l3 trigeminal ganglia and the level of expression decreased 7-fold thereafter 
between E l3 and P5 (fig 20B). Interestingly, the expression pattern of LRP6 mRNA bears 
more than a passing resemblance to the expression patterns of FZD2, FZD3, FZD4, FZD7 
and FZD9 mRNAs, suggesting that Wnts may play a role in regulating some aspects of 
trigeminal neuron development by signalling through the canonical Wnt pathway.
The developmental expression patterns of LRP5 and LRP6 mRNAs in nodose 
ganglia are somewhat similar. Both mRNAs are expressed at relatively high levels, 
compared to their peak levels of developmental expression at E l3 and both show a 
moderate increase in expression between E13 and E15. LRP5 and LRP6 mRNA expression 
levels within nodose ganglia decrease by approximately 60% between E15 and PO and the 
levels of both mRNAs increase substantially between PO and P5. The relatively high levels 
of LRP5 and LRP6 mRNAs between E13 and E18 raise the possibility that Wnts can signal 
via FZD2, FZD3, FZD4 or FZD6 down the canonical pathway to affect nodose neurons 
development at these ages. LRP5 and LRP6 mRNA expression patterns within nodose 
ganglia most closely resemble those of FZD7 and FZD9, suggesting that complexes of 
Wnts and these two FZDs along with LRP5 or LRP6 may play a role in modulating nodose 
neuron development throughout the period investigated.
LRP5 and LRP6 mRNAs were expressed at relatively low, approximately constant, 
levels between E13 and P5 in developing SCG (figs. 20 A and 20B), suggesting that if 
Wnt/FZD signalling does play a role in regulating some aspects of SCG neuron 
development, it is unlikely to involve signalling via the canonical Wnt pathway.
Tamai and colleagues (2000) reported that in Xenopus embryos, LRP6 activated 
Wnt-FZD signalling, and induced Wnt responsive genes, dorsal axis duplication and neural 
crest formation (215). In addition, a dominant-negative LRP6 mutant lacking the carboxyl 
intracellular domain blocked Wnt/FZD signalling, but not Dishevelled or (3-catenin
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activation, and inhibited dorsal axis duplication and neural crest development (215). These 
authors concluded that LRP6 functions upstream of DVL in Wnt-responding cells and 
synergizes with either Wnts or FZDs to form a ternary Wnt/FZD/LRP6 functional 
signalling complex.
DKK1
Dickkopf 1 (DKK1) is a secreted ligand for LRP5 and LRP6 that, by inhibiting the 
formation of a ternary complex between Wnt, FZD and LRP, prevents activation of the 
canonical Wnt signalling pathway (214)(218X441). but not other Wnt based signalling 
pathways (216)(441). In addition to LRPs, Dkkl interacts with another recently identified 
receptor class, the transmembrane proteins Kremen 1 and Kremen2, to synergistically 
inhibit LRP6 (218X442). Kremen proteins and Dkkl interact to regulate anteroposterior 
CNS patterning and this interaction is necessary for anterior neural development (442).
DKK1 mRNA shows a striking expression pattern within developing SCG (fig. 
21 A). Like FZD2, FZD4, FZD6 and FZD7 mRNAs, DKK1 was expressed at its lowest 
levels in E13 SCG and the level of expression increased as SCG aged. The increase in 
DKK1 mRNA expression levels between E13 and PO was of the order of 15-fold, 
suggesting that DKK1 has an important role in the developing SCG over this time, a period 
when SCG neurons are dependent on neurotrophic factors for survival and are innervating 
their peripheral targets. In accordance with the expression patterns of LRP5 and LRP6 
mRNAs within the developing SCG, my data on DKK1 mRNA expression suggests that if 
Wnts do interact with FZD2, FZD4, FZD6 and FZD7 to modulate the development of SCG 
neurons in the perinatal period, then it is unlikely that signalling is via the canonical Wnt 
signalling pathway. The expression of DKK1 mRNA within the developing trigeminal 
ganglion resembled that of FZD1 mRNA with relatively high levels of mRNA at E15 
increasing by around 50% to E l8 before gradually falling back down to E l3 levels by P5 
(fig. 21 A). DKK1 mRNA expression in the developing nodose ganglion showed a similar 
pattern to LRP5 mRNA expression with a modest increase in expression levels between 
E13 and E15, a decrease in the levels of expression between E15 and PO and a significant
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increase in the expression of DKK1 mRNA between PO and P5. In the case of DKK1 
mRNA this postnatal increase in expression was approximately 7-fold. The similarities 
between LRP5, LRP6 and DKK1 mRNA expression patterns suggests that Wnt/FZD 
signalling via the canonical pathway is under tight developmental control in the nodose 
ganglion.
Rvk
Ryk (related to tyrosine (Y) kinase), is a type I transmembrane glycoprotein that 
binds Wnt and forms a Wnt receptor complex with frizzled. RT-QPCR analysis of Ryk 
mRNA expression revealed that the levels of this mRNA were extremely low and relatively 
constant in developing SCG and trigeminal ganglia over the period analyzed (fig. 2IB). 
Whilst this was also generally the case in the developing nodose ganglion, there was a 
dramatic, approximately 20-fold, increase in Ryk mRNA expression within the nodose 
ganglion between PO and P5
Kamitory and colleagues (1999) reported Ryk’s distribution in the developing 
cerebral cortex of rats, and the results of that study showed that Ryk is highly expressed in 
neural progenitor cells in the ventricular zone and in mature neurons in the cortical plate, 
however, hardly any expression was detected in migrating neurons in the intermediate zone 
(443)(444). Furthermore, silencing Ryk results in misrouting of cranial motor nerves, 
suggesting that Ryk can contribute to Wnt-mediated axon guidance in vertebrates (445). 
Keeble (2006) showed that Ryk is a key guidance receptor in the establishment of the 
corpus callosum, and that Wnt5 is a chemorepulsive ligand for Ryk (446).
Kremen 1
Kringle containing transmembrane protein 1 (Kremen 1), is a high affinity receptor 
for DKK1 and cooperates with it to inhibit LRP signaling and the canonical Wnt signaling 
pathway (218)(442). In fact, it has been suggested that Kremen 1 acts as a gatekeeper for
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activation of this Wnt/p-catenin pathway (447). Kremen 1 mRNA was virtually undectable 
in developing SCG and trigeminal neurons at any of the ages studied (fig. 22). Although 
Kremen 1 mRNA was expressed at low, constant levels in the nodose ganglion between 
E l3 and PO, it increased dramatically by around 20-fold between PO and P5 in a similar 
manner to mRNAs of the other regulators of Wnt/FZD signaling efficacy, LRP5, DKK1 
and Ryk. The large increase in expression of FZD7, FZD9, LRP5, DKK1, Ryk and Kremen 
1 mRNAs in nodose ganglia between PO and P5 strongly suggests that either FZD7/Wnt 
and/or FZD9/Wnt signalling is playing an important role in the developing nodose ganglion 
at this time.
3.5.2 TGF-P superfamily
TGFp superfamily ligands include the TGFp, bone morphogenetic protein (BMP), 
growth and differentiation factor (GDF) and nodal-related families. These families play a 
pleiotropic role in vertebrate development, influencing diverse cellular functions in many 
cell systems, including cell specification, differentiation, proliferation, patterning, and 
migration (448). These functions require the tight control of ligand production, ensuring a 
highly ordered spatio-temporal distribution and specific activation, via receptor complexes 
of particular intracellular signalling pathways (449).
In this chapter I report the initial real time PCR screen for the expression of a large 
number of TGFp receptor superfamily members and selected ligands in the trigeminal, 
nodose and SCG ganglia at stages of development ranging from E13 to P5.
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Figure 23: Expression profiles of Alkl and Alk2. The data show the relative expression of Alkl and Alk2 
mRNA relative to GAPDH (in arbitrary units) at a number of different stages of development between El 3 
and P5 in the SCG (blue lines), nodose (pink lines) and trigeminal ganglia (green lines). Means and standard 
errors of data from three separate sets of ganglia at each stage are shown.
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Figure 24: Expression profiles of Alk3 and Alk4. The data show the relative expression of Alk3 and Alk4 
mRNA relative to GAPDH (in arbitrary units) at a number of different stages of development between E l3 
and P5 in the SCG (blue lines), nodose (pink lines) and trigeminal ganglia (green lines). Means and standard 
errors of data from three separate sets of ganglia at each stage are shown.
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Alkl
Alkl is one of the seven type I receptors for TGF-P family members, and it has been 
shown to play an important role in angiogenesis (450) and endothelial cell migration (451). 
Alkl has been shown to bind to TGF-p2 and TGF-p3 under specific experimental 
conditions (452). In addition, BMP9 and BMP 10 are two specific ligands that may 
physiologically trigger the effects of ALK1 on angiogenesis (453). The lowest level of 
Alkl mRNA expression was observed at E l3 in all three of the ganglia investigated (fig. 
23A). In developing trigeminal ganglia, Alkl mRNA levels increased steadily, by 
approximately 3-fold, between E l3 and PO before dropping slightly to P5. In developing 
SCG, Alkl mRNA levels remained steady between E13 and E l5, increased 3-fold between 
E15 and E18 and then dropped by approximately 30% between E18 and P5. The expression 
pattern of Alkl mRNA within developing nodose ganglia was a little erratic with large 
standard errors of the mean. In general, Alkl mRNA levels increased from E13 to El 5 and 
were then maintained at these higher levels until P5.
AM
Alk2 has been shown to be sufficient to induce epithelial-mesenchymal 
transformation in the heart (454), and to play an essential role in the development of cardiac 
cells (455). Although ligands signaling via ALK2 in vivo are currently unknown, it is likely 
that they include BMPs, such as BMP2, -5, -6 and -7 (456). The expression of Alk2 mRNA 
in the developing SCG shows an almost identical pattern to that of Alkl mRNA (fig 23 B). 
Alk2 mRNA is expressed at low, approximately constant, levels within developing nodose 
ganglia. In developing trigeminal ganglia, Alk2 mRNA is maximally expressed at E l3 and 
levels fall approximately 4-fold from this age to PO. Postnatally, there is an increase in the
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levels of Alk2 mRNA expressed within trigeminal ganglia, so that by P5 there is 
approximately 3-fold more Alk2 mRNA expressed than at PO.
Aik3
Alk3 has been shown to be the receptor for BMP2 (457), BMP4 (458), BMP7 (459), 
weakly to BMP6 (460) and GDF5 (461) with low affinity. The results of the developmental 
RT-QPCR screen for Alk3 mRNA revealed that this mRNA showed an almost identical 
pattern of expression in developing trigeminal ganglia and SCG (fig 24A). In both cases, 
Alk3 mRNA levels were relatively low and unchanged throughout the developmental 
period analyzed. Alk3 mRNA was expressed at significantly higher levels in the developing 
nodose ganglion compared to trigeminal ganglia and SCG. The expression pattern of Alk3 
mRNA in nodose ganglia was not dissimilar to that of Alkl mRNA. In particular, both 
mRNAs were expressed at their lowest levels in E13 nodose ganglia, both mRNAs 
increased their expression levels significantly between E13 and E l5 and Alkl and Alk3 
mRNAs were both retained at these increased levels between E l5 and P5.
A M
Alk4 is the receptor for GDF1 and GDF3 (462) that functions to modulate 
fundamental embryological events (463). Alk4 mRNA is expressed at low constant levels 
within trigeminal ganglia during the developmental period studied (fig. 24B). Alk4 mRNA 
is expressed at higher levels in the developing SCG compared to trigeminal ganglia. In the 
SCG, the lowest levels of Alk4 mRNA are expressed at E13 and expression levels steadily 
increase from E l3, by approximately 75%, to peak at E l8. There is a gradual 40% drop in 
the level of Alk4 mRNA expression in the SCG between E l8 and P5. Amongst the ganglia 
analyzed, the highest levels of Alk4 mRNA, by far, were expressed in the nodose ganglion. 
The levels of Alk4 mRNA expressed by E l3 nodose ganglia were almost 10-fold and 4-
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fold higher than in E l3 SCG and trigeminal ganglia, respectively. Alk4 mRNA expression 
levels increased approximately 50% between E l3 and 15 and then decreased slightly to 
E l8. There was an approximately 6-fold reduction in the amount of Alk4 mRNA expressed 
by nodose ganglia between E l8 and P5. The highest levels of Alk4 mRNA within nodose 
ganglia correspond to a period when nodose neurons are going through a period of 
programmed cell death regulated by the availability of target field derived neurotrophic 
factors (51). This observation raises the possibility that Alk4 may play some role in 
mediating this process.
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Figure 25: Expression profiles of Alk5 and Alk6. The data show the relative expression of Alk5 and Alk6 
mRNA relative to GAPDH (in arbitrary units) at a number of different stages of development between E13 
and P5 in the SCG (blue lines), nodose (pink lines) and trigeminal ganglia (green lines). Means and standard 
errors of data from three separate sets of ganglia at each stage are shown.
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Figure 26: Expression profiles of Alk7 and Noggin. The data show the relative expression of Alk7 and 
Noggin mRNA relative to GAPDH (in arbitrary units) at a number of different stages of development 
between E l3 and P5 in the SCG (blue lines), nodose (pink lines) and trigeminal ganglia (green lines). Means 
and standard errors of data from three separate sets of ganglia at each stage are shown.
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Alk5
Alk5, like Alkl, has been shown to regulate angiogenesis (464). Hass and 
colleagues (2009) recently described a role for Alk5 in activating the NGF system in 
pancreatic stellate cells (465). Alk5, like Alk4 and Alk7 is able to bind and be activated by 
the ligands GDF1 and GDF3 (462). Alk5 mRNA is expressed at its highest levels at E l3 in 
all three of the ganglia studied (fig. 25A). Of the three ganglia, the trigeminal ganglion 
expressed the lowest levels of Alk5 mRNA and the nodose ganglion expressed the highest 
levels. All three ganglia displayed a reduction in the expression of Alk5 mRNA between 
E13 and P5. The developmental reduction in Alk5 mRNA expression was most pronounced 
in nodose ganglia, being approximately 20-fold. The developmental reduction in Alk5 
mRNA expression was approximately 2-fold in SCG and 4-fold in trigeminal ganglia. The 
expression patterns of Alk5 mRNA suggest that Alk5 may regulate some aspect of neuronal 
differentiation in each of the three ganglia studied.
AM
Alk6 is one of the type I receptors for GDF5, GDF7, GDF9 and BMP 10 (466). Alk6 has 
been implicated in regulating axonal growth in the developing retina (467). Brederlau 
(2004) reported that Alk6 induces glial differentiation and cell survival in Adult 
hippocampal progenitor cells (468). Alk6 mRNA was barely detectable in developing 
trigeminal and nodose sensory ganglia (fig 25B). In contrast, Alk6 mRNA was expressed at 
high levels in the E13 SCG. The levels of Alk6 mRNA within the developing SCG 
decreased approximately 90% between E l3 and E l8 and remained relatively constant 
thereafter. The restriction of Alk6 mRNA expression to developing SCG and the high level 
of expression within this ganglion may indicate that this receptor plays some role in 
mediating the differentiation and/or survival of, or target innervation by, developing SCG 
neurons.
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Alk7
Alk7 is structurally similar to Alk4 and Alk5, and binds the same ligands, GDF1 
and GDF3. It has also been reported to be able to bind GDF8, activins and nodals (469). 
Carlsson and colleagues (2009) have recently linked Alk7 to metabolic disease (470). In 
contrast to the other Aik receptors that bind GDI and GDF3, nodose ganglia expressed 
negligible levels of Alk7 mRNA (fig. 26A). The expression pattern of Alk7 mRNA in 
developing SCG was similar to that of Alk4 mRNA, increasing by approximately 75% 
between E13 and E18 and then decreasing by approximately 40% between E18 and P5. The 
expression of Alk6 mRNA within developing trigeminal ganglia was somewhat erratic with 
large standard error of the mean values at each age. The levels of Alk7 mRNA expressed 
by E13 and E l5 trigeminal ganglia are high and approximately equal. Expression increases 
50% from E l5 to peak at E18 before falling 5-fold to P0 and remaining approximately 
constant thereafter.
Noggin
Noggin is a small glycoprotein originally characterized as a secretory molecule 
derived from Spermann organizer during the amphibian development (471). During 
mammalian embryogenesis, noggin is expressed in the node, notochord, dorsal somite, 
condensing cartilage, and immature chondrocytes and regulates patterning of the neural 
tube and somites (472)(202) Mammalian noggin plays an important role in early neural 
tube formation and in the adult nervous system (473). Noggin inhibits TGF-(3 signal 
transduction by binding to TGF-p family ligands and preventing them from binding to their 
corresponding receptors. Noggin has a key role in neural induction by inhibiting BMP4, 
along with other TGF-p signaling inhibitors such as chordin and follistatin (473)(202).
My data (fig 26B) revealed that noggin mRNA was barely expressed within 
developing trigeminal ganglia and SCG. However E l3 nodose neurons expressed
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significant levels of the mRNA for this TGF-p signaling inhibitor. Noggin mRNA levels 
increased approximately 50% between E l3 and E l5 in the developing nodose ganglion 
before falling 3-fold between E15 and P5. Since noggin is such an important regulator of 
TGF-p family signal transduction, the high levels and distinct pattern of expression of its 
mRNA in the developing nodose ganglion suggests that TGF-p family ligands play an 
important role in the development of nodose neurons.
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Figure 27: Expression profiles of BMPII and TGFfJ-II. .The data show the relative expression of BMPII and 
TGFP-II mRNA relative to GAPDH (in arbitrary units) at a number of different stages of development 
between E l3 and P5 in the SCG (blue lines), nodose (pink lines) and trigeminal ganglia (green lines). Means 
and standard errors of data from three separate sets of ganglia at each stage are shown.
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Figure 28: Expression profiles of ActR2a and ActR2b. The data show the relative expression of ActR2a and 
ActR2b mRNA relative to GAPDH (in arbitrary units) at a number of different stages of development 
between E l3 and P5 in the SCG (blue lines), nodose (pink lines) and trigeminal ganglia (green lines). Means 
and standard errors of data from three separate sets of ganglia at each stage are shown.
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BMPII
BMPs signal via three type I receptors (ALK2, 3, and 6) and three type II receptors 
(BMPRII, ActRIIA and ActRIIB). BMPRII and one its ligands, BMP6, have been reported 
to support survival of motomeurons in vitro (474). My RT-QPCR screen (fig 27A) revealed 
that BMPRII mRNA was expressed at relatively high, approximately constant, levels in 
both sensory ganglia analyzed throughout the developmental period studied (fig. 27A). In 
contrast, the levels of BMPRII mRNA expressed by E13 and E15 SCG neurons were 
relatively low and there was a 2-fold increase in BMPRII mRNA expression between E l5 
and E l8. The elevated levels of BMPRII mRNA expressed within the SCG at E l8 were 
maintained until P5.
TGF-B2
In mammals three TGF0s, TGF-01, TGF-p2 and TGF-p3, have been cloned, and 
although they often show overlapping functions in vitro, the isoform-specific knockout 
mice have revealed non-redundant and non-overlapping phenotypes. TGF-p2 7' mice are 
perinatally lethal and develop defects in different organs such as heart, kidney and testis, as 
well as various craniofacial defects and defects in both axial and appendicular skeleton 
(475). TGF-02 mRNA was expressed at very low levels in the E l3 SCG (fig 27B). The 
magnitude of TGF-02 mRNA expression increased gradually between E l3 and PO and was 
maintained at PO levels through to P5. The E l3 trigeminal ganglion also expressed very 
low levels of TGF-02 mRNA and these low levels were maintained at E15 and E l8. TGF- 
02 mRNA levels within the developing trigeminal ganglion increased approximately 6-fold 
between E l8 and PO before falling some 4-fold between PO and P5. In accordance with the 
situation in SCG and trigeminal ganglia, TGF-02 mRNA was expressed at relatively low 
levels, in relation to peak expression, in E l3 nodose ganglia. There was a five-fold increase 
in the amount of TGF-02 mRNA expressed within nodose ganglia between E13 and E15 
and this increase was promptly reversed between E l5 and E l8. These lower levels of TGF- 
0 mRNA expression at E18 were maintained between E l8 and P5. The dramatic peaks in 
TGF-02 mRNA expression in trigeminal and nodose ganglia, at PO and E l5, respectively,
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would seem to suggest that this TGF-p family ligand plays a defined role within these 
developing sensory ganglia at these ages by functioning in an autocrine or paracrine 
manner.
Activin receptors
Activins have a wide range of biological effects on cell growth and differentiation. 
Activins bind directly to activin receptor type 2a (ActR2a) or 2b (ActR2b). ActR2b/_ mice 
display various endocrine pancreas-related abnormalities, including islet hypoplasia and 
glucose intolerance, demonstrating the crucial role of ActR2b in the regulation of pancreas 
development (476). ActR2a'/_ male mice display multiple reproductive behavioral deficits, 
including delayed initiation of copulation, reduced mount, and intromission frequencies, 
and increased mount, intromission, and ejaculation latencies (477). My RT-QPCR screen 
revealed that ActR2a mRNA was expressed at relatively low levels in developing SCG and 
trigeminal ganglia throughout the developmental time frame investigated, suggesting that 
ActR2a does not play a role in any aspect of SCG or trigeminal neurons development (fig. 
28A). In contrast, very high levels of ActR2a mRNA were detected in E13 nodose ganglia. 
There was a gradual, almost 4-fold, drop in the levels of ActR2a mRNA expressed in the 
developing nodose ganglion between E l3 and P5, suggesting that ActR2a may play a role 
in the differentiation, early maturation or pioneer neuron target innervation of nodose 
neurons.
As in the case of ActR2a mRNA expression, ActR2b mRNA was expressed at 
relatively low, constant levels in trigeminal ganglia throughout the period studied (fig 28B). 
E13 SCG neurons expressed relatively high levels of ActR2b mRNA and these high levels 
of mRNA expression gradually decreased, approximately 6-fold, between E l3 and P5, 
suggesting that ActR2b may be involved in modulating SCG neuron differentiation, early 
maturation and initial target field innervation. High levels of ActR2b mRNA expression 
within E13 nodose ganglia increased even further over the next two embryonic days to 
reach a peak at E l5. There was a 6-fold decrease in the amount of ActR2b mRNA 
expressed within nodose ganglia between E l5 and E l8 and a further 50% decrease in the
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expression of this mRNA between El 8 and P5. The dramatic expression profile of ActR2b 
mRNA within developing nodose ganglia may indicate a role for this receptor in regulating 
neuronal differentiation in this ganglion.
GDF5
GDF5 binds specifically to BMPRlb, BMPR2 and ActR2a receptors, forming a 
heterodimeric complex that leads phosphorylation of smadl, 5, 8 and their translocation to 
the nucleus. GDF5 was initially identified as a growth factor involved in skeletal 
development and joint morphogenesis in humans and mice and has been shown to play a 
crucial role in the morphogenesis of tendons, ligaments and bones (478)(479)(480). GDF5 
mRNA was expressed at very low, approximately constant, levels in the developing SCG 
throughout the period examined (fig. 29) suggesting that it does not function in an autocrine 
or paracrine manner within the developing SCG to regulate neuronal development. At E l3, 
nodose ganglia expressed almost 10-fold more GDF5 mRNA than SCG of the same age. 
These relatively high levels of GDF5 mRNA were increased 2-fold between E13 and E15 
in the developing nodose ganglion. However, over the next 10 days the expression of 
GDF5 mRNA within nodose ganglia decreased steadily by 6-fold to reach its lowest level 
at P5. Trigeminal ganglia expressed similar levels of GDF5 mRNA compared to nodose 
ganglia at E l3 and these levels remained unchanged at E l5. There was an abrupt, 4-fold, 
increase in the expression of GDF5 mRNA between E l5 and E l8 followed by a 40% 
decrease between E l8 and PO. The reduced levels of GDF5 mRNA found in the trigeminal 
ganglion at PO compared to E l8 were maintained until P5. The high level of GDF5 mRNA 
expressed within trigeminal ganglia in the perinatal period suggests that this ligand may act 
in an autocrine or paracrine manner within this ganglion to regulate some aspect of 
neuronal or glial development. GDF5 will be the subject of chapter 4 of this thesis.
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3.53  TNF superfamily
Members of the tumour necrosis factor (TNF)/TNF-receptor (TNFR) superfamily 
are key regulators in the functioning of the immune system. They coordinate the immune 
response at multiple levels. For example, TNFa, LTa, LTp and RANKL provide signals 
required for lymphoid neogenesis, In addition, CD27, 0X40, 4-IBB and CD30 deliver co- 
stimulatory signals to augment immune responses, whilst pro-apoptotic members, such as 
TNF, CD95L and TRAIL, may contribute to the termination of the response. The biological 
function of individual family members has been examined in studies using mice over- 
expressing or lacking the gene in question. A growing appreciation of the molecular basis 
of signalling pathways activated by TNFRs has provided a framework for better 
understanding of the biology of this expanding family. However, although the rapid and 
robust activation of NF-kB and MAPK pathways is typical of acute TNF-R engagement, 
the molecular basis of sustained receptor signalling remains a mystery, in spite of its 
relevance to chronic inflammatory and immune responses (370).
DR6
Death receptor (DR) 6 (TNFRSF21), is broadly expressed by developing neurons, 
and is required for normal cell body death and axonal pruning both in vivo and after 
trophic-factor deprivation in vitro (481). DR6 is activated locally by an inactive surface 
ligand(s) that is released in an active form after trophic-factor deprivation, this ligand has 
been recently identified as being the beta-amyloid precursor protein (APP) (481). Amongst 
all the TNF superfamily receptor and ligand mRNAs that I screened, DR6 was the only 
mRNA that showed a similar developmental expression pattern in trigeminal, nodose and 
superior cervical ganglia (fig 30A). In all three ganglia, the lowest levels of DR6 mRNA 
were found at E13 and the expression of this mRNA increased gradually from E13 to peak 
at PO. The magnitude of increased DR6 mRNA expression between E l3 and PO was
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approximately 2-fold in each of the ganglia studied. After peaking at PO, DR6 mRNA 
levels decreased in all three ganglia to reach lower levels at P5. The developmental 
expression of DR6 mRNA in the peripheral ganglia studied appears to coincide with the 
timing and extent of naturally occurring neuronal cell death (51), suggesting that DR6 may 
play a role in this process.
TRAIL
The endogenous protein tumor necrosis factor receptor apoptosis-inducing ligand 
(TRAIL) (also known as TNFRSF22, Apo2L or SOBa), has been shown to induce 
apoptosis in a wide variety of transformed and cancer cells, but not normal healthy cells. 
Therefore, TRAIL is considered to be a tumour-selective, apoptosis-inducing cytokine 
(482). Given the size of the TNF superfamily, some ligands have several receptors and 
vice-versa. TRAIL has four receptors: Death Receptors 4 (DR4) and 5, and Decoy 
Receptors 1 (DCR1) and 2. TRAIL mRNA was expressed at extremely low, probably non­
functional, levels in both sensory ganglia throughout the developmental period studied (fig 
30B). However, developing SCG expressed significant amounts of TRAIL mRNA at all 
ages. TRAIL mRNA expression within the developing SCG appeared to increase around 
30% between E13 and E18 and then decrease back down to E13 levels between E18 and 
P5. However, given the large standard error of the mean value at each age, it may be that 
expression levels of TRAIL mRNA within SCG are in fact constant throughout the 
developmental period analyzed.
CD30
CD30, (also known as CD 153, TNFSF8) is a 40-kDa type II membrane associated 
glycoprotein expressed on CD4, Thl and Th2 cells, macrophages, dendritic cells (DC) and 
B cells (483). CD30 has only one ligand, CD30L, which has been reported to be expressed 
preferentially by activated or memory Th2 cells but not by resting B or T cells (484). 
CD30L/CD30 signaling has been reported to support activation and survival, and prevent
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excessive cell death of T-cells (485). CD30 mRNA was expressed at very low levels within 
E l3 nodose ganglia (fig. 31 A). However, the levels of this mRNA within nodose ganglia 
increased 8-fold between E13 and E18. After a 35% decrease in expression between E18 
and PO, CD30 mRNA levels increased 2-fold after PO to peak at P5. The lowest levels of 
CD30 mRNA were also found at E l3 in the trigeminal ganglion. The expression of CD30 
mRNA in E l5 trigeminal ganglia remained at the same levels as E l3, however, CD30 
mRNA expression increased 3-fold between E l5 and PO, before falling 30% between PO 
and P5. In the developing SCG, CD30 mRNA was expressed at relatively modest levels at 
E13 and increased approximately 2-fold between this age and E l5. There was an 8-fold 
drop in the levels of CD30 mRNA expressed in the developing SCG between E l5 and P5.
DR5
Death receptor (DR) 5 (TNFRSF10B) is one the receptors for TRAIL. Death 
receptors and their ligands are expressed in the developing nervous system, and many 
recent reports confirm their ability to trigger death of embryonic neurons and glia in vitro 
(486). However, with the exception of earlier reports concerning p75NTR, there is still 
relatively little evidence that death receptors play a role in nervous system development in 
vivo. Of the three ganglia that I studied, the highest levels of DR5 mRNA were expressed in 
the trigeminal ganglion (fig. 3IB). Peak expression of DR5 mRNA in the trigeminal 
ganglion occurred at El 3, and levels of this mRNA fell approximately 4-fold between E13 
and E l8. The amount of DR5 mRNA expressed by trigeminal ganglia increased by 75% 
between E l8 and PO and thereafter remained fairly constant between PO and P5. Nodose 
ganglia expressed several fold-lower levels of DR5 mRNA than trigeminal ganglia. At E13 
this difference was almost 5-fold. DR5 mRNA levels within developing nodose ganglia 
remained constant between E13 and E15, but fell by 50% between E15 and E18. The 
reduced levels of DR5 mRNA expressed within the nodose ganglion at E l8 were 
maintained until P5. The low levels of DR5 mRNA expressed within E l3 SCG increased 2- 
fold between E13 and E15. After E15, DR5 mRNA expression within the SCG gradually 
fell, by approximately 60%, to reach a minimum at P5.
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Figure 30: Expression profiles of DR6 and TRAIL. The data show the relative expression of DR6 and 
TRAIL mRNA relative to GAPDH (in arbitrary units) at a number of different stages of development between 
E l3 and P5 in the SCG (blue lines), nodose (pink lines) and trigeminal ganglia (green lines). Means and 
standard errors of data from three separate sets of ganglia at each stage are shown.
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Figure 31: Expression profiles of CD30 and DR5. The data show the relative expression of CD30 and DR5 
mRNA relative to GAPDH (in arbitrary units) at a number of different stages of development between E l3 
and P5 in the SCG (blue lines), nodose (pink lines) and trigeminal ganglia (green lines). Means and standard 
errors of data from three separate sets of ganglia at each stage are shown.
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Figure 32: Expression profiles of Fas and CD27. The data show the relative expression of Fas and CD27 
mRNA relative to GAPDH (in arbitrary units) at a number of different stages of development between El 3 
and P5 in the SCG (blue lines), nodose (pink lines) and trigeminal ganglia (green lines). Means and standard 
errors of data from three separate sets of ganglia at each stage are shown.
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Figure 33: Expression profiles of 4-1BB and 0X40. The data show the relative expression of 4-1BB and 
0X40 mRNA relative to GAPDH (in arbitrary units) at a number of different stages of development between 
E l3 and P5 in the SCG (blue lines), nodose (pink lines) and trigeminal ganglia (green lines). Means and 
standard errors of data from three separate sets of ganglia at each stage are shown.
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Fas
Fas (also known as Apol, TNFS6 or CD95) belongs to the subgroup of the TNF 
receptors that contains an intracellular “death domain” and triggers apoptosis. Fas is the 
receptor for Fas ligand (FasL). The Fas/FasL system is believed be involved in the deletion 
of autoimmune cells within the CNS (487). The spontaneous mouse mutants, Ipr and gld, 
which are partial loss-of-function mutants for Fas and FasL, respectively, have normal 
numbers of cortical, hippocampal, and motor neurons at birth (488)(489). However, they do 
show reduced dendritic branching of hippocampal and cortical neurons during die period in 
which synaptogenesis is occurring (489). I found the lowest levels of Fas mRNA were 
expressed within the developing SCG (fig 32A). From extremely low levels at E l3, the 
amount of Fas mRNA expressed by developing SCG increased by approximately 5-fold to 
PO and these increased levels were maintained until P5. However, even at postnatal ages 
Fas mRNA levels in the SCG were significantly lower than those expressed within either 
sensory ganglia at any time point studied. The expression levels of Fas mRNA within the 
trigeminal ganglion were relatively high and steady between E l3 and E l8. Fas mRNA 
expression levels doubled between E l8 and PO but promptly fell back to E l8 levels by P5. 
Developing nodose ganglia expressed high, relatively constant levels of Fas mRNA 
throughout the time period studied.
CD27
CD27 (TNFSRF7), is the receptor for CD27 ligand (CD27L). Little is known about 
CD27’s role in the CNS and PNS when compared to other members of the TNF 
superfamily.
CD27 is expressed by medullary thymocytes, most peripheral blood T cells, a 
subset of mature B cells, and NK cell. The biologic functions of CD27L include a co­
stimulatory signal for T-cell proliferation, generation of cytotoxic T cells, and enhanced 
cytokine secretion (490). The expression pattern of CD27 mRNA within developing SCG is
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striking (fig. 32B). CD27 is expressed at very high levels within this ganglion at E13 and 
thereafter expression drops precipitously, in a logarithmic manner, to be some 12-fold 
lower at P5. This expression pattern would seem to suggest that CD27 plays some role in 
the differentiation and early maturation of SCG neurons. In marked contrast, CD27 mRNA 
is expressed at very low levels in the E l3 trigeminal ganglion and these low levels are 
maintained between E l3 and E l8. From E l8, CD27 mRNA expression within developing 
trigeminal ganglia increases 5-fold to reach a maximum at P5. The expression pattern of 
CD27 mRNA within developing nodose ganglia is less interesting than those of trigeminal 
and superior cervical ganglia. Moderately high levels of CD27 mRNA in E l3 nodose 
ganglia steadily increase by around 25% to reach a maximum at P5, although it is unlikely 
that his increase is statistically significant.
4-1BB
4-1BB (also known as TNFRSF9, CD137) is the receptor for 4-1BB ligand (4- 
1BBL). Just like CD27, most studies involving 4-IBB and its ligand have been performed 
in the immune system. 4-IBB is expressed by activated T lymphocytes and monocytes and 
expression in primary cells is strictly activation dependent (491). Its mRNA, however, can 
also be detected in nonlymphoid cells such as epithelial and hepatoma cells after 
stimulation with IL-la (492). 4-1BBL is present on activated B cells, macrophages, 
myeloid cells, and dendritic cells (493). My data (fig 33A) revealed that the nodose 
ganglion had the highest levels of 4-IBB mRNA expression. The expression levels of 4- 
1BB mRNA were highest at E13 in the nodose ganglion and decreased by some 30% 
between this age and P5. The expression pattern of 4-IBB mRNA within developing 
trigeminal ganglia was very similar to that in nodose ganglia, although the levels of 
expression at each age were approximately 6-fold lower. 4-IBB mRNA was virtually 
undetectable within developing SCG.
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0X40
0X40 (also known as TNFRSF4 or CD 134) is the receptor forOX40 ligand 
(OX40L). 0X40 was initially identified as a T-cell activation marker and after cloning 
shown to be a member of the TNF superfamily with co-stimulatory function (494). 0X40 is 
expressed on activated CD4+T cells and a subset of CD8+ T, OX40L has been found to be 
expressed by activated T cells, B cells, dendritic cells, microglial cells and endothelial cells 
(495). 0X40 has been shown to be involved in the pathogenesis of encephalomyelitis and 
to be up regulated in MS (496). 0X40 mRNA was barely present in either of the 
developing sensory ganglia I analyzed (fig 33B), seemingly ruling out a role for OX40L in 
the development of cranial sensory neurons. In stark contrast 0X40 mRNA was expressed 
at very high levels within embryonic SCG. Peak expression of 0X40 mRNA in SCG 
occurred at El 3 and El 5. After El 5, the expression of this mRNA decreased greatly so that 
P5 SCG expressed 9-fold less 0X40 mRNA than E l5 SCG. My data raises the possibility 
that 0X40 may play a role in the differentiation and early maturation of SCG neurons.
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Figure 34: Expression profiles of OPG and TACI. The data show the relative expression of OPG and TACI 
mRNA relative to GAPDH (in arbitrary units) at a number of different stages of development between E13 
and P5 in the SCG (blue lines), nodose (pink lines) and trigeminal ganglia (green lines). Means and standard 
errors of data from three separate sets of ganglia at each stage are shown.
(A) (B)
3
£
2 CD40
1.8
1.6
1.4
1.2
1
0.8
0.6
0 .4
0.2
0
E13 E15 E18 P0  P5
7 0
Fn14
5 0
4 0SCG
Nodose
Trigeminal -g 
<
20
10
E13 E15 E18 P0  P5
SCG
• Nodose 
Trigeminal
Figure 35: Expression profiles of CD40 and Fnl4. The data show the relative expression of CD40 and Fnl4 
mRNA relative to GAPDH (in arbitrary units) at a number of different stages of development between E13 
and P5 in the SCG (blue lines), nodose (pink lines) and trigeminal ganglia (green lines). Means and standard 
errors of data from three separate sets of ganglia at each stage are shown.
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OPG
Osteoprotegerin (OPG) (TNFRSF11B) is the receptor to receptor activator of 
nuclear factor-kB (RANK) ligand (RANKL). In contrast to all other TNF receptors, OPG 
lacks transmembrane and cytoplasmatic domains and is secreted as a soluble protein. OPG 
mRNA is known to be expressed in a number of tissues (497)(498) but OPG protein is 
secreted mainly by cells of osteoblastic lineage (499). The major biological action of OPG 
is inhibition of osteoclast differentiation, inhibition of osteoclast resorptive function and 
stimulation of osteoclast apoptosis (500). OPG mRNA showed markedly different 
developmental expression patterns in each of the ganglia studied (fig. 34A). In the case of 
SCG, OPG mRNA levels were relatively low at E13 and increased 2-fold to E15. 
Expression levels at E l5 were maintained until E l8, but thereafter OPG mRNA expression 
decreased 2-fold to P5. OPG mRNA displayed a “V” shaped developmental expression 
pattern within trigeminal ganglia, whereby relatively high levels of expression at E13 fell 3- 
fold to E l8 before increasing 3-fold between E l8 and P5. Nodose ganglia expressed 
relatively low levels of OPG mRNA at E l3. OPG mRNA expression increased 2-fold from 
E13 to peak at E15, before then dropping some 4-fold between El 8 and P5.
TACI
TACI (TNFRSF13B) is the receptor for BAFF and April. Like most of the TNF 
superfamily receptors, TACI is better known for its roles in the immune system. TACI is 
mainly expressed on B cells (especially activated B cells), on a subset of T cells, in the 
spleen and in the thymus (501). TACI mRNA was expressed at low, constant levels in 
nodose neurons throughout the developmental period investigated (fig 34B). TACI mRNA 
was expressed at almost identical levels within trigeminal ganglia from E l3 to E l8 
compared to those in the nodose ganglia during this period. Interestingly, there was an 
abrupt, 10-fold, increase in the amount of TACI mRNA expressed within trigeminal 
ganglia between E l8 and PO and an almost as dramatic, 5-fold, decrease in TACI mRNA 
expression between PO and P5. This dramatic peak in TACI mRNA expression would
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seem to suggest that BAFF and/or APRIL play a crucial role in trigeminal neuron 
development in the perinatal period. TACI mRNA also showed quite a striking expression 
pattern within developing SCG. High level expression of TACI mRNA at E13 fell 
approximately 40% to E l8, after which there was a 2-fold increase in TACI mRNA 
expression to PO followed by a modest decrease in expression to P5.
CD40
CD40 (also known as CD 154 or TNFSF5) is the receptor for CD40 ligand (CD40L). 
CD40 is expressed in both immune and non-immune cell types (502). CD40L is expressed 
mainly on activated CD4+ T lymphocytes. CD40/CD40L has been shown to play a crucial 
role in cellular and humoral immune responses. In the CNS, CD40 expression is associated 
with MS lesions, Alzheimer’s disease, and amyotrophic lateral sclerosis (ALS) 
(503)(504)(505). Whether CD40 expression is causative or reactive to these disease 
processes is unknown. CD40 has been also shown to enhance inflammation through 
production of TNF-a, NO, and COX-2 (504)(506)(505). CD40 mRNA was not expressed at 
significant levels in the developing trigeminal ganglion (fig 3 5A). Within nodose ganglia, 
CD40 mRNA was expressed at moderately high, similar levels at E13 and E15. The 
amount of CD40 mRNA expressed by nodose ganglia decreased 2.5-fold between E l5 and 
E l8 and these reduced levels were maintained between E l8 and P5. By far the highest 
levels of CD40 mRNA were found in the developing SCG. The levels of CD40 mRNA 
expressed within E l3 SCG were twice that expressed by E l3 nodose ganglia and 
expression steadily increased, by approximately 80%, between E l3 and PO. The elevated 
levels of CD40 mRNA within PO SCG were maintained at P5.
Fnl4
FGF-inducible 14-kDa protein (Fnl4 but also known as TNFRSF12A or 
TWEAKR) is the receptor for TNF-like weak inducer of apoptosis (TWEAK). Fnl4 
mRNA is found in many tissues, but surface expression of Fnl4 protein has been described 
only for fibroblasts (507), endothelial (508X509), glioma (510) and neuronal cells (511).
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Nodose ganglia did not express appreciable levels of Fnl4 mRNA at any developmental 
time point studied (fig 35B). Similarly, trigeminal ganglia did not express significant levels 
of Fnl4 mRNA between E13 and E18. Although there was an approximately 10-fold 
increase in the levels of Fnl4 mRNA expressed by trigeminal ganglia between E l8 and PO, 
the magnitude of Fnl4 mRNA expression was still dramatically below that found in 
developing SCG. The expression pattern of Fnl4 mRNA within developing SCG was 
striking. At E l3, SCG expressed approximately 50-fold higher levels of this mRNA than 
sensory ganglia of the equivalent age. The high levels of Fnl4 mRNA within SCG 
increased even further, by 7-fold, between E l3 and PO and thereafter fell approximately 
40% between PO and P5. The expression pattern of Fnl4 mRNA within the developing 
SCG bears a striking resemblance to that of NGF receptor, trkA (51), suggesting that 
Fn 14/TWEAK signaling may play a role in regulating the survival of and/or target field 
innervation by developing SCG neurons.
HVEM
Herpes virus entry mediator (HVEM, TNFRSF14) is the receptor for lymphotoxin- 
related inducible ligand (LIGHT). HVEM was identified as a cellular mediator of herpes 
simplex virus (HSV) entry. Binding of HSV viral envelope glycoprotein D to this receptor 
protein has been shown to be part of the viral entry mechanism. Within the immune system, 
HVEM activates both stimulatory and inhibitory pathways, serving as a molecular switch 
by engaging two distinct classes of molecules: the TNF-related cytokines and the members 
of the Ig superfamily. HVEM engages the canonical TNF-related ligands LIGHT and 
lymphotoxin-p (LT-p). LIGHT initiates a strong co-stimulatory signal, promoting 
inflammation and enhancing immune responses. By contrast, HVEM engagement of the Ig 
superfamily members B and T lymphocyte attenuator (BTLA) and CD 160 activates 
inhibitory signaling in lymphoid cells (512).
HVEM mRNA was expressed at very low levels in developing trigeminal and 
superior cervical ganglia compared to its expression in nodose ganglia (fig 36A). Relatively
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high levels of HVEM mRNA within El 3 nodose ganglia decreased 2-fold between El 3 and 
E l5. This lower level of expression was maintained until PO, after which HVEM mRNA 
expression increased 2.5-fold to P5. In accordance with the relatively high level of HVEM 
mRNA expression within developing nodose ganglia compared to trigeminal ganglia and 
SCG, recent work from our lab has shown that LIGHT/HVEM signaling negatively 
regulates neurite growth from developing nodose neurons via NF-kB inhibition (513).
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Figure 36: Expression profiles of HVEM and BCMA. The data show the relative expression of HVEM and 
BCMA mRNA relative to GAPDH (in arbitrary units) at a number of different stages of development between 
E l3 and P5 in the SCG (blue lines), nodose (pink lines) and trigeminal ganglia (green lines). Means and 
standard errors of data from three separate sets of ganglia at each stage are shown.
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Figure 37: Expression profiles of EDAR and XEDAR. The data show the relative expression of EDAR and 
XEDAR mRNA relative to GAPDH (in arbitrary units) at a number of different stages of development 
between E l3 and P5 in the SCG (blue lines), nodose (pink lines) and trigeminal ganglia (green lines). Means 
and standard errors of data from three separate sets of ganglia at each stage are shown.
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BCMA
B cell maturation antigen (BCMA) (TNFRSF17) is the receptor for a proliferation- 
inducing ligand (April) and B-cell activating factor (BAFF). Like some of the previous 
receptors, BCMA is better known for its role in the immune system. It has been shown to 
be involved in regulating B cell differentiation, survival of long-lived bone marrow plasma 
cells and survival of plasmablasts (514). Detailed attention will be given to this receptor on 
chapter 5 of this thesis. The data from my RT-QPCR screen (fig 36B) revealed that BCMA 
mRNA was expressed at negligible levels in nodose ganglia throughout the developmental 
period investigated. Although BCMA mRNA was expressed at higher levels within 
developing SCG compared to nodose ganglia, expression levels were still significantly 
lower than in developing trigeminal ganglia. At E l3, BCMA mRNA was expressed at 3- 
fold higher levels in trigeminal ganglia than at any age in nodose ganglia and this level was 
maintained at E15 and E18. There was a dramatic, almost 7-fold, increase in BCMA 
mRNA levels between E l8 and PO which was almost completely reversed between PO and 
P5.
EDAR
Ectodysplasin (EDAR) is the receptor for EDA-1. EDAR has been reported to be 
required for normal development of several ectodermally derived organs in humans and 
mice. Edar mutations cause ectodermal dysplasias characterized by defective development 
of teeth, hairs, and several exocrine glands such as sweat glands presumably due to 
impaired NF-kB response (515). The expression patterns of EDAR mRNA within 
developing nodose and superior cervical ganglia were very similar to those of BCMA with 
low, relatively constant, levels of expression in both ganglia at each age studied (fig 37A). 
EDAR mRNA was expressed at minimal levels within E l3, E l5 and E l8 trigeminal 
ganglia. However, there appeared to be a large increase in the amount of EDAR mRNA 
expressed by trigeminal ganglia between E l8 and PO and thereafter between PO and P5, 
although the large standard error of the mean values at PO and P5 questions the validity of 
this data.
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XEDAR
X-linked ectodysplasin receptor (XEDAR) is a receptor for EDA-A2. EDA-A2, like 
EDA-1, has been implicated in the development of ectoderm-derived organs (516). 
According to the same study, XEDAR is dispensable for normal mouse development. 
However, a potential role for XEDAR in skeletal muscle homeostasis was revealed by 
EDA-A2 transgenic mice, which developed multifocal myodegeneration that was 
dependent on expression of XEDAR. XEDAR mRNA was barely detectable in the 
developing SCG throughout the period I studied (fig 37B). Maximal levels of XEDAR 
mRNA were expressed at E l3 in trigeminal and nodose ganglia, although in the latter the 
levels of XEDAR mRNA were 5-fold higher. Both ganglia displayed a significant 
reduction in XEDAR mRNA expression between E l3 and E l8. In the case of nodose 
ganglia the magnitude of this reduction was 2.5-fold, whereas for trigeminal ganglia it was 
10-fold. XEDAR mRNA levels remained constant in nodose ganglia between E18 and P5, 
whereas in trigeminal ganglia the levels of this mRNA increased 4-fold over the same 
period.
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Figure 38: Expression profiles of TROY and mSOB. The data show the relative expression of TROY and 
mSOB mRNA relative to GAPDH (in arbitrary units) at a number of different stages of development between 
E l3 and P5 in the SCG (blue lines), nodose (pink lines) and trigeminal ganglia (green lines). Means and 
standard errors of data from three separate sets of ganglia at each stage are shown.
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Figure 39: Expression profiles of BAFF-R and DR3. The data show the relative expression of BAFF-R and 
DR3 mRNA relative to GAPDH (in arbitrary units) at a number of different stages of development between 
E l3 and P5 in the SCG (blue lines), nodose (pink lines) and trigeminal ganglia (green lines). Means and 
standard errors of data from three separate sets of ganglia at each stage are shown.
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ITROY
TNFRFS expressed on the mouse embryo (TROY but also known as Taj or 
TNFRSF19) is an orphan receptor of the TNF superfamily, i.e. there is no know ligand for 
it. TROY has been shown to be broadly expressed in postnatal and adult neurons (517). The 
same study reported that TROY may be involved in either the regulation of neuronal 
precursor proliferation or the maintenance of their undifferentiated state (517). Sha Mi 
(2008) reported a possible role for TROY in CNS axon regeneration (518). The expression 
patterns of TROY mRNA were markedly different in each of the ganglia studied (fig. 38A). 
In trigeminal ganglia, TROY mRNA expression levels decreased 3-fold between E13 and 
E18 before increasing 5-fold between El 8 and PO and remaining steady, thereafter, to P5. 
In contrast, nodose ganglia showed minimal expression of TROY mRNA at E l3 followed 
by a 3-fold increase in expression levels between E13 and E l8. The elevated levels of 
TROY mRNA in the E l8 nodose ganglia were not maintained as development proceeded, 
rather expression of this mRNA decreased by 3-fold between El 8 and P5. Highest levels of 
TROY mRNA expression occurred in the developing SCG at E l3. Thereafter, expression 
decreased 2-fold to E18 and remained steady between E18 and P5.
mSOB
mSOB (also known as TNFRSF23, DcRl or DcTRAIL Rl) is a decoy receptor for 
TRAIL. As a decoy receptor, mSOB prevents DR4- and DR5-mediated TRAIL-induced 
apoptosis (519). Both of the sensory ganglia that I analyzed expressed minimal levels of 
mSOB mRNA at E l3, and both ganglia displayed an approximately 2.5-fold increase in the 
expression of this receptor mRNA from El 3 to El 5 that was followed by a modest decrease 
in expression between E l5 and E l8. In trigeminal ganglia, mSOB mRNA expression more 
than doubled between E l8 and PO, before falling back to E18 levels by P5. In nodose 
ganglia, mSOB mRNA levels remain fairly steady between E l5 and PO, before increasing 
by 50% between PO and P5. The developing SCG expressed the highest levels of mSOB 
mRNA during the embryonic period. However, after reaching a peak of expression at PO, 
mSOB mRNA levels decreased 30% between PO and P5.
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BAFF-R
B cell activating factor receptor (BAFF-R, TNFRSF13C) is the receptor for B cell 
activating factor (BAFF). Like many other members of the TNF superfamily, BAFF-R has 
been well studied in the immune system, specially its role in regulating mature B cell and 
survival and maintenance (520). In BAFF-R'7' mice, B cells develop normally up to the 
stage of IgM+ immature/transitional B cells, but cannot complete maturation in the spleen, 
as BAFF/BAFF-R-dependent survival signals are missing (521). I found that the highest 
levels of BAFF-R mRNA were expressed by the E13 and El 5 SCG (fig. 39A). After E15, 
BAFF-R mRNA levels within the developing SCG fell by 15-fold to reach a minimum at 
P5. BAFF-R mRNA showed an erratic pattern of expression in developing trigeminal 
ganglia with moderate levels of this mRNA being expressed throughout the period studied. 
E13 nodose ganglia expressed relatively low levels of BAFF-R mRNA that increased 2- 
fold to reach a peak at E15. After E15, the expression of this receptor mRNA decreased 4- 
fold to El 8 and remained relatively stable thereafter.
DR3
Death receptor (DR) 3 (also known as TNFRSF25, TRAMP, LARD or WSL-1) is 
the receptor for TL1A. DR3 has been reported to be expressed mainly in T lymphocytes 
(522). DR3 acts by binding to the adaptor molecule TRADD, which in turn endows DR3 
with dual-signaling capacity to either activate NF-kB and MAP-kinase signaling or 
alternatively trigger caspase activation and apoptosis (523)(522)(524). DR3 mRNA was 
expressed at barely detectable levels throughout the period E l3 to P5 in both SCG and 
trigeminal ganglia (fig. 39B). However, DR3 mRNA displayed a striking expression 
pattern within developing nodose ganglia. Levels of this mRNA were highest at E13 and 
E15 and fell approximately 4-fold between E l5 and P5.
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Figure 40: Expression profiles of APRIL and TNF-a. The data show the relative expression of APRIL and 
TNF-a mRNA relative to GAPDH (in arbitrary units) at a number of different stages of development between 
E l3 and P5 in the SCG (blue lines), nodose (pink lines) and trigeminal ganglia (green lines). Means and 
standard errors of data from three separate sets of ganglia at each stage are shown.
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Figure 41: Expression profiles of BAFF and Tweak. The data show the relative expression of BAFF and 
Tweak mRNA relative to GAPDH (in arbitrary units) at a number of different stages of development between 
E l3 and P5 in the SCG (blue lines), nodose (pink lines) and trigeminal ganglia (green lines). Means and 
standard errors of data from three separate sets of ganglia at each stage are shown.
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Figure 42: Expression profiles of LT^-R and TL1A. The data show the relative expression of LTfi-R and 
TL1A mRNA relative to GAPDH (in arbitrary units) at a number of different stages of development between 
E l3 and P5 in the SCG (blue lines), nodose (pink lines) and trigeminal ganglia (green lines). Means and 
standard errors of data from three separate sets of ganglia at each stage are shown.
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APRIL
A proliferation-inducing ligand (APRIL) (TNFSF13) is the ligand for BCMA and 
TACI. APRIL is processed intracellularly within the Golgi apparatus by a furin pro-protein 
convertase prior to secretion of the biologically active form. APRIL can also be expressed 
as a cell surface fusion protein with TWEAK called TWE-PRIL (525). APRIL is highly 
expressed in several tumor tissues, stimulates the growth of tumor cells (526) and promotes 
survival of normal plasmablasts and plasma cells (527) (528). Evidence has been presented 
that APRIL contribute to malignancies of B cells and plasma cells: non-Hodgkin's 
lymphoma, Hodgkin lymphoma, chronic lymphocytic leukemia, multiple myeloma and 
Waldenstrom's macroglobulinemia (529). The highest levels of APRIL mRNA were 
detected in the developing nodose ganglion (fig 40A). Relatively high level of APRIL 
mRNA at E13 increased 3.5-fold to peak at E15, before falling back to E13 levels by E18. 
APRIL mRNA levels within the nodose ganglion almost doubled between E l8 and PO 
before once again decreasing from PO to P5. APRIL mRNA was expressed at very low 
levels in E13 SCG and trigeminal ganglia. In the case of trigeminal ganglia, the expression 
of APRIL mRNA remained at fairly constant levels between El 3 and P5. In the developing 
SCG, APRIL mRNA expression increased 3-fold between E l3 and E l8, fell by 25% 
between E l8 and PO and then increased by 30% between PO and P5.
TNF-q
TNF-a (TNFSF1 A) is the ligand for TNFR1 and TNFR2. TNF-a signaling has been 
shown to have several important functions within the CNS including: injury-mediated 
microglial and astrocyte activation; regulation of blood brain barrier permeability; febrile 
responses; regulating glutamatergic transmission; modulating synaptic plasticity and 
scaling (530). TNFR1 is expressed in most cell types, and can be activated by binding of 
either soluble TNF (solTNF) or transmembrane TNF (tmTNF), with a preference for 
sol TNF. TNFR2 is expressed primarily by microglia and endothelial cells and is 
preferentially activated by tmTNF. TNF-a appears to regulate hippocampal neuronal 
development as TNF-deficient mice display accelerated maturation of the dentate gyrus and
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smaller dendritic trees in the hippocampus (531). TNF-a mRNA was expressed at very low 
levels in nodose ganglia at E l3, E l5 and E l8 (fig. 40B). However, the expression levels of 
this mRNA within nodose ganglia increased 7-fold between E l8 and PO, before halving 
between PO and P5. E13 trigeminal ganglia expressed 3.5-fold more TNF-a mRNA than 
nodose ganglia of the same age. Like nodose ganglia, the expression levels of this mRNA 
remained constant within developing trigeminal ganglia between E l3 and E l8, before 
increasing 4-fold to reach a peak at PO. The expression levels of TNF-a mRNA within 
trigeminal ganglia decreased 5-fold between PO and P5, mirroring the expression pattern of 
this mRNA in nodose ganglia. The similarity in expression patterns between nodose and 
trigeminal sensory ganglia suggests that TNF-a is functionally important in the 
development of sensory neurons. SCG express moderately high levels of TNF-a mRNA at 
E13 and expression levels fall approximately 65% between E13 and E18. After E18, the 
expression levels of TNF-a mRNA within SCG double to P5.
BAFF
B cell activation factor (BAFF) (also known as TNFSF13B, Blys, TALL-1 or 
THANK) is the ligand for BCMA, TACI and BAFF-R. BAFF has been reported to be 
critical for maintaining the development and homeostasis of normal B-cells (352). BAFF 
acts as a potent B-cell growth factor and co-stimulator of immunoglobulin (Ig) production. 
Transgenic overexpression of BAFF in mice results in elevated numbers of mature B cells, 
and development of autoimmune-like manifestations reminiscent of systemic lupus 
erythematosus (532). BAFF mRNA was expressed at the highest levels in developing 
nodose ganglia (fig 41 A). From relatively high levels of expression at E l3, BAFF mRNA 
levels in the nodose ganglion increased by 70% to peak at E l5. Thereafter, BAFF mRNA 
expression decreased to E l3 levels between E l5 and E l8, before increasing 3-fold between 
E l8 and P5. E l3 trigeminal ganglia expressed 3-fold lower levels of BAFF mRNA 
compared to El 3 nodose ganglia. The expression of this mRNA within trigeminal ganglia 
doubled from E13 to peak at E15 and then decreased by 40% between E15 and E18. These 
reduced levels of BAFF mRNA were maintained in the trigeminal ganglion until P5. E l3 
SCG expressed identical levels of BAFF mRNA to those expressed by E l3 trigeminal
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ganglia. After E l3, BAFF mRNA levels within the developing SCG increased 2.5-fold to 
peak at E l8. Thereafter, mRNA levels decreased slightly between E l8 and PO before being 
restored to E l8 levels by P5.
TWEAK
TNF-like weak inducer of apoptosis (TWEAK, Apo3L, TNFSF12) is the ligand for 
Fnl4. Studies have shown expression of TWEAK in the CNS, and reported that in response 
to a variety of stimuli, including cerebral ischemia, there is an increase in TWEAK and 
Fnl4 expression in perivascular astrocytes, microglia, endothelial cells, and neurons with 
subsequent increase in the permeability of the blood-brain barrier (BBB) and cell death 
(533). TWEAK mRNA was expressed at low, almost constant, levels within trigeminal 
ganglia over the time period investigated (fig. 4 IB). E13 nodose ganglia expressed high 
levels of TWEAK mRNA that increased even further to peak at E l5. After E l5, TWEAK 
mRNA levels within nodose ganglia decreased by 3.5-fold to E l8, remained constant 
between E l8 and PO and then increased by 75% between PO and P5. Interestingly, TWEAK 
mRNA was expressed in a similar pattern to the mRNA of its receptor, Fnl4, in the 
developing SCG (figs. 41B and 35B). TWEAK mRNA was virtually undetectable in the 
E13 SCG but its expression levels increased almost 30-fold between E13 and PO, the age of 
peak expression of Fnl4 mRNA. Unlike Fnl4 mRNA, the expression levels of TWEAK 
mRNA increased further between PO and P5.
LIB
Lymphotoxin p (LTp) (TNFSF3) is the ligand for LTp-R. Little is known about this 
ligand when compared to other members of the TNF superfamily. Cannela and colleagues 
(1997) reported expression of LTp in different glial cell types in the CNS. My 
developmental RT-QPCR screen (fig 42A) showed very low and practically constant LTp 
mRNA levels in the SCG and trigeminal ganglia throughout the developmental period 
studied. In contrast, LTp mRNA was expressed at very high levels in the nodose ganglion
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at E13. From E13 to P5, the expression levels of this mRNA within nodose ganglia steadily 
fell by approximately 3-fold.
TL1A
TNF ligand related molecule 1(TL1A, TNFSF15, VEGI) is the ligand for DR3 and 
the decoy receptor (DcR) 3. TL1A is expressed primarily in endothelial cells. DR3 is 
expressed mainly on lymphocytes, and its interaction with TL1A can provide a 
costimulatory signal for the activation of T cells (534). TL1A mRNA was virtually 
undetectable in developing SCG throughout the period studied (fig. 42B). Although TL1A 
mRNA was also virtually undetectable in the developing nodose ganglion from E l3 to E l8, 
its expression levels increased 6-fold between E l8 and PO, a level that was maintained until 
P5. Despite the increase in the expression of TL1A mRNA from E l8, the levels of this 
mRNA expressed in postnatal nodose ganglia are probably still too low to be functional. 
TL1A mRNA displays a dramatic expression pattern in developing trigeminal ganglia. 
Extremely low levels of expression at E13 increase more than 50-fold to peak at El 5. From 
E l5, the levels of TL1A mRNA expressed within developing trigeminal decreases by 8- 
fold to P5. The high levels of TL1A mRNA expressed within E15, E l8 and PO trigeminal 
ganglia is somewhat curious, since trigeminal ganglia do not appear to express functional 
levels of DR3 mRNA (fig. 39B) and hence it is unlikely that TL1A will be able to act in a 
paracrine or autocrine manner to regulate any aspects of neuronal or glial cell development 
within this ganglia.
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4. Growth differentiation factor 5 is a target 
derived growth factor that is required for correct 
target innervation by sympathetic neurons in vivo.
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4.1 Introduction
Nerve growth factor (NGF) is the paradigmatic target-derived neurotrophic factor on 
which the foundations of neurotrophic theory are based(51) In the developing peripheral 
nervous system, postganglionic sympathetic neurons and the majority of sensory neurons 
depend for their survival on a supply of NGF that is synthesized in their targets and 
conveyed by retrograde axonal transport to their perikarya where it promotes survival 
signalling (52)(535). Target-derived NGF not only governs the number of sympathetic and 
sensory neurons that survive a phase of programmed cell death that occurs shortly after 
axons reach their targets, but also acts locally on axon terminals to promote growth and 
branching within target tissues(536)(537). While several extracellular signals are known to 
promote the growth of sympathetic axons and guide them to their targets in vivo, such as 
artemin, NT3 and endothelins (538)(170)(539), NGF is the only bone fide target-derived 
factor shown to be crucial for the axons of NGF-dependent sympathetic and sensory 
neurons to grow and ramify within their distal target organs and tissues in v/vo(102)(101).
The PCR screen reported in the previous chapter has identified several 
potentially novel regulators of sympathetic neuron development, including members of the 
TGFp superfamily. In particular, I found high levels of expression of BMPR-Ib and BMPR- 
II, which form a high affinity complex for GDF5. This factor has been shown to play roles 
in tendon ligament formation (321)(322) tooth formation (323) morphogenesis of the joints 
(540) angiogenesis (325), and survival of midbrain dopaminergic neurons (541). GDF5 is 
mostly expressed at sites of cartilage differentiation in developing limbs, where it may 
function as a signal for chondrogenesis (310)(542). It has been shown that overexpression 
of GDF5 increases the length and width of skeletal elements with fused joints (317)(543). 
Brachypodism (bp) mice carry a functional mutation for the GDF5 gene. Bp mice exhibit a 
reduction in the length of the limb bones, metacarpals, metatarsals and proximal phalanges, 
in particular being severely shortened, and the middle phalanges and interphalangeal joints 
are absent (310)(540)(544).
The in vitro and in vivo studies of GDF5 in the well-characterized mouse SCG 
model system reported in this chapter have established that GDF5 is a novel, target-derived
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neurotrophic factor for developing SCG neurons that selectively promotes axonal growth 
and branching and is essential for establishing sympathetic innervation in vivo, but does not 
promote and is not required for sympathetic neuron survival.
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4.2 Results
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Figure 43: Expression of BMPRs in the developing SCG.
The data show the relative expression of (A) BMPR-lb, (B) BMPR-la and (C) BMPR-II mRNA relative to 
GAPDH mRNA (in arbitrary units) and the respective Real time PCR melting curves (showing primer 
specificity) in E13, E l5, E l8, PO and P5 SCG. Means and standard errors of data from three separate sets of 
ganglia at each age are shown.
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Figure 44: Expression of BMPR-lb in axons and growth cones.
(A) The photomicrographs show the same fields of cultures of PI SCG neurons triple-stained for 
BMPR-lb (green), TH (red) and DAPI (blue) and a merge image showing co-localisation of BMPR- 
lb and TH (B) Omission of the primary BMPR-lb antibody was used to control for non-specific 
binding of the secondary antibodies. Scale bar = 10pm.
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Expression of BMPRs in the developing SCG
I started by quantifying mRNA levels for the BMP receptors in the SCG at intervals 
throughout development by real time PCR. Briefly, RNA was extracted from the SCG of 
CD1 mouse embryos at E15, E18 and post-natal pups at PI and P5. After converting it into 
cDNA, real time PCR was carried out using primers specifically designed for BMPR-II, 
BMPR-la and BMPR-lb (for details on sequences and annealing temperatures see materials 
and methods section 2.8).
My results show that BMPR-la was expressed at the lowest level of all three 
receptors, but it was expressed constantly throughout development (fig. 43C). BMPR-lb 
was expressed at the highest level at E l5 after which its expression decreased slightly but 
remained at a relatively high level throughout the developmental period I studied (fig. 
43B). BMPR-II was expressed at a consistent level at all ages examined (fig. 43A).
The high level of expression of the BMPR-lb receptor, along with the availability of 
a selective ligand (GDF5), gave me the tools to examine the function of this receptor and its 
ligand in further detail. To determine which kind of cells in the SCG express BMPR-lb, I 
used immunohistochemistry to identify this receptor in dissociated SCG cultures from PI 
mice. These cultures were grown overnight in medium supplemented with NGF before 
being fixed and processed for triple immunohistochemistry. In these preparations neurons 
were positively identified with antibodies to TH, and cell nuclei were labelled with the 
fluorescent nuclear marker DAPI. BMPR-lb was expressed on the cell soma of all neurons 
(fig. 44A). Furthermore I found strong BMPR-lb expression on developing axons and 
growth cones, raising the possibility that growing axons may be able to respond to 
endogenous GDF5 that might be expressed en-route to or within their target tissues. Non­
neuronal cells showed no expression of BMPR-lb (data not shown). To control the 
specificity of the BMPR-lb antibody, a negative control was used in which the BMPR-lb 
antibody was omitted from the procedure. In these preparations no staining was evident 
(fig. 44B), indicating the specificity of the BMPR-lb staining shown in fig. 44A.
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Figure 45: Expression of GDF-5 in SCG compared to SCG target fields.
(A) The data show the level o f GDF-5 mRNA in the submandibular gland (SMG), nasal 
mucosa (NM) and SCG relative to GAPDH mRNA at PO in wild-type CD-I mice. (B) Data 
show the relative expression o f GDF5 in SMG (blue) compared with SCG (red). (C) Data 
shows amplifications plots for GDF5 real time PCR of the SMG time course. Means and 
standard errors o f data from three separate sets of ganglia at each age are shown.
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Figure 46: Expression of GDF5 in the SCG target tissues.
Photomicrographs show consecutive sections of SCG (A), SMG (C) and NM (E) double stained for 
GDF5 (red in (A) and (C) , green in (E)) and TH (green in (A) and (C ), red in (E)) Merge image 
showing co-localization of GDF5 and TH. Omission of the primary GDF5 antibody was used to 
control for non-specific binding of the secondary antibodies (B, D, F). Scale bar = 10pm.
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Expression of GDF5 in the developing SCG and targets
GDF5 has been shown to be a selective ligand for BMPR-lb but not BMPR-la 
(461). Given this information, and the high expression of BMPR-lb in the SCG during 
development, I used real time PCR to quantify the level of GDF5 mRNA in the SCG. I 
found that GDF5 mRNA was only just above the detection limit of real time PCR program, 
which suggests GDF5 is either not synthesized at all or synthesized at an extremely low 
level in the SCG (fig. 45 A, 45B).
To determine if GDF5 is expressed in the target tissues of the SCG, I dissected two 
such target tissues that receive a dense sympathetic innervation from the SCG (545), the 
submandibular gland (SMG) and the nasal mucosa (NM). I carried out a direct comparison 
between the expression of GDF5 in the PO SCG, SMG and NM by real time PCR, and 
found that GDF5 was clearly expressed in these targets with about a 7 fold higher level in 
the SMG compared with the NM relative to GAPDH mRNA whereas the level of GDF5 
mRNA in the SCG was barely detectable (fig. 45A). Due to the difficulty of obtaining a 
“clean” preparation of nasal mucosa, I focused on characterizing the expression of GDF5 
mRNA in the SMG. I carried out a real time PCR experiment looking at GDF5 mRNA 
expression in the SCG and SMG over a range of ages. GDF5 mRNA was not expressed in 
the SMG at E l5, but its expression steadily increased from E l5 onwards, reaching its 
maximal expression at P5 and then decreased in adulthood (fig. 45B).
The high expression of GDF5 mRNA in the SMG but not in the SCG suggested that 
GDF5 may act in a similar way to NGF developing sympathetic neurons, i.e, being 
synthesized in the target fields of these neurons and be retrogradely transported from the 
target fields to the neuron cell bodies of the SCG (546). To investigate this possibility 
further, I used two approaches. Firstly I dissected the SMG, SCG and the nasal mucosa 
from PI CD1 mice and processed them for immunohistochemical analysis using antibodies 
for GDF5. To show the innervating sympathetic axons, I also, stained the tissue for tyrosine 
hydroxylase (TH -  marker for noradrenergic neurons). For all immunohistochemistry, a 
negative control was included to control non-specific binding of the primary GDF5 
antibody.
143
In the nasal mucosa, I found strong expression of GDF5 protein in the nasal 
epithelium (fig. 46E), in the region innervated by TH-positive axons (fig.46F). 
Furthermore, I also found strong expression of GDF5 in SMG (fig. 45C). Although I found 
no significant amount of GDF5 mRNA in the SCG itself, I examined the SCG by 
immunohistochemistry. Interestingly I found that GDF5 was abundantly present in the SCG 
at P5 and co-localized with TH (fig. 46A). Sections from which the GDF5 primary 
antibody was omitted from the staining procedure, showed little or no background staining, 
indicating the specificity of the primary antibody (fig. 46B, 46D, 46F). To confirm the 
presence of GDF5 protein in the SCG, I used a different antibody against GDF5 (MP-52), 
which has previously been shown to recognize both precursor and mature forms of GDF5 
by western blot (547). In extracts of PO SCG analyzed by western blot, this antibody 
recognized two high molecular isoforms of GDF5 which correspond to those in a cell 
extract of GDF5 expressing CHO cells, which were used as a positive control (fig. 47). This 
finding agrees with the immunohistochemical data showing the presence of GDF5 protein 
in the SCG. These findings when taken in conjunction with the real time PCR data 
examining the expression of GDF5 mRNA, suggest that GDF5 is synthesized in the target 
fields of the SCG neurons, but not in the neurons themselves, and is taken up by the axons 
of the innervating neurons and conveyed by retrograde transport from the targets to the cell 
bodies of the neurons in the SCG.
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Figure 47: GDF5 protein is present in the SCG.
PO SCG extracts grown overnight and further analyzed by western blot, showing the presence of 
two high molecular isoforms of GDF5 that correspond to those in a cell extract of GDF5 expressing 
Chinese Hamster Ovary (CHO) cell line.
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Figure 48: Effect of GDF-5 on sympathetic neuron survival.
The data show SCG neurons time course survival (24h) comparison between neurons grown only 
with lOng/ml of NGF (control normalized to 100%) and lOng/ml of NGF plus lOng/ml plus 
lOng/ml of GDF5 at a number of different stages of development between El 3 and P4.
Means and standard errors of data from three separate sets of ganglia at each age are shown.
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Effect of GDF-5 on sympathetic neuronal survival
In the previous section as mentioned, the expression of GDF5 in SCG target fields 
and the presence of GDF5 protein in the SCG, suggested that GDF5 may function as a 
target-derived neurotrophic factor for developing sympathetic neurons. This implies that it 
may potentially regulate their survival or the growth and/or branching of the axons in their 
targets. I used two approaches to test these possibilities. Firstly, I examined the effect of 
adding exogenous GDF5 on sympathetic neuronal survival and axon growth in cultures of 
PI SCG neurons and secondly, carried out comparative studies of neuronal survival and 
sympathetic innervation density in wild type mice and GDF-5 deficient mice.
To investigate the possible effect of GDF5 on sympathetic neuron survival, I 
cultured SCG neurons from a number of developmental ages (E13, E15, E18, PO and P4) at 
a low density in serum-free defined medium the presence and absence of lOng/ml NGF. 
GDF5 was added at a final concentration of lOng/ml, which has previously shown to be 
saturating (548). An initial count of the numbers of neurons in a 12x12mm grid placed on 
the bottom of the dish was made followed by a second count twenty-four hours later. From 
these values, the percentage neuronal survival was calculated. To allow a direct comparison 
between all ages studied, the percentage survival after twenty-four hours for the NGF group 
at all ages was normalized to 100% and the relevant value for the NGF + GDF5 group was 
adjusted accordingly. I found that at no stage of development did GDF5 enhance or inhibit 
SCG neuron survival in the presence (fig. 48) indicating that it does not modulate the NGF 
survival response. GDF5 did not promote the survival of SCG neurons in the absence of 
NGF (data not shown), indicating that it has no direct survival promoting action itself.
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Figure 49: GDF5 dose response.
Branching (A), length (B) and sholl analysis (C) of the neurite arbors of P0 SCG neurons grown 
overnight with Caspase inhibitors, plus or minus several concentrations of GDF5 ranging from 0 to 
lOOng/ml. (D) to (H) show illustrative drawings of neuronal growth in the different experimental 
conditions.
Data from at least 150 neurons in each condition from three independent experiments are shown 
(*** indicates p<0.001, statistical comparison with control, one-way ANOVA with Fisher’s post
hoc).
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Figure 50: Effect of GDF-5 on sympathetic neurite growth.
Branching (A), length (B) and sholl analysis (C,D) of the neurite arbors of P0 SCG neurons grown 
overnight with Caspase inhibitors or NGF plus or minus GDF5. (E) to (H) show illustrative 
drawings of neuronal growth in the different experimental conditions.
Data from at least 150 neurons in each condition from three independent experiments are shown 
(*** indicates p<0.001, statistical comparison with control, one-way ANOVA with Fisher’s post
hoc).
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Figure 51: Noggin blocks effects of GDF-5 on neurite growth.
Branching (A), length (B) and sholl analysis (C) of the neurite arbors of P0 SCG neurons grown 
overnight with NGF, NGF+GDF5, and NGF + Noggin. (D) to (F) show illustrative drawings of 
neuronal growth in the different experimental conditions.
Data from at least 150 neurons in each condition from three independent experiments are shown 
(*** indicates p<0.001, statistical comparison with control, one-way ANOVA with Fisher’s post 
hoc).
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Effect of GDF5 on sympathetic neuronal growth
To investigate the possible effect of GDF5 on sympathetic neuronal growth, I 
cultured neurons in the presence of several concentrations of GDF5 ranging from 0 to 
lOOng/ml. As GDF5 does not promote sympathetic neuron survival (fig. 48) these neurons 
were kept alive by including the broad spectrum Caspase inhibitor, Boc-D-FMK 
(Calbiochem) in the medium. At least 50 neurons of each different condition were imaged 
using a fluorescence microscope and these images were analyzed using Fast -  Sholl 
analysis (for details see section 2.10 and (549)). These experiments showed that at 
concentrations >0.1ng/ml, GDF5 significantly increased the total neurite length (fig. 49A), 
branching (fig. 49B) and enhanced the Sholl profiles (fig. 49C) of PI sympathetic neurons. 
The effect of GDF5 on these parameters increased in a dose dependent manner reaching 
saturation at lOng/ml (fig. 49). As the initial experiments confirmed that GDF5 increased 
axonal growth in the absence of NGF, I next examined whether it can exert its effects in the 
presence of NGF. I cultured PI SCG neurons in the presence or absence of NGF, GDF5 or 
a combination of both. GDF5 increased total neurite length (fig. 50A), branching (fig. 50B) 
and Sholl (fig. 50C, 50D) profiles, both in the presence or absence of NGF.
To investigate whether the GDF5 neurite growth-promoting effect could be 
inhibited by the presence of the extracellular BMP antagonist Noggin which directly binds 
BMPs in the extracellular compartment and prevent functional receptor/ligand interaction 
(550)(551), I set up an experiment where I added GDF5 in the presence or absence of 
Noggin in cultures of PI SCG neurons. Analysis 24h later revealed that Noggin, 
presumably by binding to GDF5, inhibited the effects of GDF5 on neurite length (fig. 51 A), 
branching (fig. 5IB) and Sholl (fig. 51C) profiles in PI SCG neurons.
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Figure 52: GDF5 activates Smad pathway in sympathetic neurons.
Western blots showing phospho- Smad 1/5/8, total Smad 1/5/8 and (3-111 tubulin in SCG neurons 
from CD1 mice grown overnight in medium containing Boc-D-FMK before exposure to lOng/ml 
GDF5 (time ranging from 0 to 120min). Results show activation of phospho-Smad 1/5/8 after 
15min exposure.
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Figure 53: Brachypod mice show peripheral skeletal malformations
Picture of PO GDF5co"' and GDF5Ap littermates with obvious skeletal differences. (A) Overall view, 
(B) and (C) detailed view of the limb and (D) Cresyl Violet staining for unaffected (z, in) and 
GDF5Ap (zz, zv) limbs from these animals.
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Effect of GDF5 on intracellular Smad signaling in SCG neurons
In most cell systems that have been examined, the primary signal transduction 
pathway for members of TGF-p superfamily involves phosphorylation of Smad proteins 
(for review see (552)). GDF5 (like BMPs) has been shown to phosphorylate Smad 1/5/8 
upon receptor binding (553). To examine whether GDF5 induces Smad-phosphorylation in 
SCG neurons, I set up cultures of PI SCG neurons and grew them overnight in medium 
containing the broad spectrum Caspase inhibitor. Boc-D-FMK, to keep the neurons alive in 
the absence of NGF. GDF5 was added to these cultures for 0, 15, 30, 60 or 120min. Equal 
amount of protein from these cultures were subjected to Western blotting using antibodies 
specific for Phospho-Smad 1/5/8 and p-III tubulin. These experiments showed that GDF5 
induces a clear phosphorylation of Smad 1/5/8 after 15min in PI SCG neurons (fig. 52).
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Figure 54: Effect of brachypod mutation on sympathetic axon growth in vitro.
The data show (A) survival, (B) sholl analysis, (C) branching and (D) total length of P0 SCG 
neurons, grown overnight in the presence of NGF.
Data from at least 150 neurons in each condition from three independent experiments are shown 
(statistical comparison with control, one-way ANOVA with Fisher’s post hoc)
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GDF56p
Figure 55: Effect of brachypod mutation on sympathetic innervation of the nasal mucosa. 
Sympathetic innervation density in GDF5fcp and GDFS000* mice. Bar chart showing the percentage 
area of selected nasal mucosa stained for tyrosine hydroxylase in PO and P5 mice.
(** indicates p<0.001, statistical comparison with GDF5cow/, ANOVA with Fisher’s post hoc n=3 
per genotype). Scale bar = 10pm
The photomicrographs show typical tyrosine hydroxylase stained sections of nasal mucosas of 
Gdfs^  (A) and GDF5^ (B).
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Figure 56: Effect of brachypod mutation on sympathetic innervation of the SMG.
Sympathetic innervation density in GDF5*P and GDFS^"' mice. Bar chart showing the percentage 
area of selected SMG stained for tyrosine hydroxylase in PO and P5 mice.
(** indicates p<0.001, statistical comparison with GDF5com, ANOVA with Fisher’s post hoc n=3 
per genotype). Scale bar = 1 Opm
The photomicrographs show typical tyrosine hydroxylase stained sections of SMG of GDF5com (A) 
and GDF5*P (B).
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Figure 57: Reduction in innervation is not due to a loss of neurons or a loss of TH Expression.
(A) Estimates of neuronal number in the SCG of P5 GDF5A/> and GDFS00"* littermates. (B) The level 
of tyrosine hydroxylase mRNA relative to GAPDH mRNA (arbitrary units) in PO SCG dissected 
from GDFS^ and GDFS00111 littermates is shown.
Mean ± s.e.m. of data from five mice of each genotype are shown.
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Effect of brachypod mutation on sympathetic neuron growth and innervation
Brachypod (bp) mice carry a frame-shift mutation in the GDF5 gene, which results 
in a premature stop codon in the mature mRNA, leading to a loss of expression of 
functional GDF5 protein in vivo (554)(540). Bp mice exhibit a reduction in the length of the 
limb bones, metacarpals, metatarsals and proximal phalanges, in particular being severely 
shortened, and the middle phalanges and interphalangeal joints are absent(540)(554). There 
is no current information in whether these mice have any neuronal phenotype.
To investigate the effect of loss of GDF5, GDF5+/' mice were crossed to generate 
GDF5+/+, GDF5+/" and GDF56p pups. Because carriers of the bp mutation are 
indistinguishable from the wild-type mice, and cannot be conveniently genotyped a mixture 
of GDF5+/+, and GDF5+/' mice were used as control animals (hereafter referred to as 
GDF5CWI/). In mixed litters, GDF56p pups could easily be identified from all the littermates 
because of the clearly evident skeletal defects. Figure 53A shows a picture of two PO 
littermates where the skeletal differences between unaffected (fig. 53B) and GDF56p (fig. 
53C) can be easily seen. These differences were even more pronounced when sections of 
PO limbs of these animals were visualized using Cresyl Violet staining (fig. 53D).
I first investigated if the loss of GDF5 in vivo affects their ability of SCG neurons to 
extend axons in response to NGF in vitro by neurite growth in dissociated cultures of SCG 
neurons established from PI GDF5con/ and GDF5*P littermates. The cultures were grown in 
the presence of lOng/ml NGF for approximately 18h, after which digital images of neurons 
in these cultures were acquired and analyzed using Sholl analysis. PI SCG neurons from 
GDF56p mice survived as well as GDF5con/ pups (fig. 54A) and PI GDF56p neurons had no 
difference in total neurite length (fig. 54D), branching (fig. 54C) and Sholl (fig. 54B) 
profiles when compared to GDF5cow/ SCG neurons. This suggests, perhaps not surprisingly, 
that neurons from GDF56p mice retain the ability to grow and respond normally to NGF. To 
determine if the loss of GDF5 in vivo, affects sympathetic innervation in SCG target 
tissues, I compared sympathetic innervation density in GDF5co"* and GDF5*P littermates. 
The nasal mucosa and SMG normally receive a dense sympathetic innervation from the
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SCG that can be easily identified and quantified by immunohistochemistry for tyrosine 
hydroxylase (555). At PO and P5, there was a very significant reduction in innervation in 
NM (fig. 55) and SMG (fig. 56), in GD¥5bp mice when compared with their littermates 
(p<0.001). Furthermore, these defects in sympathetic innervation were still apparent at P5 
(fig. 55 and fig. 56). To rule out the possibility that the reduction in the sympathetic 
innervation density in GDFS^ mice was due to a down-regulation of tyrosine hydroxylase 
(TH) expression in SCG neurons, I quantified the TH mRNA levels and TH 
immunofluorescence in the SCG of GDF5con/ and GDF5ftp littermates. The results showed 
no significant differences in the levels of either TH mRNA or TH immunofluorescence in 
the SCG of these mice (fig. 57B), supporting the idea that the reduction the sympathetic 
innervation is the result of a reduction in the number or branching of sympathetic axons in 
the targets.
The reduction in sympathetic innervation density could not only occur as a result of 
defective axonal growth and branching, but also from a loss of the numbers of innervating 
neurons in the SCG. To determine if a loss of SCG neurons contributes to the innervation 
defect, I counted the numbers of neurons in the SCG of GDF5CWI* and GDF5*P littermates at 
P5 and found no significant difference in neuronal number (fig. 57A). Taken together these 
results suggest that GDF5 is required for the correct establishment of sympathetic 
innervation by SCG neurons, but is not required for survival of these neurons in vivo.
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4.3 Discussion
I have discovered that GDF5 is a novel target-derived factor for developing 
sympathetic neurons that promotes growth and branching of their axons and is crucial for 
the establishment of appropriate sympathetic innervation density in vivo. GDF5 acts 
independently of NGF, the only other target-derived factor shown to be required for the 
growth and ramification of sympathetic axons in their distal target organs in vivo (102), 
and its effects on sympathetic neurons differ in several important respects from those of 
NGF. GDF5 promotes axonal growth and branching from SCG neurons by BMPR-IB- 
dependent activation of Smad transcription factors, a signaling pathway that has no known 
links with the TrkA-dependent signaling events operative in the growth cones of NGF- 
responsive neurons that mediate the effects of NGF on axonal growth (556). GDF5 
promotes axonal growth from cultured neonatal SCG in the absence of NGF, and in the 
presence of NGF, GDF5 enhances axonal length and branching beyond that which is 
achieved with maximally effective concentrations of NGF alone.
In marked contrast to NGF, GDF5 does not promote the survival of SCG neurons 
in vitro and is not required for their survival in vivo. The number of SCG neurons in 
GDF5bp mice is not significantly different from that in wild type mice at stages up to P10, 
well after the period of development during which GDF5 affects sympathetic axon growth 
in vitro and innervation density in vivo. Because GDF5 begins to exert its effect on axonal 
growth and branching after sympathetic axons have reached their target organs and have 
begun to ramify within these targets under the influence of target-derived NGF, it seems 
that the subsequent impairment of terminal arborization in the sympathetic targets of 
GDF5bp mice does not impact on NGF retrograde survival signaling of the innervating 
neurons. In NT3'1' mice, however, where sympathetic axons fail to reach their targets in 
sufficient numbers, many die as a secondary consequence of failure to obtain an adequate 
supply of NGF from their targets even though NT3 does not initiate retrograde survival 
signaling itself (170).
GDF5 also contrasts with NGF in exerting its effects on axonal growth and 
branching during a very narrow developmental window immediately after birth. SCG 
neurons respond to NGF over a much more protracted period of development, extending
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from the time the earliest sympathetic axons reach their targets to well after the phase of 
programmed cell death (95)(557)(90)(558)(559). Yet, despite its transient action on 
developing sympathetic neurons, the influence GDF5 is nonetheless crucial for 
establishing appropriate levels of sympathetic innervation density. Transient activation of 
two other SCG-expressed receptors during narrow developmental windows has also 
recently been shown to be essential for the establishment of sympathetic innervation in 
vivo. Constitutive activation of the extracellular calcium sensing receptor CaSR in the 
relatively hypercalcaemic milieu of the fetus in the immediate prenatal period (560) and 
autocrine activation of GITR, a member of the TNF receptor superfamily, by its ligand 
GITRL between PI and P3 (425) are each necessary for establishing appropriate 
innervation of SCG target organs and tissues in vivo. These recent findings and our current 
study indicate that superimposed on the extended requirement for NGF signaling, three 
sequential, transient phases of CaSR, GDF5/BMPR and GITRL/GITR signaling are 
required for the establishment of appropriate levels of sympathetic innervation in the 
perinatal period. However, unlike GDF5/BMPR signaling, which promotes axonal growth 
independently of NGF, neither CaSR nor GITR promote significant axonal growth in the 
absence of NGF. GITR signaling affects axonal growth by facilitating NGF/TrkA-induced 
ERK1/ERK2 activation which is required for NGF-promoted axonal growth (425). Later in 
development, after sympathetic innervation has been established by the action of NGF and 
other factors, there is evidence that the long-term maintenance of cholinergic sympathetic 
innervation of sweat glands may become dependent on neurturin. Sweat glands express 
neurturin mRNA (561), and although the cholinergic sympathetic innervation of these 
glands develops normally in mice lacking the preferred neurturin receptor GFR-alpha2, 
this is subsequently lost in these mice in late postnatal development (562).
These findings raise the interesting question of the extent to which GDF5 
influences the development of other neurons. Although GDF5 does not affect neurite 
growth from developing NGF-responsive and BDNF-responsive sensory neurons at several 
different stages of embryonic and postnatal development, it has been reported to increase 
the number of dopaminergic neurons and enhance the growth of neurites from these 
neurons in dissociated cultures of embryonic midbrain cells (563)(547). GDF5 also 
promotes astrocyte proliferation in these cultures (547), so it is possible that its effects on
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dopaminergic neuron differentiation and/or survival may be secondary to the effects of 
increased number of astrocytes in these cultures. However, since GDF5 is expressed 
locally within the midbrain at this stage of development (547) it will be important to study 
dopaminergic neuron development in GDF5bp mice.
In summary, I have discovered the first physiological role for GDF5 in the nervous 
system as a novel target-derived factor that promotes the growth and branching of 
sympathetic axons independently of NGF during a window of development after these 
axons have started to ramify in their targets under the influence of target-derived NGF. 
However, in marked contrast to NGF, GDF5 has no demonstrable role in regulating 
sympathetic neuronal survival either in vitro or in vivo. Whereas NGF acts locally on distal 
axons to promote growth and branching (536), its survival-promoting effects require 
retrograde transport in signalling endosomes to the cell soma (170). Because the effects of 
GDF5 on sympathetic axon growth and branching may be dependent on Smad 
transcriptional activation, it is possible that these effects in vivo require retrograde signaling 
to the cell body. Whether this is indeed the case and how GDF5-promoted Smad activation 
affects axon growth are intriguing and important questions for future research.
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5. Role of TNFRSF members BCMA and TACI in 
regulating the neurotrophin survival responses of 
developing sensory and sympathetic neurons
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5.1 Introduction
The complexity of nervous system development is astounding. Neurons must be 
generated in appropriate numbers in different parts of the nervous system and have to 
extend axons, elaborate dendrites, and form synapses to ensure the exquisite specificity of 
connectivity necessary for normal function (545). Over the past few decades there has been 
a great improvement in knowledge about the families of extracellular signals that regulate 
the generation and survival of neurons and the growth and elaboration of their processes. 
The main aim of the research carried out in this thesis is to explore the potential roles in the 
developing nervous system of families of extracellular signaling proteins that have well 
characterized functions in other organs and tissues. The PCR screens reported in the third 
chapter of this thesis revealed several interesting expression profiles in developing PNS 
neurons for members of the TNFRSF with no known function in the nervous system, 
warranting further functional studies. One such set of receptors, which are the subject of the 
functional studies reported in this chapter, are BCMA, TACI and BAFFR and their ligands 
APRIL and BAFF. Whereas BCMA and TACI are receptors for both APRIL and BAFF, 
BAFFR is a selective receptor for BAFF. The functions of these receptors and ligands have 
been extensively studied in the immune system, where they play important roles in B cell 
homeostasis, differentiation, function and survival(359)(564)(565)(566)(567). However, 
little is known about their role in the nervous system. In this chapter I report the results of 
studies suggesting that BCMA signaling plays an important roles in facilitating NGF- 
promoted survival of neonatal sympathetic neurons but not NGF-promoted neurite growth 
from neurons and facilitating BDNF-promoted survival of embryonic sensory neurons but 
not BDNF-promoted neurite growth from these neurons.
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5.2 Results
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Figure 58: Expression of BCMA, TACI, BAFF and APRIL in the developing SCG.
The data show the relative expression of (A) BCMA, (B) TACI, (C) BAFF and (D) APRIL relative 
to GAPDH mRNA (in arbitrary units) and the respective Real time PCR melting curves (showing 
primer specificity in E l3, El 5, E l8, PO and P5 SCG. Means and standard errors of data from three 
separate sets of ganglia at each stage are shown
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Developmental profile of the expression of BCMA, TACI, APRIL and BAFF mRNAs 
in the SCG
From analysis of the results of the PCR screen and a consideration of the available tools to 
manipulate receptors function, I decided to investigate the potential roles of BCMA and 
TACI and their ligands, APRIL and BAFF in the developing peripheral ganglia (514). To 
do so, I first took a closer, more detailed look at the expression transcripts for these 
cytokines and their receptors in developing peripheral ganglia using real time PCR. This 
analysis revealed that both of the receptors (BCMA and TACI) are present at relatively 
high levels throughout the developmental period examined (El3 to P5) in the SCG. The 
level of BCMA mRNA (relative to GAPDH mRNA) was little changed between E l3 and 
E18 and decreased to P5 (fig. 58A). TACI mRNA levels decreased between E13 and E18, 
followed by a small increase at PO and then decreased again from PO to P5 (fig. 58B). 
BAFF mRNA (fig. 58C) and APRIL mRNA (fig. 58D) showed a very similar expression 
profile with a steady increase from E l3.
Expression of BCMA, TACI, APRIL and BAFF protein in SCG neurons
I used immunohistochemistry to study the expression of these cytokines and 
receptors in cultured SCG neurons and in histological sections of the SCG and their targets. 
Cultures of PO SCG neurons were grown overnight in the presence of NGF before being 
fixed and processed for immunohistochemistry for the specific ligands or receptors and the 
neuronal marker B-III tubulin. Results from these staining show that BCMA is expressed 
predominantly in the cell body of neurons, but it was also found at the tips of the growth 
cones (fig. 59A). Its ligands APRIL and BAFF were found to be expressed only at neuronal 
cell bodies (figs. 59B, 59C) and not at growth cones. TACI (fig. 59D) was expressed in the 
cell bodies of neurons and in non-neuronal cells. The pattern of expression of BCMA, 
TACI, BAFF and APRIL at the cell body of neurons raises the possibility of autocrine 
signaling occurring at the cell soma. The expression of BCMA on the tips of growth cones
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raises the possibility that it could interact with any of its ligands should they be expressed 
in the intermediate or distal target of these neurons (discussed later). Considering the 
relatively high expression of BCMA throughout the developmental period studied, and its 
expression in cultured PO SCG neurons, I decided to investigate BCMA protein expression 
in the SCG ganglion. Sections through the SCG were stained with anti-BCMA and TH. 
Labeling was clearly observed in the cell bodies of at least a subset of SCG neurons (figs. 
60A, B, C).
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Figure 59: Expression of BCMA, APRIL, BAFF and TACI in axons and growth cones. 
Photomicrographs show PI SCG neurons double stained for B-III tubulin (middle column) and (A) 
BCMA, (B) APRIL, (C) BAFF and (D) TACI, and a merge image (right column) showing co­
localization of these proteins with the marker B-III tubulin. Scale bar = 10pm
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Figure 60: Expression of BCMA in the SCG ganglion.
Photomicrographs show consecutive sections of the entire SCG (A), the outer part of the ganglion 
(B) and centre part (C) double stained for BCMA (red) and TH (green). Merge image showing co­
localization of BCMA and TH. Scale bar =10|im
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Figure 61: Expression of BCMA and APRIL in the SCG compared with target fields.
The data show the mRNA level of (A) BCMA and (B) APRIL in the submandibular gland (SMG), 
nasal mucosa (NM) and SCG relative to GAPDH in CD-I mice.
Means and standard errors of data from three separate sets of each tissue are shown.
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Figure 62: Expression of BCMA and APRIL in the nasal mucosa.
Photomicrographs show consecutive sections of the nasal mucosa double stained for (A) APRIL (in 
red), (B) BCMA (in red) and TH (in green). Merge image showing co-localization of BCMA and 
TH, but not APRIL and TH. Omission of a primary antibody was used to control for non-specific 
binding of the secondary antibodies (C). Scale bar = 20pm
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Figure 63: Expression of BCMA and APRIL in the SMG.
Photomicrographs show consecutive sections of the SMG double stained for (A) APRIL (in green),
(B) BCMA (in green) and TH (in red). Merge image showing co-localization of both BCMA and 
April with TH. Omission of a primary antibody was used to control for non-specific binding of the 
secondary antibodies (C). Scale bar = 20pm
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Expression of APRIL mRNA and protein in SCG targets
Because of the prominent expression of BCMA in the growth cones of PO SCG 
neurons (see above), I examined the expression of APRIL mRNA in the target tissues that 
these neurons innervate. For these studies, I dissected the submandibular salivary gland 
(SMG) and the nasal mucosa (NM) from PO animals and quantified APRIL mRNA by real 
time PCR (fig. 6 IB). These results demonstrated APRIL mRNA expression in both of these 
target tissues (fig. 6 IB). Interestingly, these target tissues also expressed appreciable levels 
of BCMA mRNA (fig. 61 A). The SMG had the highest expression of both BCMA mRNA 
and April mRNA. This may be in fact related to the innervation density, as the SMG has a 
higher innervation density when compared to the NM (568). In addition, APRIL mRNA, 
BCMA mRNA was also expressed in the targets of SCG neurons.
I used immunohistochemistry to confirm that BCMA and APRIL proteins are 
expressed in the targets and determine their localization. I prepared histological sections of 
the NM and SMG of PO animals, and double stained them for BCMA and TH, or APRIL 
and TH. In the NM, BCMA and TH were co-localized (fig. 62B), indicating that BCMA is 
expressed on the innervating axons. APRIL was expressed in the outer epithelial layer of 
the NM and did not co-localize with TH (fig. 62A), showing that it is not expressed by the 
innervating axons, but it is instead expressed by cells in the target tissue. In the SMG 
sections, BCMA and TH were likewise co-localized (fig. 63B), suggesting BCMA is also 
expressed in on the innervating axons. APRIL was much more abundantly expressed 
throughout the tissue and did not co-localize with TH, indicating it is expressed by the cells 
in the tissue (fig. 63A). In sections of the both NM and SMG no immunoreactivity was 
observed in the absence of primary antibodies, demonstrating no non-specific binding of 
the secondary antibodies (fig. 62C, 63C).
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Figure 64 : Effect of blocking BCMA, BAFF, APRIL and TACI on sympathetic neuron survival. 
The data show SCG neurons time course survival (24h) comparison between neurons grown only 
with lOng/ml of NGF (control normalized to 100%) and function blocking antibodies for the TNF 
family members. (A) lpl/ml of a-BCMA, (B) lOpg/ml of a-BAFF, (C) 5pg/m of a-APRIL and (D) 
lOpg/m of a-TACI at a number of different stages of development between E15 and P4.
Means and standard errors of data from three separate sets of ganglia at each stage are shown (*** 
indicates p<0.001, statistical comparison with control one-way ANOVA with Fisher’s post hoc).
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Figure 65: Effect of NGF dose response in sympathetic neurons.
The data show survival at (A) 24h and (B) 48h of PO SCG neurons grown overnight with several 
concentrations of NGF ranging from 0.00064 to lOng/ml (control) plus or minus lpg/ml of a- 
BCMA.
Data from three independent experiments are shown. Statistical comparison with control, one-way 
ANOVA with Fisher’s post hoc.
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The effects of BCMA, TACI and their ligands APRIL and BAFF on sympathetic 
neuron survival
To investigate a possible role for endogenous signalling involving these TNF 
members in regulating neuronal survival, I cultured SCG neurons from a number of 
developmental ages at a low density in serum-free defined medium the presence of lOng/ml 
NGF to sustain their survival with and without function-blocking antibodies against 
BCMA, BAFF, APRIL or TACI. An initial count of the numbers of neurons in a 12x12 mm 
grid placed on the bottom of the dish was made 2 hours after plating followed by a second 
count twenty-four hours later. From these values, the percentage of neuronal survival was 
calculated. To allow a direct comparison between all ages studied, the percentage survival 
after twenty-four hours for the NGF group at all ages was normalized to 100%.
These experiments showed that BCMA function blocking antibodies significantly 
reduced the survival of cultured sympathetic neurons at E l5, E l8 and PO, but not P4 (fig. 
64A, p<0.001 student paired t-tests). Similarly, a function blocking BAFF antibody 
significantly reduced the survival of SCG neurons at all ages studies, although at P4 the 
effect was marginal (fig. 64B, p<0.001 student paired t-tests). For both antibodies, the 
maximal effect on inhibiting NGF-promoted survival occurred at PO, suggesting that 
endogenous BCMA/BAFF signalling modulates the survival response of embryonic and 
perinatal SCG neurons to NGF. Blocking the function of APRIL caused highly significant 
reductions in the survival responses of SCG neurons to NGF at E l5 and PO (fig 64C, 
p<0.001 student paired t-tests). Although anti-APRIL also reduced the numbers of El 8 and 
P4 SCG neurons surviving with NGF, these reductions were not statistically significant. 
Blocking TACI function significantly decreased the survival responses of SCG neurons to 
NGF at E l5, PO and P4 (fig. 64D, p<0.001 student paired t-tests).
Considering the dramatic effect that function blocking anti-BCMA antibodies had 
on the survival of PO SCG neurons, I decided to investigate the effect of these antibodies in 
neurons cultured with different concentrations of NGF. For this, I set up a PO SCG low 
density culture with concentrations of NGF ranging from 0.00064 to lOng/ml. After 24h 
incubation (fig. 65A), irrespective of the concentration of NGF used, function blocking 
anti-BCMA antibodies significantly reduced neuronal survival. After 48h incubation (fig.
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65B), few neurons were still surviving in the lowest concentrations of NGF, but at 
concentrations of 0.4ng/ml NGF and higher, where more than 30% of the neurons were still 
surviving, anti-BCMA antibodies significantly reduced NGF-promoted neuronal survival.
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Figure 66: Effect of SiRNA transfections in sympathetic neurons survival.
Data show (A) survival of P0 SCG neurons grown overnight with NGF. Neurons were transfected 
with a scrambled sequence (control) and three different siRNAs for BCMA. Results show a very 
significant decrease in survival after 24h. Means and standard errors of data from three independent 
experiments (*** indicates p<0.001, statistical comparison with control one-way ANOVA with 
Fisher’s post hoc).
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Figure 67: Effect of knocking down BCMA gene with SiRNA in sympathetic neurons. 
Photomicrographs showing (A) Control SiRNA and (B) BCMA SiRNA in P0 SCG neurons grown 
overnight with NGF and Caspase inhibitors. Results show BCMA staining in the control 
transfections but not in the neurons transfected with BCMA SiRNA. Scale bar = 20pm.
176
siRNA-mediated knockdown of BCMA receptor expression reduces sympathetic 
neuron survival
To further confirm that inhibiting the function of BCMA impairs NGF-promoted 
sympathetic neuron survival, I designed and made plasmid based siRNAs to knockdown 
the expression of BCMA. I used the siRNA designing tool on the Ambion website 
(www.ambion.com) to find the potential siRNA target sequences based on the BCMA 
RNA sequence. This gave 8 possible sequences which I blasted on NCBI, and subsequently 
chose the three with the lowest percentage of similarity to other genes. Based on the target 
sequence I obtained the siRNA sequence from the same website. Following manufacturer’s 
instructions, I created three vectors expressing these siRNAs using the pSilencer™ 4.1- 
CMV hygro expression vector kit (Ambion), one for each of the target sequences (for 
details see section 2.10.4). These vectors were then used to transform E. coli, and 
respective plasmid DNA was extracted.
PO SCG neurons were co-transfected with an RFP expression plasmid together with 
either a BCMA siRNA expression plasmid or its corresponding control plasmid expressing 
a scrambled sequence RNA. Transfected neurons were plated in defined serum-free 
medium with lOng/ml of NGF and incubated overnight. Separate experiments in which 
neurons were transfected by electroporation using the Microporator using a mixture of RFP 
and YFP expression plasmids showed that transfected neurons co-expressed both RFP and 
YFP, indicating that both plasmids were taken up by the same neurons (data not shown). 
After 24h, all RFP positive neurons were counted using a fluorescence microscope. The 
numbers of surviving neurons in control cultures were normalized to 100%, and the number 
of neurons in the cultures transfected with BCMA siRNA expressed a percentage of the 
control. Neuronal counts revealed that all three BCMA siRNA’s significantly reduced 
neuronal survival to a similar extent (fig. 66).
To demonstrate that the BCMA siRNA constructs reduced the expression of BCMA 
protein in transfected neurons, I cultured PO SCG neurons co-transfected with an RFP 
expression plasmid and either control or BCMA siRNA in the presence of lOng/ml of NGF
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and caspase inhibitors and immunolabelled them against BCMA. As expected, I found that 
neurons transfected with the scramble control still expressed BCMA whereas neurons 
transfected with BCMA siRNA expressed virtually no BCMA, showing that siRNA 
effectively knocked down the expression of BCMA (fig. 67).
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Figure 68: Effect of blocking BCMA on sympathetic neurite growth.
Branching (A), Length (B) and sholl analysis (C) of the neurite arbors of P0 SCG neurons grown 
overnight with Caspase inhibitors and NGF (Control) or Caspase inhibitors, NGF and BCMA. (D) 
and (E) show illustrative draws of neuronal growth in the different experimental conditions.
Data from at least 150 neurons in each condition from three independent experiments are shown
179
Lack of effect of BCMA inhibition on NGF-promoted neurite growth
Given the strong reduction in sympathetic neuron survival observed using a 
function blocking antibody to BCMA, I decided to investigate whether anti-BCMA would 
have any effect on NGF-promoted neurite growth from sympathetic neurons. To test this, I 
set up low density cultures of PO SCG neurons in defined serum-free medium 
supplemented with lOng/ml of NGF and 25 pM of caspase inhibitor Boc-D-FMK (because 
anti-BCMA compromised the survival of PO SCG neurons) with or without the function 
blocking antibody against BCMA. At least 50 neurons of each different condition were 
imaged using a fluorescence microscope and these images were analyzed using Fast -  Sholl 
analysis (for details see section 2.9.5 and (549)). There were no significant differences in 
the number of branching points (fig. 66A) or mean total neurite length (fig. 66B) or Sholl 
profile (fig. 66C) displayed by PO SCG neurons treated with the BCMA function blocking 
antibody, compared to control cultures. These findings suggest that BCMA signaling 
selectively regulates NGF-promoted neuronal survival, but not NGF-promoted neurite 
growth.
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Figure 69: Expression of BCMA, TACI, BAFF and APRIL in the developing Nodose ganglion.
The data show the relative expression of (A) BCMA, (B) TACI, (C) BAFF and (D) APRIL relative 
to GAPDH mRNA (in arbitrary units) and the respective Real time PCR melting curves (showing 
primer specificity in E l3, El 5, E l8, PO and P5 Nodose. Means and standard errors of data from 
three separate sets of ganglia at each stage are shown.
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Expression of mRNAs for BCMA, TACI and their ligands APRIL and BAFF in the 
developing Nodose ganglion
To investigate the potential role of BCMA and/or TACI signalling in developing 
sensory neurons, I first measured the expression transcripts for these receptors and their 
ligands by RT-QPCR in developing nodose ganglia. There was a relatively low level of 
BCMA mRNA expression from E13 to P5 (fig. 69A). The expression of TACI mRNA was 
barely detectable throughout the entire developmental time course (fig. 69B). BAFF mRNA 
was expressed at a modest, approximately constant levels in developing nodose ganglia 
between E l3 and PO, followed by a modest increase from PO to P5 (fig. 69C). Although 
APRIL mRNA levels were modest in nodose ganglia throughout development, there was a 
clear peak of expression at E15 (fig.69D).
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Figure 70: Expression of BCMA, APRIL, BAFF and TACI in axons and growth cones. 
Photomicrographs show E l5 Nodose neurons double stained for B-III tubulin (middle column) and 
(A) BCMA, (B) APRIL, (C) BAFF and (D) TACI, and a merge image (right column) showing co­
localization of these proteins with the marker B-III tubulin. Scale bar = 10pm.
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Expression of BCMA, TACI, and their ligands APRIL and BAFF in cultured nodose 
neurons
Given the high level of APRIL mRNA expression at E l5, I decided to further 
investigate its function at this stage of development. I cultured E l5 nodose neurons in a 
serum-free defined medium in the presence of lOng/ml of BDNF to support their survival. 
After 24h, the neurons were fixed and double stained for {3-111 tubulin and either BCMA, 
BAFF, TACI or APRIL. BCMA was strongly expressed in the cell bodies and at the tips of 
their growth cones (fig. 70A). APRIL expression was restricted to the cell bodies of sensory 
neurons (fig. 70B), and although BAFF mRNA was expressed at extremely low levels in 
E15 nodose ganglia, BAFF protein was expressed in both neuronal and non-neuronal cells 
in vitro (fig. 70C). TACI was expressed in the cell bodies and processes of most E15 
nodose neurons (fig. 70D).
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Figure 71: Anti-BCMA dose response.
The data show E l5 nodose neurons grown overnight with lOng/ml BDNF (control) plus several 
concentrations of BCMA ranging from 1 to 4pg/ml of BCMA
Data from three independent experiments are shown. Statistical comparison with control, one-way 
ANOVA with Fisher’s post hoc. *** indicates pO.OOl
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Figure 72: Effect of BDNF dose response in Nodose neurons.
The data show survival at (A) 24h and (B) 48h of E15Nodose neurons grown overnight with 
several concentrations of BDNF ranging from 0.00064 to lOng/ml (control) with or withoutlpg/ml 
of a-BCMA.
Data from three independent experiments are shown. Statistical comparison with control, one-way 
ANOVA with Fisher’s post hoc.
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Figure 73: Effect of blocking BCMA, BAFF, APRIL and TACI on sensory neuron survival.
The data show Nodose neurons time course survival (24h) comparison between neurons grown only 
with lOng/ml of BDNF (control normalized to 100%) and function blocking antibodies for the TNF 
family members. (A) 5pg/ml of a-APRIL, (B) lpg/ml of a-BCMA, (C) lOpg/m of a-BAFF and (D) 
lOpg/m of a-TACI at a number of different stages of development between El 3 and P5.
Means and standard errors of data from three separate sets of ganglia at each stage are shown (*** 
indicates p<0.001, statistical comparison with control one-way ANOVA with Fisher’s post hoc).
186
The effects of blocking the function of BCMA, TACI and their ligands APRIL and 
BAFF on the survival of £15 nodose neurons
To investigate the potential role of BCMA in regulating the survival of embryonic nodose 
neurons, I set up low-density cultures of these neurons in defined serum-free medium with 
lOng/ml of BDNF (control) with or without several concentrations of the function blocking 
anti-BCMA antibody. An initial neuronal count 2h after plating was made followed by 
second and third counts twenty four and forty eight hours later. At twenty four hours, the 
function blocking BCMA antibody decreased neuronal survival in a dose dependent 
manner, reaching a maximal inhibitory effect at a concentration at lpg/ml (fig. 71 A). At 
this concentration, BDNF-promoted neuronal survival was reduced by 60%. The effects of 
the function blocking BCMA antibody in reducing the survival of E l5 nodose neurons 
were still evident after 48 hours (fig. 7IB).
The marked effect of anti-BCMA on BDNF-promoted neuronal survival of E l5 
nodose ganglion neurons prompted examination of the effect of this antibody on the 
survival of these neurons at different stages of development and studies of the effects of 
function blocking antibodies against BAFF, TACI and APRIL on survival. For these 
studies, I dissected nodose ganglia from E13, E15, E18, P0 and P5 mice and cultured them 
at low density in serum-free defined medium in the presence of lOng/ml of BDNF with and 
without with function blocking antibodies to these receptors and ligands. Anti-BCMA 
reduced BDNF-promoted survival at all ages, although the reduction was only statistically 
significant at E l5 and E l8, with the greatest (50% reduction in survival) and most 
significant (P<0.001, student’s paired t-test) effect being observed at E15. Anti-TACI also 
caused a highly significant reduction in BDNF-promoted survival at E l5 (25% reduction, 
P<0.001, student’s paired t-test), but had no significant effect on neuronal survival at other 
ages. Surprisingly, the function-blocking antibodies against APRIL (fig. 73A) and BAFF 
(fig. 73C) did not have any effect on survival of nodose neurons throughout the 
developmental period studied.
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Figure 74: Effect of blocking BCMA on sensory neurite growth.
The data show (A) survival, (B) sholl analysis (C) total length and (D) number of branching points 
of E l5 Nodose neurons, grown overnight in the presence of Caspase inhibitors and lOng/ml of 
BDNF plus or minus 1 jig/ml of a-BCMA. (E) to (G) show illustrative draws of neuronal growth in 
the different experimental conditions
Means and standard error of data from three separate sets of ganglia at each stage are shown.
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Lack of effect of BCMA inhibition on BDNF-promoted neurite growth
To investigate whether BCMA affects BDNF-promoted neurite growth, E l5 nodose 
neurons were cultured at low density in the presence of lOng/ml BDNF and a broad 
spectrum caspase inhibitor (to prevent neuronal death) with or without lpg/ml anti-BCMA. 
Analysis of neuron images by the Fast -  Sholl method showed that blocking the function of 
BCMA had no effect on either total neurite length (fig. 74C), number of branch points in 
the neurite arbors (fig. 74D) or the Sholl profile (fig. 74B). Thus, whilst BCMA signaling 
appears to be important for the survival of E l5 nodose neurons in culture, it is not 
necessary to promote neurite growth or branching. These findings suggest that, as in the 
case of NGF-response PO SCG neurons, BCMA signaling selectively regulates BDNF- 
promoted survival of E l5 nodose neurons, but does not affect BDNF-promoted neurite 
growth from these neurons.
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5.3 Discussion
To date, little is known about the roles of the TNF superfamily ligands and 
receptors in the nervous system. The studies reported in this chapter provide the first 
evidence for a role for the related TNFRSF members BCMA and TACI in the nervous 
system. RT-QPCR data indicated that mRNAs for these receptors and their ligands APRIL 
and BAFF are expressed in the SCG and nodose ganglia throughout the period studied from 
E13 to P5 (figs. 34B, 36B, 40A and 41 A). Interestingly, the higher levels of receptor 
mRNAs were present in the SCG compared with the nodose ganglia (figs. 34B and 36B), 
and the nodose ganglia expressed higher levels of the ligand mRNAs than the SCG (figs. 
40A and 41 A). In accordance with the RT-QPCR data, immunocytochemistry revealed 
expression of these receptors and ligands in cultured PO SCG and E15 nodose ganglion 
neurons. The great majority of neurons within these cultures individually expressed 
BCMA, TACI, BAFF and APRIL, and while a small number of neurons were not labelled, 
these findings suggest that these receptors and ligands are co-expressed in the majority of 
neurons. These findings together with the observation that the cell bodies of the neurons 
were immunoreactive for both receptors and both ligands raised the possibility of autocrine 
signalling taking place at the cell body of these neurons. In addition to expression at the cell 
body, BCMA was striking expressed at the growth cones of both kinds of neurons. TACI 
and BAFF were also expressed along the processes of El 5 nodose neurons. BAFF was also 
expressed by non-neuronal cells in the SCG and nodose ganglia. In addition to the 
possibility of autocrine signalling occurring within the ganglia, these expression patterns 
open up the possibility that APRIL and BAFF may affect some aspect of neuronal 
development by paracrine signalling within ganglia, non-neuronal cell to neuron paracrine 
signalling within ganglia and target field cell to axon terminal signalling. To investigate the 
matter, I used RT-QPCR and immunohistochemistry to determine the expression of APRIL 
and BCMA in two target fields of the SCG, the submandibular gland (SMG) and the nasal 
mucosa (NM). Double staining of the NM and SMG with antibodies against BCMA and 
tyrosine hydroxylase (TH) revealed that BCMA was expressed in the terminal arbors of 
sympathetic neurons innervating both structures, which is consistent with the expression of 
BCMA at the terminals of sympathetic neurites in culture. APRIL protein did not co- 
localise with sympathetic axon in these target tissues, rather it was expressed by target field
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cells. RT-QPCR demonstrated that the SMG expressed higher levels of APRIL mRNA than 
the NM and both target tissues expressed higher levels of APRIL mRNA than the SCG, 
strengthening the possibility that target field-derived APRIL might affect some aspect of 
SCG neuron development via interaction with BCMA expressed by innervating neurons. 
Surprisingly, both SCG target fields investigated also expressed substantial amounts of 
BCMA mRNA. The origin of this BCMA mRNA is unclear. It may be expressed by target 
field cells or, alternatively, it may be expressed within the SCG neurons themselves, since 
it is now becoming clear that the mRNAs of many proteins are anterogradely transported to 
terminal arbors o f axons where they are translated locally (569).
Given the fact that BCMA, TACI and their ligands APRIL and BAFF are known to 
be involved in regulating cell survival in the immune system (617)(618), I decided to 
investigate whether the inhibition of these receptors or their ligands would have any effect 
on sympathetic neuron survival. Inhibiting the function of BCMA, TACI, BAFF and 
APRIL using function blocking antibodies significantly reduced the NGF-promoted 
survival of SCG neurons at several stages of development. The greatest inhibitory effects 
were observed with anti-BCMA and anti-BAFF at PO. Anti-TACI and anti-APRIL also 
promoted highly significant reductions in NGF-promoted survival at this age, and all anti­
ligand and anti-receptor antibodies promoted highly significant reductions in NGF- 
promoted neuronal survival at both E l3 and E l8, except anti-TACI at E l8. However, by 
P4, anti-BCMA and anti-APRIL no longer exerted an inhibitory effect on NGF-promoted 
survival and anti-TACI and anti-BAFF exerted inhibitory effects that were only marginally 
significant. Dose response analysis of NGF-promoted survival of PO SCG neurons 
demonstrated that anti-BCMA reduced the survival of SCG neurons across a broad range of 
NGF concentrations. To further confirm that endogenous BCMA plays a role in facilitating 
the NGF-dependent survival of PO SCG neurons I used several different siRNAs to reduce 
the expression of BCMA and demonstrated that these siRNAs, but not control siRNAs, 
greatly reduced the survival of PO SCG neurons cultured in the presence of NGF. Because 
the above studies of the effects of function-blocking antibodies and siRNAs were obtained 
from neurons cultured at very low density, to the point that the vast majority of individual 
neurons were not touching each other, these findings suggest that autocrine signalling 
involving the BCMA and TACI receptors and the BAFF and APRIL ligands is required for
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NGF-promoted survival of SCG neurons during a developmental window that extends from 
E13 to P4.
In marked contrast to the inhibitory effect of anti-BCMA on NGF-promoted 
survival of PO SCG neurons, anti-BCMA had no effect whatsoever on the extent or pattern 
of NGF-promoted neurite growth from these neurons. This suggests that endogenous 
BCMA signaling in these neurons selectively facilitates the survival-promoting actions of 
NGF but not the neurite growth-promoting effects of NGF. Interestingly, autocrine 
signaling involving another member of the TNFRSF, GITR, and its ligand GITRL has 
recently been shown to be selectively required for NGF-promoted neurite growth but not 
NGF-promoted survival of postnatal SCG neurons(425). Furthermore, in embryonic nodose 
neurons signaling involving another TNFSF/TNFRSF ligand/receptor pair LIGHT and 
HVEM has been recently reported to be a negative regulator of BDNF-promoted neurite 
growth but has no effect on BDNF-promoted neuronal survival. From these two recent 
studies and the findings reported in this chapter, it is beginning to look as if endogenous 
signaling involving members of the TNFRSF and their cognate ligands are selective 
modulators of particular aspects of the cellular responses of developing neurons to 
neurotrophins. GITRL/GITR facilitates NGF-promoted neurite growth and branching from 
postnatal SCG neurons by selectively facilitating downstream signaling events from TrkA 
that are selectively required for neurite growth without activating these pathways directly, 
namely, facilitating activation of MEK1/MEK2-ERK1/ERK2 by NGF/TrkA (425). In 
future work, it will be important to ascertain the molecular mechanism by which BCMA 
facilitates NGF-promoted neuronal survival, and whether it does so by selectively 
facilitating signalling pathways downstream of TrkA that are required for sustaining 
neuronal survival. BAFF, for example, has been shown to regulate B cell survival via 
activation of the NF-kB pathway (570), prevents NGF-mediated survival in sympathetic 
neurons (571). For this reason, it will be important to ascertain the influence of BCMA and 
TACI signaling on NF-kB activation in SCG neurons and whether this plays any role in the 
influence of BCMA and TACI on NGF-promoted survival. Furthermore, it will also be 
informative to investigate whether the effects of BCMA and TACI signaling in SCG 
neurons are restricted to NGF-promoted survival or whether they affect the survival of 
these neurons in response to Artemin or NT-3.
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Blocking the function of BCMA and TACI also greatly reduced the survival of El 5 
nodose neurons cultured with BDNF, suggesting that endogenous signalling by these 
receptors facilitates the survival response of these neurons to BDNF. As in the case of 
SCG, blocking BCMA function did not affect neurotrophin-promoted neurite growth. 
Surprisingly, and in contrast to SCG neurons, function-blocking antibodies to either ligand 
did not affect neurotrophin-promoted survival of E l5 nodose neurons. This raises the 
question of the ligand or mechanism by which BCMA and TACI are presumably activated 
in cultured embryonic nodose neurons. It is possible, however, that there is redundancy in 
the ligand receptor interactions such that blocking a single ligand is insufficient to 
sufficiently disrupt receptor action by the remaining ligand to the extent that it affects 
BDNF-promoted neuronal survival. For this reason, it would have been informative to have 
studied the consequences of treating the neurons with function blocking antibodies to both 
ligands in combination. Likewise, experiments involving different combinations of function 
blocking antibodies to receptors and ligands would have been informative in addressing 
issues of potential redundancy and potential combinatorial effects of BCMA and TACI 
signalling in sympathetic neurons. Furthermore, had time permitted, it would have been 
informative to study the effects of exogenous soluble ligands on the survival and growth of 
neurites from cultured nodose and SCG neurons in the presence and absence of 
neurotrophins. These experiments would have been particular pertinent given the 
immunohistochemical findings that suggest that APRIL could potentially act as a target- 
fleld derived factor for developing SCG neurons.
Perhaps the most pressing and important further studies will be to investigate the 
physiological relevance of the in vitro observations reported in this chapter by studying the 
phenotype of mice lacking BCMA, BAFF, APRIL or TACI genes. Does deletion of these 
genes singularly and/or in combination lead to a reduction in the number of neurons in the 
SCG and nodose ganglia? If so and there are accompanying reductions in innervation 
density in target tissues, if neuronal death is prevented by generating double knockout mice 
with the BAX gene, will innervation density remain unaffected or will there be changes that 
might be explained by disrupted ligand receptor signalling in the target tissues in the case 
of BAX/BCMA or BAX/APRIL double knockout mice compared with BAX mice? 
Furthermore, are other populations of neurons and their projections affected? Clearly, the
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novel findings reported in this chapter not only provide evidence for the first role for 
BCMA and TACI signalling in neurons but also form the basis of an important body of 
future research.
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